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To date, over 70 monoclonal antibody (mAb) biopharmaceuticals have been 
approved, allowing effective treatment of serious diseases such as cancer. In 
addition to improving human health, these powerful medicines are very valuable, 
generating billions of dollars in sales annually. Like all proteins, environmental 
changes can cause mAbs to unfold, misfold and aggregate. Aggregation can 
block the progress of mAbs to market, as aggregates have been linked to adverse 
effects in patients. The hydrodynamic forces mAbs encounter during their 
manufacturing process have long been thought to be one of the causes of 
aggregation. This link remains tenuous, however, partly due to a lack of 
knowledge surrounding how specific flow fields (e.g. shear and extensional flows) 
perturb protein structure. 
To assess the effects of flow on therapeutic protein aggregation, a recently 
developed, bespoke Extensional Flow Device (EFD) was characterised, which 
mimics the hydrodynamic forces mAbs encounter at manufacturing scale. In this 
thesis, the model proteins BSA and three mAbs (WFL, mAb1 and STT) were 
subjected to the defined fluid fields present in the EFD, with the resulting 
aggregates characterised using an array of biophysical techniques. The data 
show that protein aggregation can be induced by extensional flow. The extent of 
aggregation depends on a protein’s sequence and topology, in addition to the flow 
conditions and buffer composition. For example, the mAbs WFL and STT show 
disparate aggregation behaviour following hydrodynamic stress, despite having 
>99 % sequence identity, with the generic mAb1 somewhere in between the two. 
Reinforced by data from a screen of 33 clinically relevant mAbs, the data in this 
thesis support future use of the EFD to: explore flow-induced protein aggregation 
mechanisms; improve mAb bioprocessing and; screen mAb candidates to select 
sequences and/or formulations which are resistant to potentially deleterious 
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1.1 Protein folding, misfolding and aggregation 
 
Proteins are one of Nature’s most important classes of macromolecule, carrying 
out many vital life processes. Proteins are biological polymers, made up of amino 
acid monomers .There are 20 such canonical α-amino acids which constitute the 
molecular building blocks of a protein (Voet and Voet, 2011). These amino acids 
are linked together by peptide bonds to form a polypeptide chain. The primary 
sequence contains all of the necessary chemical information to allow the protein 
to fold into its correct three-dimensional structure (Anfinsen et al., 1961; Anfinsen, 
1973). Structural collapse and burial of hydrophobic amino acid residues into the 
core of proteins, via the hydrophobic effect, makes this process 
thermodynamically favourable (Cheung et al., 2002; Fersht, 1999). 
It was originally thought that proteins fold along a linear pathway. But this is 
simplistic, especially considering the vast number of conformations available to a 
nascent polypeptide chain other than the correctly folded, native three-
dimensional structure. Levinthal proposed that no protein would be able to 
randomly sample these conformations to get to the desired structure on a 
biologically relevant timescale and that it must therefore be a guided search 
(Levinthal, 1968). As the protein folding field came into fruition, the ‘pathway’ idea 
(from unfolded to folded protein) evolved to that of an energy landscape (Anfinsen, 
1973; Englander and Mayne, 2014). Proteins fold energetically downhill, 
decreasing their conformational freedom in the process (Dill and Chan, 1997; 
Englander and Mayne, 2014). These two ideas are summarised in Figure 1.1. 
There is not necessarily one exclusive route through which a protein can fold to 
the native state; this can occur through various paths (Radford et al., 1992; 
Radford and Dobson, 1995). Any intermediate states on the pathway can have 
some secondary structure, but often lack the packed hydrophobic core of a 
properly folded protein. These partially structured intermediates have thus been 
described as ‘molten globules’ (Roder and Colón, 1997).  
These intermediate states present proteins with an additional problem; they are 
susceptible to being trapped in ‘off-pathway’ kinetic wells. These misfolded 
species are capable of self-associating in a process called aggregation (Dobson, 
2004; Jahn and Radford, 2008). Proteins are described as metastable entities, in 
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that there is a fine energetic balance between their native and structurally 
perturbed intermediate states. ΔGunfold is of the order of 20-60 kJ mol-1 for the 
unfolding of a protein from the native state (Fersht, 1999). 
 
Figure 1.1 Representation of a protein folding pathway (left) and 
‘folding funnel’ (right). On the folding pathway, the unfolded protein (U) 
must go through transition states (X‡). Any intermediates (I) may be trapped 
by kinetic barriers (red). Once these have been traversed, the protein can 
fold into the native structure (N), which has the lowest free energy (G). The 
folding funnel illustrates how some protein folding pathways have many 
more intermediate states and kinetic traps than others. This means one 
route may be much smoother than another going from the unfolded to the 
correctly folded native state (N). Figure adapted from Englander and Mayne, 
2014. 
The number of favourable intramolecular contacts within a protein increases as it 
folds from the unfolded to the native ground state (Fersht, 1999). But favourable 
intermolecular interactions can also form between proteins, allowing them to form 
complexes (Garcia-Seisdedos et al., 2017). Whilst protein oligomerisation can be 
functionally desirable with natively folded proteins as the substrates, it is generally 
deleterious to function if this occurs with unfolded or misfolded proteins (Jahn and 
Radford, 2008; Roberts, 2014; Williamson, 2012). An aggregate can thus be 
defined as any proteinaceous entity composed of two or more non-native protein 
monomers (Ratanji et al., 2014). The increased number of intermolecular, 
contacts (typically hydrophobic and van der Waals) which form between the 
proteins in an aggregate can make aggregation enthalpically favourable. This is 
especially true of ordered, fibrillar aggregates- amyloid fibrils (Jahn and Radford, 
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2008; Roberts, 2014; Voet and Voet, 2011). Amyloids are primarily characterised 
by their cross-β architecture, making them very stable (Chiti and Dobson, 2009; 
Roberts, 2014; Wei and Roberts, 2010). 
Aggregates can form either reversibly or irreversibly, depending on the protein in 
question and its environment (Mahler et al., 2009; Wang et al., 2010; Wang and 
Roberts, 2010). Aggregation pathways are generally described by long-standing 
models such as the Lumry-Eyring Nucleation Polymerisation (LENP) model 
(Andrews and Roberts, 2007; Li and Roberts, 2009; Lumry and Eyring, 1954). 
The exact pathway a protein traverses will once again depend on its physico-
chemical environment and the nature of the protein itself (Figure 1.2) (Roberts, 
2014). 
 
Figure 1.2. Schematic of a protein aggregation pathway. The association 
of natively folded monomers to form complexes can often be functionally 
desirable (A). Environmental perturbation (See Section 1.2.4) can lead to 
structural perturbation of the native protein, causing it to partially unfold (B). 
These partially unfolded species can then aggregate to form dimers (C) and 
trimers (D). These reversible association steps can continue in an ordered 
(E) or disordered fashion (E’). Ordered aggregates can eventually form 
(amyloid fibrils, F) or insoluble amorphous aggregates (G). These final 
species are formed irreversibly, representing the thermodynamic end-point 




Aggregation is thus a key problem faced by proteins. In vivo, cells use a variety 
of strategies to prevent this from happening to nascent proteins synthesised on 
the ribosome. A network of molecular chaperones (such as Hsp70 and Hsp90) 
bind to the exposed hydrophobic residues of folded and misfolded proteins to 
prevent their aggregation (Morán Luengo et al., 2018; Young et al., 2004). 
Chaperonins, such as GroEL, use the power of ATP to sequester unfolded 
proteins in vivo and assist their folding (Yan et al., 2018). Sometimes these 
mechanisms break down, leading to aggregation diseases  (Dobson, 2004; Jahn 
and Radford, 2008) or bacterial cell death (Khodaparast et al., 2018). However, 
how environmental stresses perturb proteins, as well as how proteins evade 
aggregation in vitro, remain key questions in the protein aggregation field. These 
questions will be posed time and again in this thesis. 
 
1.2 Introduction to biopharmaceuticals 
 
1.2.1 . Biological molecules as therapies: A revolution in 
modern medicine 
 
Small-molecule therapies, such as aspirin, have been used to treat diseases for 
in excess of 100 years (Sneader, 2000). However, as time and biochemical 
knowledge have progressed, larger biological molecules have been developed as 
therapeutic entities (Walsh, 2003). These therapies, commonly referred to as 
biologics or biopharmaceuticals, have been in existence in a modern guise for 
much less time than small molecules. The different modes of action afforded to 
biologics compared to their small-molecule counterparts make them 
therapeutically advantageous. Vaccines such as those against tuberculosis and 
tetanus are amongst the most common and powerful early biologics (Walsh, 
2003).  
Protein-based therapies have emerged as the dominant player in the biologics 
sphere (Aggarwal, 2014). Early examples include blood factors, e.g. Factor VIII 
(Schramm, 2014) and insulin (Zhou et al., 2016), initially derived from mammalian 
sources such as human blood donations or cattle pancreases, respectively. 
Animal-derived therapeutics pose obvious moral and ethical questions. The 
advent of recombinant DNA technology lead to the first recombinant human 
protein therapeutic, Humulin® (human insulin), being developed by Eli Lilly and 
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approved by the Food and Drug Administration (FDA) in 1982 (Sanlioglu et al., 
2013). Since this time, many other recombinant enzymes and proteins have been 
approved for therapeutic use in the 1980’s and beyond (Appendix 1 in (Walsh, 
2003)). The advantages and disadvantages of small-molecule drugs and 
biopharmaceuticals are summarised in Table 1.1. 
 
Table 1.1 A selection of some of the advantages and disadvantages of 
biopharmaceuticals compared to small-molecule drugs. Advantages are 
underlined in green, with disadvantages underlined in red. 
Small-molecule drug Biopharmaceutical 
Organic chemistry is 
an older and well-
established field 










Large size (10’s-100’s 
kDa) makes analysis 
complex 
Increased toxicity risk 
due to off-target 
interactions 
Off-target interactions 
less likely, leading to 
low toxicity 
Potential for weaker 
interaction strength 
with target 
Potent, highly specific 
binding to the target 
 
1.2.2 Monoclonal antibodies (mAbs): The dominant 
products in the biopharmaceutical arena 
 
Very recently, cell and gene therapies are emerging as the latest classes of 
biopharmaceutical being developed to treat individual patients with great success 
(Bajgain et al., 2018; Dunbar et al., 2018). However, the monoclonal antibody 
(mAb) has emerged as the most profitable and most important class of biologic 
over the last thirty years (Aggarwal, 2014), with over 74 approved to date and 
several hundred currently in clinical trials (Carter and Lazar, 2018; Strohl, 2018). 
Additionally, mAbs are also widely used as diagnostic reagents in biochemical 





Antibody structure and function 
 
Antibodies (Abs) are the immunoglobulin proteins used by the humoral immune 
system to bind to foreign macromolecular entities. These proteins feature 
immunoglobulin domains of ~110 residues, comprising a β-sheet rich 
Immunoglobulin (Ig) fold (Voet and Voet, 2011; Williamson, 2012). A conserved 
disulphide bridge ‘staples’ the two sheets of the Ig fold together (Huber et al., 
1976). The structure and topology of the Ig domain is shown in Figure 1.3.  
 
Figure 1.3. Topology diagram for a constant Ig domain. The four beta 
strands in dark blue comprise the inner sheet of the Ig domain, whilst those 
in light blue comprise the outer sheet. Black lines denote the loops 
connecting the strands. The blue and red lines at the end of strands A and G 
denote the N- and C-termini respectively. The orange line denotes the 
disulphide bond linkage. Adapted from (Spada et al., 1998). 
Abs are heterodimeric proteins comprising two heavy chains and two light chains 
(Schroeder et al., 2010). The light chains possess two Ig domains, whereas the 
heavy chains possess either four or five Ig domains (Schroeder et al., 2010; 
Williamson, 2012). 
Humans possess five different isotypes of antibody, which differ in terms of their 
type of heavy chain: IgM (950 kDa), IgA (360–720 kDa), IgE (190 kDa), IgD (160 
kDa) and IgG (150 kDa) (Schroeder et al., 2010; Voet and Voet, 2011). The IgG 
isotype dominates the biopharmaceutical sector, due to them possessing long 
half-lives in vivo (Schroeder et al., 2010). As such, IgGs will be the focus of the 





Figure 1.4. The structure of IgG1 molecules. Schematic (left): Each 
ellipse represents one β-sheet rich Ig domain. The heavy chains (dark 
turquoise) and light chains (light turquoise) are connected with disulphide 
bridges (orange). The heavy chains have three constant domains (CH1–3) 
whilst the light chains only possess one (CL1).   Two disulphide bridges 
connect the heavy chains together near the flexible hinge region (blue lines) 
of the molecule. The bottom half of the antibody represents the crystallisable 
fragment (Fc), whereas the top half of the molecule is the antigen binding 
fragment (Fab). Three hypervariable loops are responsible for antigen 
binding in each of the two variable domains (VH and VL for variable heavy 
and light respectively) at the top of the molecule. Crystal structure (right): 
The crystal structure of an IgG1, colour-coded as in the schematic. CDRs in 
the variable domains are coloured in red and pink (VH and VL) respectively. 
N-linked glycans are coloured in green. Schematic adapted from (Buss et 
al., 2012). Crystal structure from (Saphire et al., 2001).  
The variable regions of an antibody bind to their target antigens which reside at 
the top of the antigen binding Fab region (Figure 1.2). The motif recognised by 
the antibody is called the epitope, whilst the binding interface on the antibody is 
called the paratope (Feige and Buchner, 2014; Schroeder et al., 2010). 
Computational analysis of antibody paratopes have shown they are enriched in 
aromatic amino acids (Tyr, Phe and Trp), in addition to short-chain hydrophilic 
amino acids (Ser, Thr, Asn, Asp and Gly) (Peng et al., 2014). These residues help 
drive the specificity and high affinity of mAbs to their targets. The loops which 
afford antibodies their binding ability are known as complementarity-determining 
regions (CDRs) (Tiller and Tessier, 2015). 
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The hinge and Fc regions can also play important roles in the antibody’s function. 
The hinge region affords an IgG conformational flexibility. IgGs can be further 
categorised into different subclasses (Vidarsson et al., 2014). These subclasses 
are IgG1, IgG2, IgG3 and IgG4. They have various structural differences which 
affect their function in vivo: their hinge regions can be of varying length (IgG3’s 
have hinges four or five times the length of the other classes’); the number of 
disulphides connecting the heavy chains can differ (IgG1 and IgG4 = 2, IgG2 = 4 
and IgG3s = 11) and their so-called effector functions, mediated through the Fc 
region, can differ widely (Buss et al., 2012; Vidarsson et al., 2014). 
The Fc region contains a conserved Asn297 residue in the CH2 domain, which is 
glycosylated in all IgGs (Vidarsson et al., 2014). The glycan greatly impacts the 
conformation of an IgG (Krapp et al., 2003; Zhang, 2015), affecting not only Fc 
receptor binding (Lin et al., 2015) but also the thermal stability of the mAb as a 
whole (Zheng et al., 2011). 
Cells possess several different receptors capable of binding to the Fc region 
(Wang et al., 2008). FcRn binding is important in maintaining the long half-lives of 
IgGs in vivo, as FcRn binding ‘recycles’ mAbs inside cells (Wang et al., 2008). 
Other receptors give IgGs ‘effector function’. Interaction with the Fcγ receptor can 
trigger antibody-dependent cellular cytotoxicity (ADCC) (Buss et al., 2012). mAbs 
can also activate the complement system through binding to the C1q receptor 
(Buss et al., 2012; Williamson, 2012). This ultimately results in death of the target 
cell (Carter and Lazar, 2018). IgG1 and IgG3 mAbs are far better at activating 
these latter mechanisms than IgG2 and IgG4s, thus one can tailor the isotype of 
the mAb to suit the desired mechanism of action (MoA) (Buss et al., 2012; Carter 
and Lazar, 2018). This wide diversity also explains why mAbs are so common in 
the biopharmaceutical arena. 
New mAb modalities 
 
A mAb in its conventional form is not the only type of antibody therapeutic in 
development or even on the market (Aggarwal, 2014; Carter and Lazar, 2018; 
Elgundi et al., 2017; Rodgers and Chou, 2016). The discovery that camelids 
(camels, llamas, alpacas etc.) produce antibodies which lack a light chain in 1993 
(Hamers-Casterman et al., 1993) has led to their increasing use as research tools 
(Hu et al., 2017) and potential therapeutics (Peyvandi et al., 2016). These 
‘nanobodies’ (Nbs) are much smaller than their mAb counterparts, consisting of 
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just one variable domain, giving them high levels of tissue penetration (Hu et al., 
2017). Other antibody fragment molecules have been constructed, including 
single-chain variable fragments (scFvs) (Weisser and Hall, 2009), as well as just 
the Fab fragments (if Fc function is unnecessary) (Kennedy et al., 2017). scFvs 
consist of one VH and VL domain connected together with a short GS-linker 
(Weisser and Hall, 2009). Fab fragments can exist as either monomers or as a 
Fab’ dimer (i.e. a full-length mAb minus the Fc region) (Kennedy et al., 2017). Fc 
fusion proteins have also been generated, whereby proteins or peptides are fused 
to an antibody Fc to extend the in vivo half-life of the former molecule. Etanercept 
is the most prominent example of an Fc-fusion, with this Tumour Necrosis Factor 
(TNF)-α inhibitor having 2016 sales exceeding $8.9 bn (Strohl, 2018).  
Advances in protein engineering have allowed biotechnologists to construct 
various novel modalities from antibody fragments to increase the functionality of 
the final molecule. For example, two different binding specificities can be exhibited 
by bi-specific antibodies (bsAbs). This can involve swapping the chains of two 
individual mAbs to create a hybrid, or the conjugation of antibody fragments onto 
a full-length mAb (Chiu and Gilliland, 2016; Kontermann and Brinkmann, 2015; 
Tiller and Tessier, 2015). These multi-functional molecules are finding promise in 
treating various cancers (Ayyar et al., 2016). A detailed description of the 
numerous methods employed to engineer these chimeric molecules is beyond the 
scope of this introduction. One method of note though is the ‘knobs-into-holes’ 
methodology. Here, mutations are introduced into the CH3 domains of each heavy 
chain, yielding a ‘knob’ in one chain’s CH3 domain and a ‘hole’ in the other.  
Additional disulphide engineering makes the heterodimerisation step efficient 
(Merchant et al., 1998). The Ab fragments and bsAbs discussed above are 




Figure 1.5. Antibody fragments and a ‘knobs-into-holes’ bispecific 
antibody (bsAb). The nanobody (Nb) is the smallest antibody-based fragment, 
consisting of just one Ig domain derived from camelids. Structure = PDB 1MEL 
(Desmyter et al., 1996). Single-chain variable fragments (scFvs) typically consist 
of a variable heavy and light chain tethered together with a flexible glycine-
serine linker. Sometimes, Fabs possess enough desired functionality to be used 
in isolation. Functional peptides (red curves) or proteins can be conjugated to Fc 
domains as an Fc-fusion. Finally, bi-specific antibodies generated using the 
‘knobs-into-holes’ method have two completely different halves, thus these 
molecules can bind to two different antigens. Adapted from Strohl, 2018. 
Antibody-drug conjugates (ADCs) are another major family of antibody-based 
biopharmaceuticals. These molecules exploit the high specificity of the antibody 
to its target to deliver a drug ‘payload’ to the required site (Ducry, 2012; Kennedy 
et al., 2017; Tiller and Tessier, 2015). Often, the conjugated drugs are highly 
potent cytotoxic agents. In isolation, off-target interactions with the drug would 
lead to side-effects being observed in patients, which are greatly reduced when 
administered as an ADC (de Goeij and Lambert, 2016). Three ADCs have been 
approved to date, with many more in development (Kennedy et al., 2017; Mullard, 
2018). ADCs have three key components: the cytotoxic drug, a conjugating linker 




Figure 1.6. Schematic of the antibody-drug conjugate (ADC) Kadcyla® 
(Ado-Trastuzumab emtansine). Trastuzumab (Herceptin®) targets HER2 
positive breast cancer cells. The conjugation of the microtubule-inhibiting drug 
entansine via a stable maleimide thioester linkage. Multiple copies of the drug 
conjugate to the mAb. The mAb and drug are not drawn to scale. Structure 
adapted from Elgundi, 2016. 
The large number of lysine residues adorning the surface of antibodies allows one 
to conjugate drugs to these sites, as has been done for Kadcyla® (Akkapeddi et 
al., 2016). However, optimising the conjugation conditions to obtain the correct 
drug:antibody ratio (DAR) is a key consideration in the development of ADCs 
(Ducry, 2012). Cysteine residues are often used as well, either by reducing the 
intact Ab (Doronina et al., 2003) or by introducing them through engineering 
(Junutula et al., 2008). There is however a risk of forming disulphide-linked 
aggregates during the conjugation step, or scrambling the disulphides in the Ab 
(Chudasama et al., 2016) More site-specific conjugation strategies are being 
developed to obviate these issues (Akkapeddi et al., 2016). The chemistry of the 
linker is critical, as chemically labile linkers would be cleaved prematurely in the 
blood stream. This could lead to premature release of the drug, causing toxic side-
effects (Kennedy et al., 2017). Some linkers are designed to be cleaved in vivo 
following targeting to the lysosome (Erickson et al., 2006). Kadcyla®, for example, 
features a non-cleavable linker, which increases the stability of the molecule 
(Chen et al., 2016). 
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In summary, the affinity of antibody-based molecules to their targets, as well as 
the wide number of functionalities that can be incorporated into them accounts for 
their dominance in the biopharmaceutical market.   
 
1.2.3 Biochemical engineering: Selection, expression, 
purification and formulation of therapeutic antibodies 
 
In order for a candidate therapeutic protein to become a finished, marketed 
product, various steps must be traversed. This can be summarised by a drug 
development pipeline (DiMasi et al., 2016; Walsh, 2003), as shown in Figure 1.7. 
In the early stages of the pipeline, drug targets are identified and lead compounds 
are discovered (Walsh, 2003). Following optimisation of these compounds, pre-
clinical studies are performed on animal models, before licenses are sought to 
begin clinical trials in humans (Plenge, 2016; Walsh, 2003). 
Clinical trials are generally broken down into four stages (Piantadosi, 2017; 
Walsh, 2003): Phase I (20–100 patients), where doses are adjusted to find the 
safest levels; Phase II (100–300 patients), where the safety, activity and efficacy 
at a set dose is assessed; Phase III (1000–3000 patients), where the new 
treatment is compared to alternatives or placebos to really assess the impact the 
medicine will have compared to those already on the market and Phase IV (Post-
marketing), where patients taking the approved medicine are monitored. Phase 











Figure 1.7. An overview of the drug discovery pipeline. Basic research 
identifies the culprits of disease, which are to be targeted by drugs. Lead 
compounds are identified which interact with the target in a desirable fashion. 
After optimisation, toxicity studies are performed in animal models, before the 
material is tested in humans. During clinical trials, dosing regimens, toxicity and 
efficacy are monitored in carefully chosen patient groups. Trials often start with 
small groups (tens of patients) before growing to involve hundreds to thousands 
of patients. If efficacious and safe, a licensing application is made to a regulatory 
body, such as the US Food and Drug Administration (FDA) or the European 
Medicines Agency (EMA). The whole process can take 10–15 years and cost 
billions of dollars. Adapted from (DiMasi et al., 2016; Walsh, 2003) 
As this thesis focusses on therapeutic antibodies, the discovery, manufacture and 
delivery of this class of proteins will be discussed in the remainder of this section. 
Antibody discovery 
 
In vivo, B-cells produce antibodies against antigens detected by the humoral 
immune system. However, billions of different B-cells are necessary to produce 
the many different antibodies (estimated at 1010–1012) found in humans (Elgundi 
et al., 2017; Williamson, 2012). These polyclonal antibodies would not generally 
be desirable as drug products. The revolutionary work of Köhler and Milstein in 
1975 developed monoclonal antibodies using mouse hybridoma technology 
(Köhler and Milstein, 1975). This technique is summarised in Figure 1.8. Briefly, 
it involves the fusion of mutant mouse myeloma cells with spleen cells from a 
mouse immunised against an antigen X. Selection for ‘hybridoma’ cells leads to 
proliferation of cells producing the antibody against the antigen X (Brekke and 
Sandlie, 2003). This swiftly led to the approval of the first monoclonal antibody 
therapy, Orthoclone OKT3 in 1986, a murine mAb which prevents kidney organ 
transplant rejection (Rodgers and Chou, 2016). However, the murine lineage of 
the mAbs derived in this fashion meant immunogenic effects were sometimes 
observed in patients (Kuypers and Vanrenterghem, 2004). Consequently, gene 
technologies were developed to ‘humanise’ mAbs by adding mouse variable 
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domains into a human mAb scaffold to make a chimeric mAb (Morrison et al., 
1984) or humanise all of the scaffold except the CDRs by grafting in the mouse 
CDRs (Jones et al., 1986). Alternatively, genetically engineered mice can be used 
to produce fully human IgGs (Lonberg et al., 1994). 
 
Figure 1.8. Overview of mouse hybridoma technology. i) A murine myeloma 
cell line is generated. ii) These cells are fused with mouse spleen lymphocytes 
(B-cells) following immunisation against a desired antigen (target). iii) The 
myeloma cells lack the ability to grow on HAT medium, thus only those which 
successfully fuse with the murine spleen cells will survive to form a hybridoma. 
iv) B-cells usually do not survive for long when cultured in vivo unlike the 
hybridomas, which readily produce antibodies against the desired antigen. 
Screening the clones to identify those producing the murine mAb allows one to 
grow these cells at scale to make the product. Murine mAbs (pink) can cause 
immunogenic effects in humans, hence engineering strategies have been 
developed to make chimeric or humanised mAbs (purple = human sequence). 




The other key breakthrough that enabled the development of fully human mAbs 
was phage display technology (Rodgers and Chou, 2016; Winter et al., 1994). 
Briefly, this involves the expression of human VH and VL genes on bacteriophage 
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coat proteins, e.g. pIII (Smith, 1985) . Such fusions do not affect the infectivity of 
the phage, which readily displays the protein of interest on its surface. Importantly, 
this technology avoids the use of immunisation or hybridoma technology, reducing 
the ethical concerns associated with antibody technologies (Marks et al., 1991). 
The great ‘success story’ to emerge from phage display was the approval of 
adalimumab (Humira®) in 2002. This phage display-derived mAb is used in the 
treatment of chronic inflammation and had 2017 sales exceeding $18bn, making 
it the most valuable drug in terms of sales in the world (Urquhart, 2018). How 
these filamentous phages are used to select for paratopes with high affinity for 
their epitopes is summarised in Figure 1.9. 
 
Figure 1.9. Overview of phage display technology.  i) Desired variable heavy 
and light chain sequences are selected. ii) These sequences are cloned into 
plasmids, transformed into bacteria and expressed. iii) Infection with filamentous 
phage results in expression of the scFv of interest on the phage’s coat protein. 
iv) Immobilisation of the antigen of interest and panning with the phages allows 
one to rapidly screen for binding, eliminating non-binders. v) E. coli are re-
infected to allow the binding phage DNA to be isolated and identified. Repeating 
the cycle increases the affinity for the target. Adapted from Brekke and Sandlie, 
2003; Clark, 2006.  
Another development to increase the throughput and identification of potent 
human mAbs was yeast display technology (Feldhaus et al., 2003). Briefly, this 
involves the generation of a scFv library, which is incorporated into yeast, which 
express the scFv on their surface. One can then use flow cytometry-based 
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methods to sort and enrich binders from non-binders (Chao et al., 2006). Yeast 
display offers a further advantage in that Saccharomyces cerevisiae is a 
eukaryote. This means human scFv fragments will go through the same ER-
trafficking pathways as occurs in the body, thus the folding and processing of 
these proteins is highly suited to this system (Elgundi et al., 2017). This 
technology is summarised in Figure 1.10 and Appendix Figure 1. 
 
Figure 1.10. Overview of yeast display technology. i) The scFv sequence of 
interest (from a library) is expressed on the surface of yeast as a fusion protein 
(Appendix Figure 1). ii) The antigen of interest is conjugated to magnetic beads. 
iii) Incubation with the yeast allows one to pull out and expand binding cells 
using magnetism-assisted cell sorting (MACS). iv) The antigen of interest is 
conjugated to a fluorophore. v) Cells which bind the antigen are sorted and 
expanded using fluorescence-assisted cell sorting (FACS). This can be repeated 
with a mutagenized library to increase the affinity for the antigen. vi) Individual 
clones are sequenced, with the affinity of the scFv: antigen complex determined. 
Adapted from Boder et al, 2012; Chao et al, 2006. 
 
Finally, in vitro ribosome display has also emerged as a novel antibody discovery 
strategy (Hanes et al., 2000; Zahnd et al., 2007). This technique can screen very 
large (1013 clones>) libraries of scFvs in an entirely in vitro fashion, negating the 
need to use microbes or animals (Elgundi et al., 2017). This technique is 




Figure 1.11. Overview of ribosome display. i and ii) The scFv library is 
prepared and cloned into the ribosome display plasmid. iii) The Polymerase 
Chain Reaction (PCR) amplifies the amount of plasmid DNA. iv) The insert is 
transcribed in vitro to yield the mRNA (green line). v) The mRNA is translated in 
vitro, but stalls on the ribosome due to a lack of stop codon. vi) The lack of stop 
codon also means the mRNA-ribosome-protein complex remains intact. This 
complex is screened against immobilised antigen as in phage display (Figure 
1.8). vii) Binding complexes are dissociated, then reverse transcription PCR 
performed on the mRNA. viii) This generates successful binding sequences 
which can be modified to increase target affinity in another round of display. ix) 
Desirable sequences can then be clones into E. coli vectors for expression and 
characterisation. Adapted from Hanes et al. 2000; Zahnd et al, 2007. 
Once candidate sequences are identified that bind to the target using any of the 
technologies above, one or more rounds of affinity maturation are then performed. 
This essentially exploits the error-prone PCR used to make the highly diverse 
sequence library to try and increase the binding affinity of the scFvs, selected by 
e.g. phage/ribosome display, for their targets (Chiu and Gilliland, 2016; Groves 
and Nickson, 2012). Typically, the long-loop VH CDR3 is mutated, as this often 
has the biggest impact on a mAb’s affinity for its antigen, in addition to limiting the 
number of mutated sequences one needs to generate (Yang et al., 1995). Once 
potent, human or humanised mAbs have been identified, the drug development 
process can really begin, allowing companies to focus on producing ever larger 
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quantities of the molecule of interest as the pipeline progresses. This will be 
discussed in the following sections. 
Mammalian cells for mAb expression 
 
Being multi-domain proteins with numerous post-translational modifications (such 
as glycosylation), full-length monoclonal antibodies are generally produced in 
mammalian expression systems (Elgundi et al., 2017; Spadiut et al., 2014). Of all 
of the cell systems available, the Human Embryonic Kidney 293 (HEK-293) cell 
line is typically used to transiently express mAbs at the research scale (Russell et 
al., 1977; Vink et al., 2014). Conversely, the Chinese Hamster Ovary (CHO) cell 
has become the ‘workhorse’ of the biopharmaceutical industry in terms of being a 
production cell line (Birch and Racher, 2006; Jayapal et al., 2007; Walsh, 2003). 
The plasmids used to code for the protein of interest, together with their selectable 
markers and promoter sequences, is usually transfected into the cells using 
electroporation or using cationic lipids to facilitate DNA entry into the target cells 
(Li et al., 2010). Ideally the cell line of interest will: be transfected efficiently; be 
easy to screen for transfection (e.g. using methotrexate if the cell line is usually 
deficient in dihydrofolate reductase (DHFR), with the gene for the latter enzyme 
present in the plasmid bearing the protein of interest) and produce high titres of 
quality recombinant protein (Birch and Racher, 2006). 
Once the cell line has been selected, it must be made into a cell bank, which is 
usually thawed, expanded in small-scale cell culture and the inoculum expanded 
before the cells enter a large-scale bioreactor (Fieder et al., 2005; Shukla and 
Thömmes, 2010). 
 
Bioprocessing: From bioreactor to purified mAb 
 
Monoclonal antibody production is described as a ‘platform process’- largely all 
products of this type are produced in a very similar fashion (the ‘platform’). A 
typical mAb production process is shown in Figure 1.12, with each of the individual 





Figure 1.12. Schematic of a typical mAb manufacturing process. Many 
inoculum steps are necessary to have the desired cell density to begin large 
scale fermentation and over-expression of the product of interest. Cells are 
usually separated from product during centrifugation and depth filtration (silver 
and light orange arrows). The clarified feed stock is then loaded onto a Protein A 
column to capture the mAb product. Elution of the product at low pH can be 
beneficial for virus inactivation (dark green arrows). Polishing steps using ion-
exchange chromatography (IEX) allow any residual impurities to be removed 
prior to nanofiltration/virus filtration (light green arrows). Ultra-/dia-filtration 
concentrates the product and buffer-exchanges it into the desired formulation 
buffer. This may be frozen for use at a later stage, or the product put into vials 
(light purple arrow). The product can then be transported (dark purple arrow) to 
hospitals/pharmacies ahead of administration to the patient. Adapted from 
Shukla and Thömmes, 2010. 
 
Following the inoculum steps, cells are grown in a production-scale bioreactor. 
For some mAb products, this can take place at 20,000 L scale (Birch and Racher, 
2006). The bioreactor design is critical to the survival of the cells (Nienow, 2006). 
Probes are often built in to monitor pH, temperature and dissolved oxygen (DO) 
content. Various feed lines can maintain these parameters should they change 
during production (Nienow, 2006). The turbines/impellers used to keep the cells 
in suspension and the medium mixed are often of a ‘marine’ design to minimise 
potential damage to mammalian cells (see Section 1.4.2) (Varley and Birch, 
1999). These systems grow cells in disposable bags, with advantages being 
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reduced infrastructure costs and cleaning times compared with stainless steel 
bioreactors (Rogge et al., 2015).   In modern production, components of the cell 
medium are usually chemically defined, as the traceability and uniformity of the 
medium exceeds that of serum-derived media (Birch and Racher, 2006). 
Furthermore, there are fewer ethical implications for the product as compared to 
when animal-derived media is used (Li et al., 2010).  An emerging trend in 
upstream processing (USP) is the use of single-use bioreactors for smaller scale 
(e.g. 2000 L) cultures (Challener, 2017). A typical cell culture at scale takes ~15 
days, with the batch often being ‘fed’ during the stationary phase to increase the 
titre of product (Li et al., 2010). Modern production cell lines can produce several 
g L-1 of mAb product (Azevedo et al., 2009). 
Following these USP steps, the product must be separated away from any 
contaminants and cell components during downstream processing (DSP). DSP is 
often thought to be the bottleneck of bioprocessing, especially given the ever 
larger titres of mAb produced from USP (Capela et al., 2017; Kelley, 2009). The 
initial clarification steps are usually referred to as primary recovery steps (Shukla 
and Thömmes, 2010). Typically, centrifugation is used to remove the cells away 
from the product. The centrifuge is typically of a disk-stack design, which 
minimises the drying of the product, as well as the subjection of cells and product 
to overly harsh flow conditions (see Section 1.4.2) (Hutchinson et al., 2006). A 
depth filter of reasonable porosity (> 0.2 μm)  is used to provide yet more 
clarification of the feed stream (van Reis and Zydney, 2007). Care must be taken 
during processing to avoid the formation of a so-called ‘filter cake’; fouling and 
clogging of the membrane which slows the transition of the feed stream through 
the bioprocessing pipeline (Goldrick et al., 2017). 
The defined structures of antibodies can be exploited to purify them from solution. 
Protein A chromatography has emerged as the key capture step in mAb 
purification (Gagnon, 2012). Protein A is a ~45 kDa virulence factor produced by 
Staphylococcus aureus which predominantly binds to the Fcs of IgGs in vivo 
(Palmqvist et al., 2002). This protein is usually produced recombinantly in high 
quantity, chemically bound to chromatographic resins and packed into a column. 
At high production scale, Protein A columns can be over a metre in diameter 
(Wang and Mann, 2009). The true price of Protein A resin is estimated to cost ~ 
€10,000 L-1 (Franzreb et al., 2014). The ubiquitous nature of Protein A 
chromatography, in addition to many technological improvements in Protein A 
resin, mean it is likely to continue to dominate mAb capture in the future (Dransart 
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et al., 2018). mAbs are usually eluted from Protein A resin by decreasing the pH. 
Whilst this may adversely impact product quality (see Section 1.2.4), this does aid 
the inactivation of any viruses present in the feed. A viral hold tank may therefore 
appear at this stage of the bioprocess (Mazzer et al., 2015; Shukla and Thömmes, 
2010). 
Following Protein A chromatography, polishing steps are necessary to remove 
any residual contaminants, such as DNA, viruses, medium components and host 
cell proteins (HCPs) from the process feed (Shukla and Thömmes, 2010). 
Typically, anion/cation exchange or hydrophobic interaction (HIC) 
chromatography are used for this purpose (Capela et al., 2017). Membrane 
chromatography has been developed for this purpose, as the faster flow-through 
compared to traditional column chromatography can help accelerate the 
purification of the mAb product (van Reis and Zydney, 2007). A virus filtration step 
(pore size of ~ 20 nm) will remove any viruses that have not been cleared by the 
previous unit operations (van Reis and Zydney, 2007; Shukla and Thömmes, 
2010). 
Once the product is purified, it can be buffer exchanged into its fill/finish or 
formulation buffer. This is usually done using an ultrafiltration/diafiltration (UF/DF) 
step, with the flow set-up in a tangential flow arrangement as opposed to dead-
end (Figure 1.12). This step is crucial, as many mAb-based products have to be 
delivered into patients at high concentrations (50–150 mg mL-1) (Baek and 
Zydney, 2018; Elgundi et al., 2017; Eschbach and Vermant, 2008). The product 
then undergoes filling and finishing. This could be into vials/ pre-filled syringes for 
clinical/home administration (Mitragotri et al., 2014; Wang, 1999) or lyophilisation 
(freeze-drying), often at a dedicated facility, to be reconstituted before 
administration to the patient (Vollrath et al., 2018). The transportation of the 
finished drug product can be very important, as will be discussed in Section 1.2.4 
Formulation and delivery of therapeutic monoclonal antibodies 
 
The components of a biopharmaceutical formulation are very important for both 
the colloidal and kinetic stability of the product, as well as its pharmacokinetics 
(Wang, 2015). The need for an aqueous environment to maintain the correct 
three-dimensional structure of a protein means that therapeutic mAbs are 
formulated as liquids, except where lyophilised. Oral delivery of a mAb would lead 
to proteolysis of the drug in the stomach, hence mAb-based products are 
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generally delivered intravenously or through sub-cutaneous injection into the 
patient (Wang et al., 2008). Intravenous delivery requires patient hospitalisation, 
which increases the cost of treatment and inconveniences the patient (Snelling, 
2008). Biopharmaceutical companies have thus sought to move towards 
subcutaneous administration of mAbs in recent years (Eisenstein, 2011; Wang, 
2015). Whilst this means that the product can be administered by the patients 
themselves (or with the assistance of a district healthcare worker) in their own 
home (Snelling, 2008), the product has to be kept stable in solution at 4°C for up 
to two years (Randolph and Carpenter, 2007). Furthermore, pre-filled syringe 
devices have had to be developed to facilitate injection of the drug into the patient 
(minimising both the length of time needed for delivery and pain) (Mitragotri et al., 
2014). 
This formulation challenge has been a big issue for the biopharmaceutical 
industry. However, common buffer components and excipients have been 
identified to allow mAb products to be administered in this fashion. These typically 
include amino acids such as histidine and arginine, polyols such as trehalose and 
mannose and surfactants such as polysorbate (Tween®) 20 and 80 (Daugherty 
and Mrsny, 2006; Wang, 1999; Zbacnik et al., 2017).  
In summary, the manufacture of therapeutic antibodies, from identification of 
mAbs which bind tightly to the desired target in-vitro, to the final formulated 
product is a complex process. Factors which adversely affect the molecule 
(efficacy and safety) form the subject of the next section. 
 
 
1.2.4 ‘The aggregation problem’ in the 
biopharmaceutical industry  
 
Once administered into a patient, therapeutic antibodies will seek their target, 
typically an extracellular membrane protein or a secreted protein present in the 
blood (Rodgers and Chou, 2016). Any contaminants present in the product will 
also be injected into the patient. Whilst these may be benign, it is well documented 
that adverse reactions can be a consequence in patients, with severity ranging 
from intolerance to the medicine to anaphylaxis and death (Büttel et al., 2011; 
Moussa et al., 2016; Rosenberg, 2006; Wang et al., 2012). Gradual intolerance 
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and/or resistance of these expensive medicines, whilst not life-threatening, 
increases the gap between the cost of the drug and its benefit in patients. For 
example, Humira® patients can form anti-drug antibodies to adalimumab which 
neutralise the latter’s therapeutic effect (Van Schouwenburg et al., 2014). The risk 
aggregates pose to patient safety and drug efficacy means their levels are 
monitored closely by the drug regulators such as the US FDA, e.g. US 
Pharmacopeia (788) for injectable drugs (Pharmacopeia). Typically, aggregate 
levels are kept below 5% of the total protein content, though no ‘defined’ level is 
set by the regulator (Mahler et al., 2009; van Reis and Zydney, 2007). 
Aggregation can occur at any point in a biopharmaceutical’s lifetime (Cromwell et 
al., 2006). Some antibodies can begin to show signs of aggregation when 
expressed at low level (1–10 mg) in HEK cells  early on in development (see 
Figure 1.6) (Dobson et al., 2016). This could be due to inherently aggregation-
prone sequences within the protein of interest (Meric et al., 2017) (see Section 
1.3.1). It is of great industrial importance to identify rapidly mAb candidates which 
display aggregation propensity early on in development, as this decreases the 
likelihood of encountering problems later down the development pipeline (Jain et 
al., 2017). 
For a mAb to enter clinical trials, larger quantities of material are needed. This is 
when bioprocessing itself can induce aggregation in certain mAbs. Aggregation 
can take place during cell culture for a variety of reasons, including: over-
expression of large quantities (5–10 g L-1) of protein, which will stress the cells’ 
protein quality control machinery (chaperones, chaperonins etc.) (Powers and 
Balch, 2013); changes in pH and temperature in the bioreactor which could induce 
aggregation in certain proteins (Jing et al., 2012), extractables and leachables 
from the plastics found in single-use bioreactors (BPSA Extractables and 
Leachables Subcommittee, 2007) and stirring in the bioreactor (see Section 1.4). 
Aggregation at this early stage decreases the amount of material that can be 
purified downstream. 
Aggregation could also occur during downstream processing, due to: pH and ionic 
strength changes encountered during chromatography (Cromwell et al., 2006; 
Mazzer et al., 2015; Wang, 1999); interactions between the protein and stainless 
steel surfaces inducing aggregation (Bee et al., 2010); adsorption of hydrophobic 
mAbs and aggregates at air-water interfaces (Bee et al., 2012; Koepf et al., 2018) 
and adverse interactions/fouling of membranes (van Reis and Zydney, 2007). 
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Aggregates which form during DSP could render a drug ‘unmanufacturable’, 
halting its development (Kola and Landis, 2004). 
At the formulation stage, many strategies are employed to mitigate aggregation 
of the product and to afford the drug a long shelf-life (see Section 1.2.3). Arginine 
is a commonly employed excipient in biopharmaceuticals, as this amino acid is 
thought to block hydrophobic interactions between mAbs with its aliphatic side 
chain and interact electrostatically with side-chains on the mAb via its charged 
termini and guanidinium R-group (Baynes et al., 2005; Kim et al., 2016). 
Surfactants such as Polysorbate 20 and 80 are often used to compete with 
therapeutic proteins for the potentially damaging air-water interfaces that are 
encountered throughout manufacture, storage and administration (Agarkhed et 
al., 2017; Bee et al., 2011; Koepf et al., 2018; Zheng et al., 2017). For example, 
these damaging interfaces can also be formed when the product undergoes 
freeze-thaw (Hawe et al., 2009) or upon reconstitution from a lyophilised powder 
(Mahler et al., 2009). These protective excipients can breakdown in the presence 
of UV light, with the resulting products causing damaging effects such as oxidation 
and cleavage of the mAb (Kerwin, 2008; Kim et al., 2016; Mahler et al., 2009; 
Tamizi and Jouyban, 2016). As well as oxidation, deamidation is a particularly 
challenging problem for formulated mAbs, potentially leading to reduced activity 
and increased levels of aggregation (Daugherty and Mrsny, 2006; Phillips et al., 
2017; Tamizi and Jouyban, 2016). 
The formulated mAb is usually filled into vials or pre-filled syringes. In this fill-finish 
operation, the harsh hydrodynamic stress imparted onto the drug product may 
influence its aggregation (Section 1.4) – this is particularly concerning as the 
biopharmaceutical does not undergo any further purification after this stage 
(Cromwell et al., 2006). The drug product must then be transported before being 
administered/dispensed to a patient. The storage conditions and hydrodynamic 
forces generated during transport may all influence the aggregation of the 
product. This is very difficult to control from outside the manufacturing 
environment (Fleischman et al., 2017).  
One of the final hurdles to overcome for the development of a commercially 
successful antibody-based biopharmaceutical is the injection into patients at high 
concentration (>50 mg mL-1). If delivered subcutaneously, the product is usually 
supplied as a pre-filled syringe (Eisenstein, 2011), with the barrel lubricated with 
silicone oil (Bee et al., 2011). There is a growing body of literature to suggest that 
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silicone oil may influence the aggregation, and subsequent immunogenicity of 
biopharmaceuticals, led by Carpenter, Randolph and colleagues (Chisholm et al., 
2015; Gerhardt et al., 2015; Teska et al., 2016). The high concentration of the 
product may increase its viscosity, making injection into the patient slow and 
potentially painful (Mitragotri et al., 2014). Methods of improving and predicting 
the ‘syringeability’ of biopharmaceuticals in on-going, but complex (see Sections 
1.3 and 1.4) (Baek and Zydney, 2018). All of these potential stresses, which could 
induce the aggregation of a mAb-based biopharmaceutical, are summarised in 
Figure 1.13. 
 
Figure 1.13. Potential inducers of mAb aggregation. The stresses mAbs 
encounter are physical, chemical and mechanical in nature. How mAbs respond 
to these stresses is sequence dependent. 
With aggregation being a concern throughout a biologic’s lifetime, regulatory 
bodies have sought to force biopharmaceutical companies to minimise such 
issues through the ‘Quality by Design’ (QbD) framework. This was implemented 
by the International Council for Harmonisation (ICH), comprising a group of the 
world’s largest drug regulators in an attempt to standardise their expectations 
regarding drug safety. QbD can be defines as “a systematic approach to 
development that begins with predefined objectives and emphasises product and 
process understanding and process control, based on sound science and quality 
risk management” (ICH, 2009). This essentially means engineering ‘quality’ into 
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the process of making a drug, to achieve the desired Target Product Profile (TPP). 
The TPP includes criteria such as maximal levels of aggregate in the final drug 
product, glycosylation pattern, potency etc.  Deviations from the TPP may hinder 
the ‘developability’ of a mAb. Developability can be broken down into 
‘manufacturability’ (the ease of making the product in the manner discussed in 
Section 1.2.3), safety (the specificity for the target in a patient and a lack of side-
effects) and activity (the pharmacodynamics and kinetics of the drug) (Zurdo et 
al., 2015). Aggregation can clearly impact the developability of a 
biopharmaceutical. Computational and experimental methods are thus employed 
to respectively predict and characterise aggregation. These methods form the 
subject of the next section. 
 
1.2. Techniques used to study biopharmaceutical 
aggregation 
 
1.3.1 In silico predictors of aggregation-prone regions 
 
Hydrophobic amino acids are usually buried in the core of a protein when it folds 
(Williamson, 2012). Partial unfolding of a protein, instigated by the various 
stresses biopharmaceuticals encounter (see Figure 1.12) can expose these 
usually buried hydrophobic patches to the solvent. These regions can then self-
associate, i.e. the protein can aggregate (Roberts, 2014). Regions within proteins 
that have been predicted and experimentally verified to self-associate are called 
aggregation-prone regions (APRs) (Fernandez-Escamilla et al., 2004; Meric et al., 
2017). An APR can be defined as a region of a protein 5–15 amino acids in length, 
typically hydrophobic in character, that often forms aggregates rich in β-content 
(Ganesan et al., 2016; Khodaparast et al., 2018; Meric et al., 2017). 
Various APR prediction algorithms exist, all with distinct caveats and 
assumptions. A comprehensive review of all of them is beyond the scope of this 
thesis. The algorithms can generally be divided into those which analyse just the 
primary sequence of the protein (termed ‘intrinsic’) and those which map any 
APRs onto a structure of the protein in question (termed ‘structure-corrected’). 
Many APR predictors were developed using proteins/peptides which either form 
amyloid or β-rich aggregates (Meric et al., 2017). One of the best characterised is 
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the TANGO algorithm (Fernandez-Escamilla et al., 2004). This statistical 
mechanics algorithm uses the physicochemical properties of an amino acid 
stretch (five residues), its hydrophobicity, charge at a particular pH etc. and 
computationally determines what conformations this residue could occupy in an 
aggregate. Those with a β-sheet propensity ‘TANGO’ score above 5% were found 
experimentally to be more amyloidogenic, i.e. more aggregation-prone than those 
below the threshold (Fernandez-Escamilla et al., 2004).  
TANGO has recently been paired with the FoldX force field (Schymkowitz et al., 
2005) to create Solubis (van der Kant et al., 2017). This programme identifies the 
APR ‘hot-spots’ using TANGO, whilst identifying whether or not the regions are 
stabilising to the protein structure using FoldX (which calculates the free energy 
of a protein from its structure (Schymkowitz et al., 2005)). This script virtually 
mutates the amino acids in a TANGO zone to ‘gatekeeper’ residues (Arg, Glu, 
Asp, Asn and Pro (Rousseau et al., 2006)) to evaluate the contribution of the 
TANGO zone to the stability of the protein. Mutation of a residue buried in the 
hydrophobic core of a protein to a gatekeeper would be destabilising. Conversely, 
mutation of exposed hydrophobic residues is stabilising to the overall protein. A 
pre-requisite of this algorithm is the availability of a 3D structure or homology 
model. 
Whilst TANGO and Solubis predict generally aggregation-prone regions, the 
Waltz algorithm (also developed by Serrano, Schymkowitz, Rousseau and 
colleagues) specifically predicts amyloidogenic regions within proteins. This is 
based on a bioinformatics and experimental analysis of hexapeptides linked to 
amyloid. Of particular note, the algorithm scores the position of an amino acid in 
terms of its likely contribution to form an amyloid fibril, as the conformation of such 
residues is crucial to the formation of the very regular amyloid fibril (Maurer-Stroh 
et al., 2010). 
A similar algorithm is the prediction of amyloid structure aggregation (PASTA) 
(Trovato et al., 2007). As well as predicting the intrinsic APRs within an input 
sequence, it calculates the energy of forming a parallel or anti-parallel β-sheet. 
The cross-β core gives amyloid fibrils their high stability, thus understanding the 
likelihood of forming such species is desirable. A recent improvement to the 
algorithm (PASTA 2.0) incorporates a larger reference dataset, in addition to 
understanding the individual effect of certain mutations on the stability of the 
protein being analysed (Walsh et al., 2014). 
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AGGRESCAN is another web-based algorithm which detects APRs or ‘hot spots’ 
within protein sequences. This uses a dataset based on the aggregation of 
amyloidogenic proteins, to which sliding windows (5–11 residues) of the input 
sequence are compared. The a4v represents the aggregation propensity of an 
amino acid based on its neighbouring residues, whilst the HST is the “hot spot” 
threshold- essentially the average aggregation propensity of the twenty canonical 
amino acids based on their frequency in proteins (de Groot et al., 2005).  A hotspot 
is defined as “five or more sequentially continuous residues with an a4v larger 
than the HST and none of them is a proline (aggregation breaker)” (Conchillo-
Solé et al., 2007). Recently, a structure-corrected version of AGGRESCAN has 
been developed (AGGRESCAN-3D) which incorporates the specific structural 
environment of a protein’s amino acids, improving the algorithm’s ability to predict 
the aggregation of partially unfolded proteins (Zambrano et al., 2015). 
The Spatial Aggregation Propensity (SAP) algorithm is one of very few which 
focusses on therapeutic, rather than amyloidogenic, proteins. This algorithm 
performs molecular dynamics (MD) simulations to compute the dynamically 
exposed solvent-accessible surface area of a mAb, then corrects this value to 
represent the time-averaged hydrophobicity of these patches on the surface of 
the protein. A homology model of the mAb can be input into SAP and mutations 
made in silico, to engineer mAbs with reduced hydrophobic patches and therefore 
reduced aggregation propensity (Chennamsetty et al., 2009). A later paper from 
the same group combined the SAP score with the in silico calculated net charge 
of the mAb in a given formulation to generate the ‘developability index’. mAbs 
predicted to be aggregation-prone tended to correlate with long-term shelf life 
data (Lauer et al., 2012). 
The prediction of the aggregation propensity of proteins has not been the sole 
focus of computational biologists over the last decade. The CamSol algorithm can 
compute the intrinsic solubility of a protein from its primary sequence, as well as 
a corrected CamSol score that accounts for the protein’s structure (Sormanni et 
al., 2015). A CamSol score below -1 identifies ‘poorly-soluble’ regions, whereas a 
CamSol score exceeding +1 suggests the region is highly soluble. A sliding 
seven-residue window is used for the calculation. The algorithm, in a similar 
fashion to SAP, has been used to guide protein engineering, to make mutations 
which improve the solubility of therapeutic proteins (Sormanni et al., 2015; 




Table 1.2. Summary of the aggregation algorithms. 
Algorithm Amyloid-focussed? Structural Information? 
TANGO Yes, but also β-rich 
aggregates. 
No 
Solubis Same as TANGO Yes 
PASTA Yes Informed the algorithm 
design, but structure not 
fed into the programme 
AGGRESCAN Yes In 3D version 
SAP No Yes- crucial to its function 
CamSol No- solubility is the focus  If desired, yes. 
 
The ability to predict the of aggregation propensity and solubility of proteins, 
including those of therapeutic interest facilitates the screening and re-design of 
proteins with desirable biophysical properties (Deng et al., 2016). In isolation 
however, each in silico method in isolation cannot predict the 
‘developability’/‘manufacturability’ of therapeutic proteins due to the diversity of 
aggregation mechanisms. Various in vitro methods, which probe different length 
scales and sample sizes, must be employed in order to gain a holistic 
understanding of a therapeutic protein’s propensity to aggregate. These methods 
will be discussed in the rest of this section. 
 
1.3.2. Spectroscopic and spectrometric techniques to 
probe higher-order structure 
 
Within the QbD paradigm, a detailed understanding of the product is expected by 
the regulator (see Section 1.2.4). The TPP of a biopharmaceutical often includes 
features such as the extent of glycosylation, post-translational modifications, and 
presence of correct disulphides etc. Spectroscopic techniques (Mahler et al., 
2009) and more recently, mass spectrometry are employed by the 
biopharmaceutical industry to assess the conformational stability and integrity of 
biologics (Chen et al., 2011; Tian and Ruotolo, 2018). These techniques are used 








Spectroscopy can be defined as the interaction of electromagnetic radiation with 
matter (Pavia et al., 2010). The chemical environment of a biomolecule, from its 
local conformation to its solution conditions, affects how it will respond to 
electromagnetic radiation. The wavelength of the radiation crucially affects which 
parts of a protein are probed in a spectroscopy experiment (Williamson, 2012). 
Fourier Transform Infra-Red (FTIR) spectroscopy works on the basis of protein 
amide backbones stretching asymmetrically, which causes changes in dipole 
moments. Amide bonds, and by extension proteins, can therefore absorb infra-
red radiation (Pavia et al., 2010). FTIR probes the secondary structure of a 
protein, with the local conformation of each amide bond affecting the wavenumber 
(the reciprocal of wavelength, with units of cm-1) absorbed (Yang et al., 2015; Zölls 
et al., 2012). The amide-I region between 1600–1700 wavenumbers is the main 
region of interest in an FTIR measurement. A broad band at ~1630 cm-1 is usually 
indicative of an intramolecular, antiparallel β-sheet,(e.g. in mAb solutions), whilst 
α-helices give a band at 1652 cm-1 (Campbell, 2012; Harn et al., 2007; Yang et 
al., 2015). The spectrum is usually processed by taking its second derivative (to 
separate overlapping peaks), as well as subtracting the water peak from the 
amide-I region at 1640 cm-1 which would ordinarily mask the protein’s signal (Yang 
et al., 2015). The HOS of the biopharmaceutical sample can thus be determined, 
generating a ‘spectral fingerprint’. Any deviation away from the native state 
spectrum could be indicative of aggregation. FTIR can be performed on both liquid 
samples and lyophilised (solid) samples, making it quite versatile (Yang et al., 
2015; Zölls et al., 2012). However, these data are fairly low resolution in isolation 
(Jiskoot et al., 2012). 
Circular dichroism (CD) spectroscopy is another commonly employed technique 
to probe the secondary structure of biological molecules, complementary to FTIR 
(Zölls et al., 2012). It works on the differential absorption of left- or right-handed 
circularly polarised light (CPL) by a chiral molecule (Zaccai et al., 2017). CPL is 
formed from the sum of two electromagnetic waves which are perpendicular and 
phase-shifted with respect to one another (Campbell, 2012). Proteins are chiral 
molecules, as they are made up of L- amino acids. A protein’s secondary structure 
can be probed using far-UV radiation (190-250 nm), whilst tertiary structure can 
be probed in the near UV region, based on the position of aromatic residues in 
the protein of interest (Zaccai et al., 2017). α-helices give a characteristic double 
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minimum at 209 and 222 nm, whilst β-sheets have one maximum at 198 nm and 
one minimum at 218 nm (Kelly et al., 2005). Loss of ellipticity in these secondary 
structural regions could be indicative of unfavourable conformational changes in 
the biopharmaceutical. Whilst CD is a very sensitive technique, the need for low 
protein concentrations (~0.2 mg mL-1) and UV-silent buffers (Kelly et al., 2005) 
could impede the use of CD for biopharmaceuticals in their final, formulated state 
(Harn et al., 2007; Sharma et al., 2014). 
Raman spectroscopy can also be used to gain a spectral fingerprint of a protein 
sample (Zölls et al., 2012). It works on the basis of an incident photon interacting 
with a molecule and being scattered at a longer or shorter wavelength to that of 
the incident photon. Molecules are Raman-active if rotation or vibration, brought 
about by the incident photon, is accompanied by a change of polarisability. 
Photons which lose energy following collision undergo Stokes scattering, whilst 
those which gain energy undergo anti-Stokes scattering (Atkins and de Paula, 
2010). Raman spectral bands are weaker than IR signals as only 1 in 107 photons 
undergo Stokes scattering. Water barely scatters in the Raman region, thus 
solvent type is not an issue (Campbell, 2012). Raman has been developed 
recently to distinguish silicone oil droplets from protein in biopharmaceutical 
formulations which are administered by pre-filled syringes, a much discussed 
issue in biopharmaceutical analysis (Lankers et al., 2008) (see Sections 1.2.3 and 
1.2.4), in addition to monitoring protein unfolding under flow (Ashton et al., 2009; 
Ashton et al., 2010; Carpenter et al., 1999) (see also Section 1.4.4). 
Both intrinsic and extrinsic fluorescence techniques are used to analyse the extent 
of aggregation in protein therapeutic products. Fluorescence involves the 
excitation of a molecule, followed by emission of a photon upon relaxation. This 
is always of a longer wavelength than that of the incident photon. Tryptophan (Trp) 
residues are the most prominent fluorophores in proteins (Chen and Barkley, 
1998). 
Joubert et al. monitored the intrinsic fluorescence of a mAb solution by exciting 
the Trp at 280 nm and monitoring emission at 285–450 nm (Joubert et al., 2011). 
Unfolding causes Trp residues to emit photons of longer wavelengths than when 
they are buried in the hydrophobic core of a protein, based on their exposure to a 
more polar environment. This can help determine whether or not a protein is 
folded (Mahler et al., 2009), in addition to determining if aggregation has occurred 
depending on the change in emission wavelength observed (Joubert et al., 2011). 
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Mis-folded or aggregated proteins tend to have exposed hydrophobic surfaces. 
Extrinsic fluorophores such as 8-Anilino-1-napthalenesulfonic acid (ANS) 
(Joubert et al., 2011), SYPRO Orange (He et al., 2010) and Thioflavin T (ThT) 
(Chakroun et al., 2016) have all been used to monitor the unfolding aggregation 
of proteins. These dyes bind to hydrophobic regions of the protein, which 
increases their fluorescence signal based on their chemical environment. 
Fluorescence is very sensitive, so small (μM) amounts of sample are needed 
when extrinsic dyes are used in the analysis. The greater the extent of 
aggregation in the sample, the stronger the fluorescence emission (Sharma and 
Kalonia, 2010). 
The formulation of a biopharmaceutical, e.g. the presence of surfactants, may 
alter the fluorescence characteristics of the chosen dye (Carpenter et al., 1999; 
Mahler et al., 2009; Wang, 1999). The fluorophore itself may not bind to partially-
unfolded native species amongst the conformational ensemble (Sharma and 
Kalonia, 2010) , or prefer to bind to one conformer of aggregate, e.g. ThT’s 
preference to bind to amyloid fibrils (Thompson et al., 2015). 
Nuclear Magnetic Resonance (NMR) is increasingly being used as a means to 
interrogate aggregation in biopharmaceuticals (Kiss et al., 2018; Wishart, 2013). 
A comprehensive overview of NMR theory is beyond the scope of this thesis. 
Briefly, nuclei  which possess spin (such as 1H, 13C, 15N, 31P in biomolecules exist 
in two degenerate spin states: spin up and spin down (Pavia et al., 2010). These 
two states have a small energy difference in the presence of a magnetic field 
(Williamson, 2012). Nuclei either align with the magnetic field (lower energy state) 
or oppose it (higher energy state). The net sum of all of nuclear spins is an energy 
difference called the magnetisation (Williamson, 2012). A radio frequency pulse 
is therefore used to excite the nuclei further, causing them to precess. The energy 
of the radio wave matches the magnetisation. Removing the radio pulse causes 
the nuclei to relax, which can be detected. The chemical environment of a 
spinning nucleus dictates the frequency at which it resonates, known as the 
chemical shift. The resolution of NMR can thus be at the atomic level (Williamson, 
2012). In terms of biopharmaceutical analysis, NMR spectra can be difficult to 
interpret due to the large size of the protein samples and the naturally low 
abundance of 13C and 15N (Wishart, 2013). NMR is increasingly being used in the 
biopharmaceutical industry thanks to technological advancements in 
spectrometers decreasing sample concentrations  (Berkowitz et al., 2012). NMR 
is especially being used to analyse the extent of glycosylation/ HOS of mAb-based 
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biopharmaceuticals (Berkowitz et al., 2012; Kiss et al., 2018; Poppe et al., 2015; 
Wishart, 2013). Recently, NMR methods have been developed to study protein 
aggregation based solely on the water relaxation signal; something which is 
generally regarded as undesirable in biological NMR (Feng et al., 2015). The 
spectroscopies discussed in this section are summarised in Table 1.3. 
Table 1.3. Summary of the spectroscopic methods mentioned above. 
Technique Advantage Disadvantage 
FTIR Solid or liquid samples H2O can mask signal 
CD Sensitive methods Buffer composition is important 
Raman Very non-invasive to the 
sample 
Low resolution data obtained, 
i.e. not atomic-level 
Intrinsic 
Fluorescence 
Sensitive method Ensemble technique 
Extrinsic 
Fluorescence 
Wide array of different 
fluorophores available 
Buffer environment can affect 
the performance of the dye 
NMR Powerful method, capable of 
atomic level resolution 
Resolution limited with large 
proteins, e.g. mAbs 
 
 
Mass spectrometry-based techniques 
 
Mass spectrometry (MS) is used extensively in the analysis of 
biopharmaceuticals, as it requires very small quantities of protein. The technique 
involves the ionisation of the sample, with the ions then sorted/analysed and then 
detected. Mass spectrometers measure the mass to charge ratio (m/z) of ions 
(Campbell, 2012; Glish and Vachet, 2003). Amino acid modifications and 
incorrect/missing post-translational modifications can all be detected by 
subjecting a biopharmaceutical to analysis with MS or tandem mass spectrometry 
(for sequencing from which residue level information is gleaned) (Bobst et al., 
2008; Phillips et al., 2017; Rosati et al., 2014). Electrospray ionisation (ESI) was 
developed as an ionisation method for proteins in the 1980’s (Fenn et al., 1990). 
For ESI, the biopharmaceutical must be transferred from the formulation buffer 
into a volatile buffer such as ammonium acetate (a volatile solution commonly 
used at pH 6.8) or ammonium bicarbonate, which could lead to the observation of 
artefacts in the gas-phase (Konermann, 2017). Native proteins in the gas-phase 
generally occupy fewer (and lower) charge states than when unfolded, thus this 
technique can assess whether a protein is unfolded or not (Tian and Ruotolo, 
2018) (see Figure 1.14a).  
34 
 
An extension of this method is ion- mobility-mass spectrometry (IM-MS). Here, 
after ESI, the ions are extracted into the vacuum of the mass spectrometer. They 
are then allowed to drift through a region filled with an inert gas, which impedes 
their passage through the mass spectrometer. More expanded ions, with a larger 
surface area, collide more frequently with the gas atoms, thus arrive at the 
detector much later than their compact counterparts of the same mass and m/z 
values (Chen et al., 2011). While IM-MS is being used more in the analysis of 
mAbs (Ferguson and Gucinski-Ruth, 2016), its use is limited by expensive 
instrumentation and the tendency for mAbs to collapse in the gas-phase; i.e. have 
a collisional cross-section measured by IM-MS much smaller than that expected 
from orthogonal methods (Devine et al., 2017; Ferguson and Gucinski-Ruth, 
2016; Pacholarz et al., 2014).  
Chemical cross-linking is becoming an attractive option for mapping protein-
protein interactions using mass spectrometry (Figure 1.14b). Various linker types 
and conjugating group chemistries are employed, but those that react with 
common nucleophiles in proteins (lysines and cysteines) are mainly used (Leitner, 
2016). Protein complexes can be ‘trapped’ by the covalent cross-linker, digested 
and then sequenced using mass-spectrometry, with the additional advantage that 
the covalent modification between peptide and cross-linker is not labile, allowing 
one ample time to analyse the sample (Leitner, 2016). Once again, this has been 
used for mapping antibody self-interactions (Devine, 2016) However, cross-
linking can generally be difficult to optimise and perform (Iacobucci and Sinz, 
2017), meaning it is not yet routinely used for epitope mapping (Opuni et al., 
2018). 
Finally, various covalent labelling strategies can be employed to capture 
molecular snapshots of reactive and solvent-accessible residues using specific 
chemical labels (Borotto et al., 2015; Mendoza and Vachet, 2009) and hydroxyl 
radicals (Watson and Sharp, 2012; Zhang et al., 2015b). These ‘footprinting’ 
approaches (Figure 1.14c) can be powerful for the reasons discussed above, but 
can suffer from generating large amounts of data to analyse (Rinas et al., 2016) 
and, in the case of hydroxyl radical footprinting, the requirement for specialist 
equipment (Xu and Chance, 2007; Zhang et al., 2014; Zhang et al., 2015b).   
Hydrogen-Deuterium Exchange (HDX) MS is becoming gradually more 
widespread to assess the HOS of mAbs (Tian and Ruotolo, 2018), having been 
used to measure the dynamics and folding of smaller proteins for several 
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decades, e.g. (Clarke and Itzhakit, 1998; Malhotra and Udgaonkar, 2016). Briefly, 
the method works on the fact that when incubated in a deuterated solvent, the 
protons along a protein’s backbone will exchange with deuterons, depending on 
the solvent-accessibility of these residues, pH, temperature and the chemical 
nature of the residues involved (Clarke and Itzhakit, 1998). The deuterium 
incorporated into a protein increases the latter’s mass. Following quench and 
digest (usually with Pepsin at ~ pH 2), the peptides which exchanged (i.e. 
incorporated D) can be mapped back onto the full-length protein (Wei et al., 2014) 
(Figure 1.14d). This has been used to map mAb association interfaces (Dobson 
et al., 2016) and epitopes (Li et al., 2017), as well as conformations of biologics   
(Nazari et al., 2016). However, the method has many condition-dependent steps 
which can affect its reproducibility, such as the fast back-exchange of D to H. 
These mean analyses need to be ultrafast, with temperatures kept as low as 
possible and pH maintained at pH 3 (hence pepsin is used as the protease. These 
issues can be better controlled by the development of commercially available 
automation (Wales et al., 2008). 
In addition to detecting the modifications above, amino acid modifications and 
incorrect/missing post-translational modifications can all be detected by 
subjecting a biopharmaceutical to analysis with tandem mass spectrometry 
(MS/MS) (Bobst et al., 2008; Phillips et al., 2017; Rosati et al., 2014) (see Figure 
1.14e). This typically involves the enzymatic digest of a protein of interest, 
followed by the on-line separation of peptides by liquid chromatography en route 
to analysis by mass spectrometry. This allows one to re-assemble the peptides to 
determine the overall sequence of the protein , so-called ‘bottom-up’ proteomics 
(Tian and Ruotolo, 2018). These mass spectrometry-based methods are 







Figure 1.14. Mass spectrometry-based methods to study HOS in proteins 
including mAbs. a) ESI is a soft ionisation method, preserving the native 
structure of proteins in the gas-phase (blue peaks). Unfolded proteins have 
more protonation sites exposed, thus they occupy more charge states (red 
peaks). b) Chemical cross-linkers typically feature electrophilic groups with good 
leaving group ability, stapling neighbouring reactive proteins together. These 
can be homofunctional (green circles) or heterofunctional as desired. c) 
Hydroxyl radical footprinting can be performed using a KrF laser to fragment 
H2O2 into hydroxyl radicals which covalently label solvent-accessible residues. 
Specific labelling reagents, such as Koshland’s reagent (for Trp residues, blue 
box) can also be used. d) HDX-MS is useful for mapping the solvent-accessible 
surface area of proteins. The degree of deuterium uptake can be quantified after 
analysing the protein via e) Proteolytic digestion, followed by LC/MS allows one 
to identify a protein from its peptide fragment. Residue-level information can be 
gained if tandem mass spectrometry (MS/MS) is employed, mapping 
modifications etc. as above. Adapted from Tian and Ruotolo, 2018. 
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1.2.3. Separation-based methods to probe 
biopharmaceutical aggregation. 
 
As suggested in Figure 1.2, aggregates have different physicochemical 
characteristics to native, monomeric proteins. Size-exclusion chromatography 
(SEC) separates proteins on the basis of size (volume and molecular weight) and 
shape. The technique works by using a column packed with a porous gel matrix, 
e.g. Sepharose. The pores in the gel beads only allow proteins of a certain size 
(i.e. hydrodynamic radius) to permeate through them, whilst larger 
proteins/aggregates are excluded. These proteins will thus be eluted from the 
column much faster than the smaller, natively folded protein. UV absorbance at 
280 nm is used to detect protein elution, based on tryptophan being the strongest 
absorbing chromophore in proteins. This is plotted with respect to elution volume 
to produce a chromatogram. The area under the curve of the chromatogram is 
proportional to the total mass of protein eluted. Protein standards of known 
molecular weight are used to calibrate the column; i.e. to relate the known 
protein’s molecular weight to its elution volume. Proteins between 0.1–600 kDa 
can be effectively separated, depending on the choice of SEC column and 
conditions (Price and Nairn, 2009). Advantageously, SEC is relatively easy to 
perform thus it has been the standard separation-based technique for aggregate 
studies of biopharmaceuticals for many years, often coupled with High-
Performance Liquid Chromatography (HPLC) to offer a short analysis time of ~15 
minutes (Chaudhuri et al., 2014; Jain et al., 2017; Joubert et al., 2011; Mahler et 
al., 2009; Price and Nairn, 2009; Wang, 1999). 
However, the method is not perfect, as sample-matrix interactions, they can occur, 
affecting the sample’s elution (Dobson et al., 2016; Nicoud et al., 2014). These 
effects can be minimised by controlling the ionic strength and pH of the running 
buffer (Nicoud et al., 2014). Hydrophobic interactions can create false elution 
volumes and thus inaccurate determinations of molecular weight (Philo, 2006).  
An additional disadvantage of SEC is that the method assumes all proteins are 
spherical. Also, SEC is not suitable for the analysis of insoluble aggregates, as 
particulate matter would foul the column. Therefore, samples and buffers are 
typically passed through a 0.22 µm filter before use. Furthermore, soluble 
aggregates could dissociate reversibly in the running buffer, as the running buffer 
can greatly dilute samples. Consequently, the dispersity of the eluted protein may 
not accurately reflect the aggregated state of a biopharmaceutical formulation 
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prior to injection onto the column (Mahler et al., 2009). Therefore, orthogonal 
techniques are necessary to validate the results of SEC analysis. 
Analytical Ultra Centrifugation (AUC) is one such orthogonal method that has 
been used to separate monomeric proteins from their oligomers/aggregates and 
to quantify these species in a variety of studies (e.g. (Scott et al., 2002; Yang et 
al., 2016). For aggregate analysis, AUC is usually operated in sedimentation 
velocity (SV) mode, as the increasing force (several thousand xg) applied to the 
molecules separates larger species from smaller ones. The sedimentation 
coefficient and diffusion coefficient (see Section 1.3.5) can be used to then 
calculate the molecular weight of the sample, from the work of Svedberg (Arakawa 
et al., 2006; Price and Nairn, 2009; Zaccai et al., 2017). Advantageously, SV-AUC 
can be performed in the original sample buffer, provided it is not too viscous. 
However, sample analysis can be difficult, the instrumentation is expensive and 
the technique is destructive to the sample (Arakawa et al., 2006). 
In addition to centrifugation, asymmetrical flow field-flow fractionation (AF4) is 
being used as an orthogonal method to SEC (Bria et al., 2016; Mahler et al., 2009; 
Ripple and Dimitrova, 2012; Zölls et al., 2012).  How the method works is shown 
in Figure 1.15. AF4 can separate and characterise particles of 1 nm–100 µm in 
size, without the need for a stationary phase (Zölls et al., 2012). One potential 
issue with AF4 is the tendency of protein aggregates to adhere to membranes, 
thus fouling it (Ripple and Dimitrova, 2012). As discussed in Section 1.2.3, this 
issue is observed throughout the manufacturing process of biopharmaceuticals 
(Goldrick et al., 2017). This could potentially then promote further aggregation in 
the instrument, as surfaces are known to influence the aggregation of 





Figure 1.15. Schematic of AF4. The sample flows into the system, where it 
then encounters a cross-flow, forcing the solutes towards the membrane. 
Smaller species (e.g. monomeric proteins, blue circles) can diffuse away from 
the membrane faster than their larger counterparts (e.g. aggregates, green 
circles), thus they are detected earlier. Adapted from (Postnova, 2018). 
A plethora of other, novel technologies have emerged over the last decade from 
academic and research laboratories to separate and size aggregates, including: 
adaptations of traditional electrophoretic methods (Halfmann and Lindquist, 
2008); microfluidic technologies to separate monomers from aggregates such as 
Taylor-Dispersion Analysis (TDA) (Hawe et al., 2011) and other emerging 
microfluidic methods (Arosio et al., 2016; Kopp and Arosio, 2018); as well as novel 
chromatographic methods such as cross-interaction chromatography (Jacobs et 
al., 2010). These assays are too numerous to discuss in detail but are mentioned 
as they are allowing scientists to quantify protein aggregation in ways that way 
not possible using traditional methodologies. These traditional methods are 
summarised in Table 1.4. 
Table 1.4. Summary of the traditional separation-based methods for 
aggregate analysis. 
Technique Advantage Disadvantage 
SEC The industry ‘gold-
standard’ method, well-
established 
Column unable to resolve 
oligomers over broad mass 
range 
AUC Minimal sample 
preparation 
Complex analysis and 
destructive 
AF4 Can separate species 





1.2.4. Light scattering and related methods to detect, 
size and count aggregates in solution 
 
Sub-visible particles are the utmost concern to regulators and biopharmaceutical 
manufacturers (Wang et al., 2012). These are too large to be separated from 
monomeric proteins and oligomers by SEC and too small to be analysed through 
visual inspection. These particles thus fall in the range of 0.1 µm–100 µm (24). 
Light-scattering methods are principally used to determine the size of particles in 
the 1–100 nm size range but can be used to analyse species up to ~5 μm in size. 
Static Light Scattering (SLS) is a commonly used technique in which laser light is 
elastically scattered by a sample. Elastic scattering occurs when the sample’s 
electrons scatter the incident radiation in all directions at the same frequency, i.e. 
no energy is lost (Mahler et al., 2009; Wyatt, 1993; Zölls et al., 2012). This is also 
called Raleigh Scattering (Campbell, 2012). The light scattered by a 
macromolecule can have different phases; thus, the scattered light waves can 
interfere constructively and destructively with one another. The intensity of this 
scattered light is proportional to the molar mass of the scatterer, as well as its 
shape (Wyatt, 1993).This technique is called Multi-Angle Laser Light Scattering 
(MALLS). A schematic of this process is shown in Figure 1.16. 
 
Figure 1.16. Schematic of Rayleigh scattering and detection. Incident 
photons, hνi, are scattered by macromolecules. The blue and purple regions of 
the molecule (e.g. two subunits of a protein) can scatter the photon differently if 
the molecule is greater than ~ 10 nm in radius. Interference between these 
scattered photons then has an angular dependence, represented by θ. This in 
turn is related to the root-mean square radius of the macromolecule. Adapted 
from (Minton, 2016). 
MALLS is frequently combined with SEC, in order to produce a rapid technique 
that can not only separate soluble aggregates, but determine their absolute 
molecular weight as well, based on the hydrodynamic radius of the protein 
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(Campbell, 2012; Wyatt, 1993). This has been done for model proteins (Oliva and 
Farin, 2001) as well as those of biopharmaceutical interest (Chaudhuri et al., 
2014; Philo, 2006).  
SEC-MALLS is a powerful technique, as any discrepancies in elution volume 
caused by aggregate-matrix interactions (SEC only) can usually be clarified with 
the MALLS detection (Philo, 2006). This is because the molecular weight 
determined by MALLS is not affected by elution volume, provided the eluted 
fraction’s concentration and ‘differential refractive index increment’ or dn/dc is 
known (24, 37). For a non-glycosylated protein, this value is constant = 0.186 ml/g 
(Oliva and Farin, 2001). It is important to note however, that mAbs are usually 
heavily glycosylated (Section 1.2.2), so calibration may be necessary when SEC-
MALLS is used in the analysis of these products. The latest developments in SEC-
MALLS allow for the analysis of mAbs with very small sample volumes of 1–6 μL 
(Hsieh and Wyatt, 2017). 
Dynamic Light Scattering (DLS) is the other common scattering technique. It is an 
ensemble technique which monitors the change in scattered light intensity over 
time due to Brownian motion of the particles (Arakawa et al., 2006; Campbell, 
2012; Hassan et al., 2014; Minton, 2016; Zaccai et al., 2017). Buffer molecules 
collide with the solute molecules, causing the phases of their scattered photons 
to fluctuate. A particle’s hydrodynamic radius can be determined from 
measurement of its diffusion coefficient, based on Stokes-Einstein equation 




   
Equation 1.1 Stokes-Einstein equation for determining the hydrodynamic radius 
(Rh) of a particle using DLS (SI unit = m). kB = Boltzmann constant, T = absolute 
temperature (K), η = dynamic viscosity (kg m-1s-1), D = Diffusion coefficient         
(m2 s-1). 
Protein particles in biopharmaceuticals between 1 nm and ~5 µm in size can be 
detected and sized by DLS, provided the sample is not too concentrated (Fischer 
and Schmidt, 2016; Minton, 2016). Larger particles scatter much more intensely 
than smaller ones, i.e. Intensity, I α r6 (Filipe et al., 2010; Minton, 2016; Philo, 
2006). This means a large bias is placed on larger oligomers and particles than 
smaller ones. Filipe et al. established that DLS cannot differentiate between two 
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sets of particles in a polydisperse system unless they differ in size by at least three 
fold (Filipe et al., 2010). 
The size ratio between aggregates in a biopharmaceutical formulation may be 
smaller than 1:3, meaning potentially immunogenic aggregates may not be 
detected. The technique should therefore be used semi-quantitatively in 
conjunction with other techniques; a widely-held view within the 
biopharmaceutical community (Fischer and Schmidt, 2016; Mahler et al., 2009). 
A related method to DLS is Fluorescence Correlation Spectroscopy (FCS). Rather 
than measuring the fluctuations of elastic scattering with time, FCS measures 
fluctuations in fluorescence emission intensity with time (Haustein and Schwille, 
2007; Zaccai et al., 2017). The sample of interest is typically fluorescently labelled, 
thus the increased sensitivity of the dye allows one to detect single-molecules at 
a time (Zaccai et al., 2017). The confocal volume of the apparatus used to detect 
the molecules is of the order of 1 fL (Haustein and Schwille, 2007). It has been 
used to detect oligomers in amyloid aggregation mechanisms (Guan et al., 2015; 
Tipping et al., 2015), as well as now being developed to track antibody 
aggregation in academic research groups (Imamura et al., 2017). The specialised 
equipment and the need for fluorescently labelled protein has probably limited the 
utilisation of FCS routinely in industry despite the advantages mentioned above. 
Many new techniques have been developed in recent years to aid the counting 
and characterisation of nanoparticles. Nanoparticle Tracking Analysis (NTA) 
utilises a camera to visualise and track the motion of particles which dynamically 
scatter laser light, within the confines of a defined field of view (Carr and Wright, 
2015; Filipe et al., 2010). The lower limit of resolution for the technique for 
proteins/soft matter is around 50 nm (Zhou et al., 2016). Although this appears 
disadvantageous in comparison to DLS, as NTA cannot size and detect 
monomeric proteins, NTA has the ability to distinguish between particles in 
polydisperse samples with greater sensitivity. DLS can only distinguish between 
particles that have a three-fold size difference (Filipe et al., 2010). NTA can 
distinguish between particles (including therapeutic protein aggregates) which 
have a ~0.5 to 2-fold size difference (Filipe et al., 2010; Vasudev et al., 2015). 
Furthermore, the instrument can determine the concentration of each pool of 
particles, based on the defined amount of sample illuminated by its laser (Zhou et 
al., 2016). NTA tracks particles individually, whereas DLS is an ensemble 
technique; hence the latter may not fully represent the aggregated nature of the 
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sample (Filipe et al., 2010; Vasudev et al., 2015). A schematic of the apparatus is 
shown in Figure 1.17. 
 
Figure 1.17.  Schematic of the NTA technology. Incident laser light (642 nm) 
is passed through a glass prism inside the sample chamber. The angle of 
incidence and the functionalization of the surface (black rectangle, grey outline) 
together create an intense, thin laser beam. This means the light scattered from 
the particles can be seen at 20x magnification using a microscope (top). 
Coupling a charge-coupled device camera to the microscope allows one to 
capture videos of the moving particles. The videos are then processed by the 
Nanosight® software and the sizes and concentrations of particles in the sample 
are generated. Figure adapted from Carr and Wright, 2015.  
Traditional methods for the identification and quantification of sub-visible and 
visible particles in biopharmaceutical samples include light obscuration (Hawe et 
al., 2009), turbidity (Wolfrum et al., 2017) and visual inspection (Mahler et al., 
2009). Limitations of these methods include a lack of resolution between different 
scattering species using turbidity (Barnard et al., 2011) and human error (visual 
inspection (Melchore, 2011). However, newer technologies are rapidly being 
developed to size and count particles in this space, including Micro Flow Imaging  
MFI) (Hamrang et al., 2015; Zölls et al., 2013) and Resonant Mass Measurement 
(RMM) (Christie et al., 2014; Zheng et al., 2017; Zölls et al., 2013). This expansion 
of the analytical repertoire is providing researchers with many new ways to 
characterise particles and aggregates in mAb products that weren’t possible ten 
years ago. Many of the methods mentioned discussed in Section 1.3 have been 
used to study flow-induced unfolding and aggregation of proteins, which is 
discussed in the next section. 
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1.4 Fluid flows and their effects on molecular and 
cellular structure 
 
Proteins are exposed to a variety of different stresses in their lifetime, as 
discussed in Sections 1.1–1.3. However, one of the most under-studied areas is 
how hydrodynamic forces influence the unfolding and aggregation of proteins. 
This remains a very controversial topic in the field. This section of the introduction 
will lead into the aims and objectives of this PhD thesis. 
1.4.1 Defined fluid fields: Shear flow vs extensional flow 
 
Fluid mechanics is the field devoted to the study of the physical properties of fluids 
over space and time. In order to understand how flows influence the molecules 
being transported within them, it is crucial to define their underlying fluid 
mechanics. Of the various types of fluid flow, two of the most common are shear 
flows and extensional (elongational) flows (Bekard et al., 2011). Shear flows exist 
when layers of fluid (lamellae) travel over one another at differing velocities in the 
direction of the flow. This generates a velocity gradient perpendicular to the 
direction of the flow (Figure 1.18a) (Thomas and Geer, 2011). The word ‘shear’ 
has often been misused as an umbrella term to describe any hydrodynamic force 
(Thomas and Geer, 2011). Conversely, an extensional flow is generated where 
fluid is forced to accelerate, with a linear velocity gradient generated in the 










Figure 1.18. Schematic examples of shear flow (a) and extensional flow (b). 
a) Friction at the pipe wall leads to the pressure-driven flow adopting a parabolic 
profile, with the fluid moving fastest in the centre and slowest at the wall. The 
shear rate is thus maximal at the wall. b) A contraction in the pipe forces the 
fluid to accelerate to overcome the contraction. Each arrow represents a velocity 
vector, with length proportional to the velocity. An abrupt contraction (lower 
figure) leads to a rapid increase in the fluid velocity in the direction of the flow. 
Adapted from Bekard et al. 2011; Thomas and Geer, 2011. 
 
Key equations for shear and extensional flows 
 
Shear flows are usually described in terms of the shear rate, γ, which describes 
the velocity gradient perpendicular to the direction of flow. This gradient arises 
from thin lamellae of fluid travelling over one another at different velocities, 





Equation 1.2. Equation for shear rate, γ (s-1). ν = velocity of each layer in the 







The shear rate is maximal at the pipe wall (Figure 1.18a). Furthermore, the force 
a shear flow imparts on the pipe wall (expressed per unit area) is described as 





      = 𝜂𝛾 
Equation 1.3. Equation for shear stress at a pipe wall, τ (N m-2). η is the dynamic 
viscosity of the fluid (N s m-2) and γ is the shear rate (s-1). 









Equation 1.4. Equation for strain rate ε̇ (s-1), which is the change in strain ε, with 
time, t. Strain can be described as the relative change in the length (in m) of a 
fluid element, or object within the flow from its original length, lo, to a final length, 
lf. As strain is dimensionless, the strain rate has units of s
-1.  
It is often important to discuss the flow in terms of being laminar (the fluid moving 
in defined layers as discussed above, like a gentle stream) or turbulent (merged 
streamlines and vortexes, like white-water rapids). The flow regime can be 





Equation 1.5. Equation for Reynolds number, where ρ = density of the fluid       
(kg m-3), ν = velocity of the fluid (m s -1), L = characteristic length (m), η = 
dynamic viscosity of the fluid (N s m-2 or kg m s-1). In a pipe flow, L can be 
substituted with the diameter of the pipe (in m). 
The Reynolds number essentially describes the ratio of inertial to viscous forces 
in the fluid. A Reynold’s number below 2000 is indicative of a laminar flow, whilst 
one exceeding 4000 is indicative of a turbulent flow (King, 2002), with an ill-
defined transition region between 2000–4000. 
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Devices to generate shear and extensional flows 
 
As well as the simple pipe designs shown above, researchers have developed 
many ways to generate shear and extensional flows. Viscometers are often used 
to generate these flows, especially those with a Couette flow design (Figure 
1.19a). These devices can subject samples to defined shear rates for prolonged 
periods of time (Bekard et al., 2011; Fardin et al., 2014). The four-roll mill design 
has been employed to subject proteins to both shear and extensional flows, 
depending on the direction each of its rollers are rotated (Figure 1.19b) (Simon et 
al., 2011) –see Section 1.4.4. Another common way to generate extensional flow 
is to use a so-called cross-slot device, where fluids are made to collide with one 
another, generating an extensional flow (Figure 1.19c) (Perkins et al., 1997; 












Figure 1.19. Schematics of commonly employed flow devices from the 
literature. a) A Couette flow device. The sample is placed in the device and the 
inner cylinder is rotated at a defined rate, inducing shear in the fluid. The plan 
view (right-hand image) shows the velocity gradient in the flow device, with the 
flow being slowest at the stationary, outer cylinder wall. b) Plan view of a four-
roll mill apparatus. Protein solution is input into the device (similar to a, but with 
four Teflon rollers inside) and sealed. The rollers can be rotated independently 
in the directions indicated to generate extensional (black arrows) or shear flow 
(white arrows). c) A cross-slot device to generate extensional flow. Fluid is input 
into the device from opposing directions (blue arrows). The streams collide, 
generating extensional flow (white arrows). The fluid then exits the channels (red 




The exact design of flow device used depends on the sample volume, whether or not 
optics and other in situ measurements are being performed, as well as whether or not 
the device is custom-made or commercially available. How these different devices, 
and the flow they generate, affect molecules and cells will be discussed next. 
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1.4.2 Effects of flow and hydrodynamic forces on cells 
 
Many researchers have investigated how flow affects mammalian cells for both 
medical (e.g. Jain et al., 2016) and biotechnology purposes (e.g. Sinha et al., 
2015). It is thought that shear flows in the body affect the positions of red blood 
cells in the body’s vasculature (Carboni et al., 2018), as well as their morphology 
(Lanotte et al., 2016). Blood can be described as a non-Newtonian fluid, as its 
viscosity changes when it is subjected to shear stress (Davies, 2009). Shear 
stress in the body can vary, from 1 x 10-3 Pa (N m-2)  in regions of the body with 
poor circulation to a few Pa (Abaci et al., 2015).  
It is thought that shear and extensional flows can deform red blood cells, 
particularly in cases of atheroma where blockages generate extensional flows 
(Balaguru et al., 2016). Various microfluidic devices have been built to investigate 
these haematological phenomena, with geometries akin to those shown in Figure 
1.18 (Carboni et al., 2016; Carboni et al., 2018; Fitzgibbon et al., 2015; Lanotte et 
al., 2016). The effects on the cells can have knock-on effects on proteins found in 
the blood (see Section 1.4.4). 
From a biotechnological perspective, it was originally thought that mammalian 
cells are susceptible to the effects of hydrodynamic forces during large scale 
manufacture (Chisti, 2006; Nienow, 2006). It was thought that this damage could 
occur due to: impellers physically breaking cells open during fermentation; the 
high fluid flows generated during mixing (Varley and Birch, 1999); harsh shear 
flows cells encountered during DSP (Jain et al., 2005). Whilst it has been shown 
that extensional flows can mechanically deform cells (Bae et al., 2016), Hoare 
and colleagues subjected mammalian cells to shear flow and did not observe any 
damage (Hutchinson et al., 2006; Joseph et al., 2016; Rayat et al., 2016). It is 
instead thought that the bursting of cavities and bubbles during fermentation could 
be the main cause of damage, which has been alluded to previously (van Reis 
and Zydney, 2007). The collapse of air cavities in fluids is thought to generate 
strong extensional flows, which would have the potential to damage cell 
membranes in bioreactors if not controlled (Hariadi et al., 2015). 
In summary, it is thought that cells can be deformed by shear and extensional 
flows depending on their physiological environment, especially in the case of 
certain diseases. Whilst mammalian cells are thought to be fairly robust to fluid 
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flows, they are indeed susceptible to cavity collapse. How molecules are affected 
by flows are the subject of the following sections.  
 
1.4.3 Effects of flow on polymers and DNA 
 
PG de Gennes carried out ground-breaking work on how flows affect non-
biological polymers in solution in the 1970’s (De Gennes, 1974). This laid out the 
quantitative framework behind how polymers can undergo coil-stretch transitions, 
influenced by shear and extensional flows. This work partly led de Gennes being 
awarded the 1991 Nobel Prize in Physics (NobelPrize.org and AB, 2018). Cathey 
and Fuller built upon this work, where they made clear that the properties of a 
solution, in particular its viscosity, have a major impact upon the ease by which a 
polymer undergoes chain elongation in a shear flow (Cathey and Fuller, 1990). 
The relationship between extensional flow and temperature on polymer breakage 
was also examined (Odell et al., 1990). In-situ measurements on flexible polymer 
distortion under shear flow was another technical advancement (Dunstan et al., 
2004). 
In terms of linear biological polymers, DNA has been used by many groups as a 
model system. The fact DNA can intercalate fluorescent molecules means it has 
been exploited for single-molecule studies of its dynamics under extensional 
(Perkins et al., 1997) and shear flows (LeDuc et al., 1999; Smith et al., 1999). 
These high-impact studies demonstrated the stretching and tumbling of DNA 
molecules, sometimes forming dumbbell structures in the flow. This occurs at very 
low strain and shear rates (<5 s-1) (LeDuc et al., 1999; Perkins et al., 1997; Smith 
et al., 1999). 
Since plasmid DNA has to be produced at scale for use in biotechnology (Kong 
et al., 2010), how flow can damage DNA has been another area of study. Hoare 
and colleagues have investigated how shear and extensional flows can damage 
(unfold and fragment) supercoiled plasmid DNA, at strain rates ranging from 1.7 
x 104 s-1 (Zhang et al., 2007)  to ~ 3 x 105 s-1 (Meacle et al., 2006) and shear rates 
of ~ 3.5 x 105 s-1 (Levy et al., 1999). These high strain and shear rates were 
generated using capillary devices with abrupt contractions (see Figure 1.18b). 
The authors found that extensional flow seemed to be the dominant factor in 
causing the observed uncoiling of the DNA, especially after subjecting the 
samples to multiple flow events (Meacle et al., 2006; Zhang et al., 2007).  
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The fundamental and applied studies discussed suggest that flow-induced 
unfolding and aggregation of proteins is feasible. Studies that demonstrate this 
are described in the final section of this introduction. 
 
1.4.4 Effects of flow on proteins 
 
As mentioned in Section 1.2.4, hydrodynamic forces could be a contributing factor 
to the damage of biopharmaceutical proteins. More generally, researchers have 
been interested in understanding if and how shear and extensional flows affect 
proteins more generally for over 50 years (Bekard et al., 2011; Charm and Wong, 
1970a; Thomas and Geer, 2011). More recently, proteins of physiological 
importance have been the subjects of flow studies. These will be discussed first. 
Flow studies on elongated proteins 
 
von Willebrand Factor (vWF) is one of the best studied proteins under flow, 
described by Timothy Springer as the “Jedi knight of the bloodstream” (Springer, 
2016). This several MDa glycoprotein is 10s to 100s nm in length and “feels the 
force” of its hydrodynamic environment, allowing both the regulation of its length 
(Lippok et al., 2016; Zhang et al., 2009) and the unfolding of its platelet binding 
site when the force is sufficient (Aponte-Santamaría et al., 2015; Sing and 
Alexander-Katz, 2010). This latter event triggers the blood coagulation process. 
These studies have all shown that this large, elongated protein, is unfolded at 
relatively low strain rates (1 x 103 s-1) (Fu et al., 2017; Sing and Alexander-Katz, 
2010). Fibrinogen is another blood glycoprotein involved in coagulation. Shearing 
of this protein at physiologically relevant shear rates led to a loss of clotting activity 
over time (Charm and Wong, 1970b). The authors proposed that the shear 
environment in vivo could account for regulation of this protein. 
Fluid flows have also been used to influence the aggregation of proteinaceous 
biomaterials. Dragline spider-silk has remarkable strength, making it a desirable 
material to make recombinantly (Egan et al., 2015). Rammensee et al. developed 
a microfluidic chip which mimics the spider’s silk gland, where shear flow aligns 
silk spidroin proteins, which then assemble into β-sheet rich silk under extensional 
flow (Rammensee et al., 2008). Often, very high concentrations of protein are 
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used in these devices (>500 mg mL-1) (Andersson et al., 2017) , which will affect 
the hydrodynamic forces applied to the proteins. 
Flow studies on globular proteins 
 
Charm and Wong subjected catalase, rennet and carboxypeptidase to shear in a 
viscometer at shear rates up to 1155 s-1 for up to 90 minutes. In the absence of 
an air-water interface, they found that the enzymatic activity of these proteins 
decreased by up to 50% (Charm and Wong, 1970a). The authors suggested this 
was due to the “breaking of tertiary structure when the enzyme is appropriately 
oriented in the shear field” (Charm and Wong, 1970a). Tirrell and Middleman built 
on these studies, subjecting urease to shear and monitoring its ability to break 
down urea during and post-shear. They found that this 484 kDa protein did lose 
activity after shear, but could partially recover, i.e. once the shear flow was 
removed, the enzyme regained activity (Tirrell and Middleman, 1975). 
Conversely, Thomas and Dunhill subjected bovine liver catalase to shear rates 
varying from 636 to 1x 106 s-1. They saw little to no loss of activity of the enzyme 
in this closed system, citing air-water interfaces as a possible major cause of 
catalase’s activity in other groups’ studies (Thomas and Dunnill, 1979). In 1997, 
recombinant human (rh) DNAse was shown to be unaffected by shear alone, 
whilst rh Growth Hormone formed aggregates under the same conditions (Maa 
and Hsu, 1997). Jaspe and Hagen performed a seminal study in 2006, where they 
exposed cytochrome c to very high shear rates (2 x 105 s-1), yet saw no unfolding 
monitored by in situ Trp fluorescence. They proposed that a shear rate exceeding 
1 x 107 s-1 would be necessary to unfold a 100 residue protein (Jaspe and Hagen, 
2006). Two therapeutic proteins, recombinant human growth hormone and an 
IgG1 were stressed in a Couette shear device for up to 30 min at a shear rate = 
3,840 s-1. No unfolding of either protein was observed by  in situ  CD (Brückl et 
al., 2016).  
In contrast to these studies, many groups have observed protein unfolding under 
shear flow. Ashton et al. performed in situ  Raman spectroscopy on lysozyme 
(Ashton et al., 2009), followed by BSA, insulin, β-lactoglobulin and other proteins 
(Ashton et al., 2010). Deviation in the Raman spectra of these proteins, from those 
of the quiescent samples, increased as a function of protein size. Bekard and 
Dunstan also observed deviations in BSA and insulin structure using in situ 
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methods, such as CD and fluorescence, under shear (Bekard et al., 2012; Bekard 
and Dunstan, 2009). 
Simon et al. subjected three globular proteins (lysozyme, bovine serum albumin 
(BSA) and alcohol dehydrogenase (ADH)) to stress under shear and extensional 
flows in a four-roll mill apparatus. They found that extensional flows were more 
damaging (i.e. brought about more aggregation) to these proteins than shear 
flows and that larger proteins (BSA and ADH) were more susceptible to flow 
effects than lysozyme, forming larger aggregates and in greater quantity (Simon 
et al., 2011). Using the same apparatus, the group have characterised the 
aggregation of monoclonal antibodies under flow (Wolfrum et al., 2017). 
How flow affects mAb aggregation has obvious implications given the discussion 
of the effects of aggregation in Section 1.2.4. The literature is fairly divided on 
what the main factors driving hydrodynamic aggregation of mAbs are (Bekard et 
al., 2011). Bee et al. subjected a concentrated mAb solution (150 mg mL-1) to 
stress under high shear (γ = 2.5 x 105 s-1), yet saw no aggregation. Duerkop et al. 
very recently subjected mAbs and other globular proteins to stress under high 
shear (γ = 1 x 108 s-1). They observed minimal aggregation for these proteins, 
except when cavitation was present (Duerkop et al., 2018). The Bracewell group 
have subjected a variety of mAbs (including IgG1s and IgG4s) to defined shear 
stresses and have observed protein aggregation (Biddlecombe et al., 2007; 
Biddlecombe et al., 2009; Tavakoli-Keshe et al., 2014). For an IgG4, it was found 
that the roughness of the surface in the shear device played the largest role in the 
aggregation of the mAb (Biddlecombe et al., 2009). More recently, this work has 
been applied to samples under high shear rates, where shear was thought to 
influence the aggregation (Nanda et al., 2017). 
There is thus a clear divide between those who think flow can, a) perturb protein 
structure and b) induce/influence protein aggregation, and those who do not. The 
discrepancies between different studies can be put down to the following: different 
apparatus used to subject the proteins to stress under flow; the purity and origin 
of the proteins used in the study; topology and size (MW) of the proteins used; 
the protein concentration and buffer conditions used; the absence or presence of 
air-water and water-solid interfaces within the device; the time scale of exposure 
to the flow field in question and the method(s) of detection used to monitor 
‘damage’ to the protein. Addressing these discrepancies form the basis of this 
PhD thesis, which is outlined in the next section. 
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1.5 Basis of the study 
 
With these studies in mind, my colleague (now Dr) John Dobson (School of 
Mechanical Engineering, University of Leeds) designed and built a device which has 
the ability to subject proteins to extensional flow fields, followed by high shear rates. 
Extensional flows have generally been neglected, except where reference has been 
made to polymers or elongated proteins being more sensitive to extensional rather 
than shear flow, e.g. (Springer, 2016) and the work of Simon et al., 2011. Building a 
device able to apply known and modulatable extensional flow fields would allow one 
to validate this hypothesis for a range of model proteins. 
The extensional flow device (EFD), referred to as the EFD or ‘the device’ herein, was 
designed and built with the following criteria in mind: production of a laminar, non-
turbulent flow; generation of extensional flow by an abrupt contraction in the flow; a 
low volume to minimise the amount of protein needed; low flow rates to minimise the 
engineering challenge to achieve high strain rates whilst maintaining laminar flow. 
Two syringes connected via a capillary fit the above criteria (see Materials and 
Methods); similar to the extensional flow setup shown in Figure 1.18b (lower panel). 
Molecules entering the contraction would be subjected to strain (i.e. extensional flow) 
at the point of contraction, followed by high shear rates along the length of the 
capillary. 
BSA was initially selected as a model protein, as it has been shown by many groups 
to unfold and/or aggregate under both shear and extensional flow fields (Ashton et 
al., 2010; Bekard et al., 2012; Simon et al., 2011). A wide-array of biochemical 
(Peters, 1996), structural (Majorek et al., 2012) and aggregation data (Bhattacharya 
et al., 2011; Bhattacharya et al., 2014; Militello et al., 2003) are also available for this 
573 residue, α-helical protein. Once the initial characterisation of the system was 
performed, these data would be implemented by investigating the behaviour of model 







1.6 Aim and Objectives 
 
The overall aim of this project is to understand how extensional and shear flows 
affect proteins and induce their aggregation. Specifically, the effects of flow on 
therapeutic proteins is the focus of this thesis. The objectives to achieve this are: 
 To identify robust experimental conditions and analytical methods to 
monitor the aggregation of BSA, induced by extensional flow. 
Experimental techniques would be selected from the literature, including 
spectroscopic, scattering and mass spectrometric methodologies, then 
combined to understand the aggregation pathway of this model protein.  
 
 To subject model monoclonal antibodies to stress in the EFD, comparing 
their observed aggregation behaviour to that of BSA and similar proteins 
in the literature.  
 
 To modify the solvent and flow conditions in the EFD to explore a wide 
parameter space. Experimental design would be driven by both the 
fundamental fluid mechanics from above, as well as relevant literature 
from the biopharmaceutical industry. 
 
 To use an array of different biophysical and biochemical techniques, to 
develop a predictive, general mechanism for how monoclonal antibodies 
aggregate under extensional flow. 
 
 To understand how the EFD compares to orthogonal and orthologous 
assays for biopharmaceutical aggregation. Using a set of previously 
studied proteins, bioinformatics and statistical approaches will be used to 
compare different assays and methodologies to the EFD and the data 





























2. Materials and Methods 
2.1. Materials 
2.1.1 Equipment 
Gel-filtration chromatography (purification) equipment 
 ÄKTA Prime (GE Healthcare) 
 Superdex 26/60 S200 column (GE Healthcare) 
 Superdex 10/300 GL column (GE Healthcare) 
Extensional flow equipment 
 Breadboard base (Thor Labs) 
 Syringe Clamps (Thor Labs) 
 Ferrule compression fittings (Hamilton) 
 Gilson P10 O-ring (Gilson) 
 Borosiliate glass capillaries (Sutter Instruments) 
 Ceramic capillary cutter (Sutter Instruments) 
 Arduino Microcontroller (Arduino) 
 Stepper motor (Haydon Switch and Waterbury CT Instrument Co.) 
 Gas-tight 1 mL syringes 1001 RN model (Hamilton) 
Analytical instruments and equipment 
 miniDAWN TREOS + QELS module (Wyatt) 
 Nanosight LM10 (Malvern Panalytical) 
 JEM1400 Transmission Electron Microscope (JEOL) 
 Eppendorf 5810 Benchtop Centrifuge (Eppendorf) 
 Optima TLX Ultracentrifuge (Beckman Coulter) 
 TLA100 rotor (Beckman Coulter) 
 Ultrospec 2100 Pro UV/Visible spectrophotometer (Amersham 
Biosciences) 
 UV-transparent cuvettes (STARSTEDT)  
 Thickwall Polycarbonate ultracentrifuge tubes (Beckman Coulter) 
 GenFuge 24D Benchtop centrifuge (Progen) 
 Electrospray Ionisation capillaries (Sutter Instruments) 
 Synapt High Definition Mass Spectrometer (Waters) 
 Gel Documentation UV-transluminator (SynGene) 
 QuantaMaster spectrofluorimeter (Photon Technology International) 
 1 cm path length fluorescence cuvette (Hellma Analytics) 
 Synapt G2Si Mass Spectrometer (Waters) 
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 P680 HPLC pump (Dionex) 
 ASI-100 Automated sample Injector (Dionex) 
 PDA-100 Photodiode Array Detector (Dionex) 
 STA-565 Column holder (Dionex) 
 Polypropylene HPLC (0.5 and 1.5 mL) vials  (ThermoFisher) 
 HPLC caps (ThermoFisher) 
 G3000 SWXL gel filtration HPLC column (TOSOH) 
Gel electrophoresis equipment 
 Glass plates (ATTO) 
 Magnetic clamps (ATTO) 
 Silicone rubber gaskets (ATTO) 
 Electrophoresis tank (ATTO) 
 Electrophoresis cables (ATTO) 
 Powerpac Basic (Bio-Rad) 
 Orbital Shaker (AQS Shaker Manufacturing) 
Software 
 ASTRA 6.1 (Wyatt) 
 NTA 2.3 (Malvern Panalytical) 
 Image Capture Engine Software 6.02 (AMT) 
 Microsoft Excel 2010 (Microsoft) 
 Origin (Pro 8.1 and 2017) (OriginLab Corp.) 
 MassLynx 4.1 (Waters) 
 MATLAB (Version unknown) (Mathworks) 
 Genetool Version 4.03 (SynGene) 
 CamSol webserver (Section 2.2.17) 
 StavroX 3.6.0.1 (University of Halle) 
 Chromeleon 6.4 (Dionex) 
 ProtPARAM webserver (Section 2.2.17) 
 Clustal Ω webserver (Section 2.2.17) 
 ABodyBuilder webserver (Section 2.2.17) 
 Solubis webserver (Section 2.2.17) 





2.1.2 Chemicals (all reagent grade unless stated) 
Buffer salts and acids  
 HPLC-grade Ammonium acetate stock solution (7.5 M) (Sigma-Aldrich) 
 L-Arginine (Acros Organics) 
 Sodium succinate dibasic hexahydrate (Sigma-Aldrich) 
 Sodium acetate (Sigma-Aldrich) 
 L-Histidine (Sigma-Aldrich) 
 Sodium phosphate monobasic (Sigma-Aldrich) 
 Sodium phosphate dibasic (BDH Lab Supplies) 
 4-(2-Hydroxyethyl)piperazine-1-ethanesulphonic acid (HEPES) (Sigma) 
 Sodium chloride (Fisher Scientific) 
 Tris {(trishydroxymethyl)aminomethane} base (Fisher Bioreagents) 
 Guanidine hydrochloride (Sigma-Aldrich) 
 Urea (Thermo) 
 Hydrochloric acid (37% w/w) (Honeywell/Fluka) 
 Nitric acid (70% w/w) (Honeywell/Fluka) 
 Glacial acetic acid (95% w/w) (Fisher Scientific) 
Dyes (covalent and non-covalent) and covalent cross-linkers 
 Alexa-488 (Molecular Probes/ Invitrogen) 
 Uranyl acetate (2% w/v) (source unknown) 
 5-{2-(iodoacetamido)Ethylamino}Napthalene-1-sulphonic acid 
(IAEDANS) (Molecular Probes/Invitrogen) 
 Nile Red (Sigma-Aldrich) 
 8-Anilinonapthalene-1-sulphonic acid (ANS) (Sigma-Aldrich) 
 bis(sulfosuccinimidyl)suberate (BS3) cross-linking reagent (Thermo 
Scientific) 
 BS3-d4(deuterated) cross-linking reagent (Thermo Scientific) 
Electrophoresis-related chemicals 
 Protein Plus Protein Dual Xtra molecular weight ladder (Bio-Rad) 
 Instant Blue (Coomassie Brilliant Blue) stain (Expedeon) 
 SilverXpress Silver Staining Kit (Invitrogen) 
 10x Cathode buffer (Crystal buffers Tris-Tricine SDS) (Severn Biotech) 
 10x Anode buffer (2M Tris.HCl pH 8.8) (home-made) 




 Tetramethylethylenediamine (TEMED) (Sigma) 
 Ammonium persulphate (APS) (Sigma-Aldrich) 
Miscellaneous chemicals used 
 Bromophenol blue (Sigma-Aldrich) 
 Glycerol (Fisher Scientific) 
 Dithiotherirol (DTT) (Formedium) 
 Tris(2-carboxyethyl)phosphine hydrochloride (TCEP) (Aldrich) 
 
2.2. Methods 
2.2.1. Proteins used in the study and their preparation 
 
Preparation of Bovine Serum Albumin (BSA)  
 
BSA was purchased from Sigma Aldrich at ≥98% purity. The protein was 
reconstituted at a concentration of ~ 35-55 mg mL-1 in 0.22 μm-filtered and de-
gassed 25 mM ammonium acetate buffer, pH 5.1. The protein was purified by gel-
filtration chromatography using a 26/60 Superdex 200 column (GE Healthcare), 
pre-equilibrated with 25 mM ammonium acetate buffer, pH 5.1. The protein was 
loaded onto the column in 3.5 mL injections, with the column operated at 1 mL 
min-1 with an AKTA Prime (GE Healthcare). Fractions were pooled and the purity 
of the protein validated by SDS-PAGE using a 12% (w/v) SDS-PAGE gel (see 
Section 2.2.2). The purified, monomeric BSA was stored in frozen aliquots at -20 
°C until needed.  
Prior to stress experiments, aliquots were thawed at room temperature and where 
necessary, concentrated by centrifugal filtration using a 30 kDa cut-off centifugal 
filter (Merck Millipore) at 4,000 rpm in an Eppendorf 5810 centrifuge. Samples 
were then filtered using a syringe-driven 0.22 μm filter (Merck Millipore and JET 
BIOFIL) and the concentration of the sample determined by UV-Visible 






Preparation of MedImmune mAb solutions  
 
Antibodies from MedImmune Ltd were supplied as frozen, 1 mL aliquots (following 
Protein A chromatography). These were defrosted, aliquoted and snap-frozen in 
liquid nitrogen. The tubes of protein were then stored at -80 °C until further use. 
The three mAbs procured from MedImmune are all of the IgG1 class: MEDI1912 
(called WFL herein), MEDI1912_STT (called STT herein) (Dobson et al., 2016) 
and Nip109 (called mAb1 herein). For use in flow experiments, aliquots were 
defrosted on ice, then dialysed for 4 hrs into the desired buffer using 3.5 kDa cut-
off GeBA Dialysis tubes (Generon). The buffers used in the thesis were: 150 mM 
ammonium acetate, pH 6.0; 125 mM L-arginine + 20 mM sodium succinate, pH 
6.0; 10 mM sodium acetate, pH 6.0; 10 mM sodium succinate, pH 6.0; 10 mM L-
histidine pH 6.0, 10 mM sodium phosphate pH 7.2 and 100 mM sodium 
phosphate, pH 7.4. All buffers were filtered through a 0.22 µm filter, de-gassed 
and stored at 4°C.  Following dialysis, the proteins were driven through a 0.22 μm 
filter and their concentration determined using UV-visible spectroscopy. 
Preparation of Adimab protein solutions 
 
IgG1 samples from Adimab were supplied frozen on ice in 5 mL aliquots (Jain et 
al., 2017) (purified by Protein A chromatography). Samples were defrosted, 
aliquoted, snap-frozen in liquid nitrogen and stored at – 80 °C until required. mAb 
samples were dialysed into filtered and de-gassed 25 mM HEPES, 150 mM 
sodium chloride, pH 7.3 in the same manner as above. Following dialysis, these 
mAbs were also passed through a 0.22 μm syringe filter and their concentrations 
determined using UV-visible spectroscopy. 
Protein concentration determination 
  
Protein concentrations were determined using an Amersham Biosciences 
Ultrospec 2100 Pro UV/Visible spectrophotometer. UV-transparent cuvettes 
(STARSTEDT) were used to measure the A280 of the reference and protein 
samples. The molar extinction coefficients (ε280) and molecular masses (Mw) for 
the proteins used in the thesis are shown in Appendix Table 1.1. Once 
determined, the protein solutions were diluted to the appropriate concentration 




2.2.2 Sodium dodecyl sulphate-polyacrylamide 
gel electrophoresis (SDS-PAGE)  
 
Plate setup 
Two SDS-PAGE gels were prepared by placing a silicone gasket in between a flat 
glass plate and a raised spacer plate (ATTO). This creates a 1.5 mm gap in 
between the plates. This was repeated to make the second gel. The moulds were 
clamped and then the appropriate gel solution added. In two-component (stacking 
and resolving gels), the resolving gel was cast, a layer of Milli-Q H2O added and 
allowed to set for one hour. The stacking gel was then cast, a 12- or 14- lane 
comb added to create the wells, then the gel left to set for at least one hour to set. 
Where no stacking gel was used, the separating gels were cast and the comb 
inserted immediately, before allowing the gels to set. This setup creates two, 80 
mm x 100 mm gels. For all gels, APS and TEMED were added last to each 
mixture, before vortexing and casting the gel. 
 
‘Conventional’ SDS-PAGE gels 
The components for 12% (w/v) SDS-PAGE gels are detailed in Table 2.1. 
Table 2.1. Gel components for 12% (w/v) SDS-PAGE gels. 




Milli-Q H2O 6.4 3 
30% acrylamide:bis-acrylamide solution 8 0.7 
1.5 M Tris.HCl, 0.4 % (w/v) SDS pH 8 5.2 1.25 
10% (w/v) ammonium persulphate (APS) 0.05 0.1 










Chemical cross-linking SDS-PAGE gels 
Initial cross-linking gels were prepared according to Devine, 2016. This is shown 
in Table 2.2. 
Table 2.2. Initial cross-linking gel recipe 
Component Resolving gel (mL) Stacking Gel 
(mL) 




3 M Tris.HCl, 0.3 % (w/v) SDS pH 8.45 5 1.55 
Glycerol 2 - 
10% (w/v) ammonium persulphate 
(APS) 
0.1 0.1 
TEMED 0.04 0.04 
 
Later gels (as indicated in Chapter 5) were prepared with a revised, 8% (w/v) gel 
as follows in Table 2.3.  
Table 2.3. Lower % (8% w/v) SDS-PAGE gel for later cross-linking 
experiments 
Component Resolving gel (mL) Stacking Gel 
(mL) 




3 M Tris.HCl, 0.3 % (w/v) SDS pH 8.45 2.05 1.3 
Glycerol - - 
10% (w/v) ammonium persulphate 
(APS) 
0.1 0.1 
TEMED 0.04 0.04 
 
Semi-denaturing SDS-PAGE gels 
For SD-SDS-PAGE, 6% (w/v) gels were prepared with no stacking gel as follows: 
Table 2.4. 6% (w/v) SD-SDS-PAGE gel recipe 
Component Resolving gel (mL) Stacking Gel 
(mL) 




3 M Tris.HCl, 0.3 % (w/v) SDS pH 8.45 2.6 - 
Glycerol - - 
10% (w/v) ammonium persulphate 
(APS) 
0.1 - 




SDS-PAGE samples were either run in tandem or individually with a blank with 
the equipment listed in Section 2.1. Samples were diluted with either 6x loading 
buffer (300 mM Tris.HCl, pH 6.8, 300 mM DTT, 6% (w/v) SDS, 0.3 % (w/v) 
bromophenol blue and 60% (v/v) glycerol) or in SD-SDS-PAGE native loading dye 
(as above minus SDS and DTT), prepared by Dr Amit Kumar. Samples were 
loaded into the gels and electrophoresed according to the relevant section herein. 
In the gel electrophoresis tank, the cathode buffer contained 100 mM Tris.HCl, 
100 mM Tricine, 0.1% (w/v) SDS, pH 8.3, whilst the anode buffer contained 400 
mM Tris.HCl, pH 8.8. 
 
2.2.3 Extensional flow apparatus and experimental 
setup 
 
The EFD consists of two, 1 mL Hamilton Syringes (1001 RN SYR), drilled at the 
end to accommodate a 0.3 mm internal diameter (I.D) borosilicate glass capillary 
(Sutter Instruments). The capillary length was 75 mm in all experiments, except 
shear experiments where capillaries were cut to either 50 mm or 37.5 mm long 
with a ceramic cutter (Sutter Instruments), then flame-finished in a Bunsen burner. 
Prior to each run, the syringes and barrels were washed with 2% (v/v) Hellmanex-
III solution (Hellma Analytics), then Milli-Q water, then the appropriate filtered and 
de-gassed buffer. Compression fittings (Hamilton) and O-rings (Gilson) were fitted 
to the capillary and connected to one syringe. The setup was inspected to ensure 
it was sealed with buffer (i.e. no air-bubbles), then 0.5 mL of protein solution drawn 
slowly into the syringe through the capillary, before removal of any obvious air-
bubbles. The syringes were then sheathed in silicone tubing and clamped to the 
EFD with syringe clamps (Thor Labs). Once connected and sealed, the syringes 
were driven at a set plunger velocity by a stepper motor (Haydon Switch and 
Waterbury CT Instrument Co), programmed by an Arduino Microcontroller. Unless 
stated otherwise, this velocity = 8 mm s-1 (strain rate = 11,750 s-1, shear rate 
52,000 s-1, see Section 3.1). The protein solution was shuttled between the two 
syringes for the desired number of passes, then the motor stopped, the rig 
disconnected and the solution expelled slowly into an Eppendorf tube down the 
side to avoid cavitation. One pass is defined as the emptying of one syringe and 
the re-filling of another. For a frame of reference, one pass at 8 mm s-1 takes ~6 
s, thus 100 passes takes ~ 10 minutes. 
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Control protein samples, unless otherwise stated, were incubated at ambient 
temperature in an Eppendorf tube for the duration of the longest flow experiment 
prior to analysis. These samples will be referred to as ‘native’ or ‘quiescent’ herein. 
Images of the flow device and apparatus are shown in Figures 2.1 to 2.3. 
 
Figure 2.1a. Syringe and capillary used for extensional flow stress 
experiments. Ai= Rubber Gilson O-ring, ii= Ferrule, iii = Steel syringe cap. B = 
0.3 mm (inner diameter) capillary (75 mm length). C = Hamilton syringe, 




Figure 2.1b. Mechanical driver of the extensional flow device. A = 
Microcontroller unit. The number of cycles is shown on the display once the rig 







Figure 2.1c. The connected syringes in the extensional flow device. A = 
syringe driver which moves towards the motor shown in 2.1b (to the left) when 
the device starts and vice-versa. B = Syringe clamps which hold the syringes in 
place. C = stainless steel rod which connects the two syringe drivers to the 
stepper motor. D = Stainless steel baseplate to keep the rig level. The sample 
syringe is loaded on the right hand side. 
 




Quiescent or stressed protein samples were analysed by batch-mode DLS using 
a Wyatt miniDawn TREOS system, equipped with an additional quasi-elastic light 
scattering (QELS- synonym for DLS) detector. All mAb samples were analysed 
without prior dilution. 5 mg mL-1 BSA samples were diluted 1:2 with 25 mM 
ammonium acetate pH 5.1, whilst 10 mg mL-1 BSA samples were diluted 1:5 with 
the same buffer prior to analysis. A five-minute buffer baseline was recorded in 
the Astra 6.1 software, followed by injection of 250 µL sample into the instrument. 
DLS data were collected for five minutes, before 1 mL of 0.22 μm-filtered and de-
gassed buffer was injected and a second, five-minute baseline collected. The flow 
cell was then cleaned by injection of 1–2 mL (each) of 1M Nitric acid, MilliQ H2O 
and then buffer. The buffer was kept on ice to minimise cavitation (air bubble 
formation) in the instrument. Three-minutes of DLS data were analysed in the 
Astra 6.1 software.  
Theoretical (data processing) 
As stated in Section 1.3.4, DLS measures the fluctuation of scattered light as a 
function of time. A second order correlation function describes these fluctuations 







Equation 2.1. I (t) is the intensity of the scattered light at a time t (s). < > 
brackets indicate averaging over all time. 
The correlation function is based on the delay τ, i.e. the amount the intensity trace 
shifts from the original prior to averaging. For a monodisperse sample, the 
correlation function is given in Equation 2.2: 
𝑔(2)(𝜏) = 𝐵 + 𝐴𝑒(−2𝛤𝜏) 
Equation 2.2. B = baseline for the correlation function at infinite delay, A is the 
correlation function amplitude at zero delay and Γ is the decay rate. 
Γ is found by fitting a non-least linear squares algorithm to the measured 
correlation function data (performed by the Astra software). The diffusion 











Equation 2.3.  n0  is the refractive index of the solvent, λ0 is the vacuum λ (i.e. 
not in solution) of the incident photon and θ is the scattering angle. 
Finally, the Stokes-Einstein Equation is used to determine the hydrodynamic 
radius of the particle (see Equation 1.1, Section 1.3.4). Example correlograms 
obtained from DLS were fitted to a single-exponential decay in Origin with 
Equation 2.4. 
 




Equation 2.4. Single Exponential Decay equation fit to correlation function data 
throughout the report. A is the amplitude, y0 is the y axis intercept, x0 is the x-
axis intercept and τ is the delay time. 
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Non-monodisperse samples were further analysed to determine the 
hydrodynamic radii (average or distributions) of species in solution. DLS data can 
be subjected to both Cumulants and Regularisation analysis in Astra. The 
Cumulants analysis permits the calculation of the z-average (mean) radius and 
width (standard deviation) of a solution (Hanlon et al., 2010). These values can 
then be used to calculate the polydispersity index (PDI) of the solution according 
to Equation 2.5 (Roger et al., 2016). 




Equation 2.5. Calculation of Polydispersity index (PDI) from the square of the 
‘width’ of the z-average radius (s.d. in nm2) and the square of the z-average 
radius (nm2). 
The Regularisation algorithm is much more complex (Provencher, 1982), but 
essentially fits as few single-exponential decays as possible to best describe the 
DLS data (Hassan et al., 2014; Minton, 2016) . The y-axis of a regularisation plot 
is the differential intensity fraction (log nm-1) against the size of the species in 
solution (nm). All data were processed in Microsoft Excel and plotted in Origin. 
 
2.2.5 Nanoparticle Tracking Analysis 
 
Experimental 
Native and stressed BSA samples (5 and 10 mg mL-1) were diluted to the same 
extent as in Section 2.2.4, to minimise noise. 250 μL of protein sample was 
injected against gravity into a Nanosight LM10 instrument (Malvern Panalytical), 
equipped with a 642 nm laser. Upon checking for expulsion of air, three, 90-
second long videos were recorded in the NTA 2.3 software. The instrument 
settings were as follows: screen gain = 1, detection threshold = 10nm, T = 22°C, 
η = 0.95 cP and camera brightness = 4–12 (to minimise background noise). 
Following data capture, the sample was withdrawn by syringe. The apparatus was 
then disassembled and cleaned stringently with 70% (v/v) ethanol solution. 
Compressed air was used to remove residual ethanol in the entry and exit ports 
of the instrument. 
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Theoretical (data processing) 
The three videos (per sample) were batch processed in the NTA 2.3 software, 
where the 2D motion of the particles in time (from the videos) was used to 
calculate the apparent diffusion coefficient of the particles and count them (see 
Section 1.3.4).  The particle size is reported as hydrodynamic diameter in nm. The 
collated data were then averaged in Microsoft Excel 2010 and plotted in Origin 
Pro. 
2.2.6 Transmission Electron Microscopy (TEM) 
  
Experimental 
Native and stressed BSA samples (5 and 10 mg mL-1) were diluted to the same 
extent as in Section 2.2.4, to avoid over-staining the EM grids. A colloidal carbon-
coated copper EM grid (prepared by Martin Fuller, University of Leeds) was 
immersed in 20 μL of protein sample for 45 s. Excess sample was then blotted off 
onto Whatman filter paper, before the grid was washed and blotted in 3 x 10 μL 
of Milli-Q H2O.  The grid was stained by immersing the sample in 10 μL of 2% 
(w/v) uranyl acetate solution, before immediately blotting the sample and allowing 
it to air-dry (~1 minute). The grid was then stored in a protective holder for at least 
24 hours before imaging on a JEOL JEM1400 TEM at 120 kV.  
Data processing 
Images were recorded at 1,000x and 10,000x magnification using the AMT 
software provided with the instrument. Images were cropped to size using 
Microsoft Paint. 




Two x 200 μL of quiescent and stressed protein sample (two tubes per sample) 
were loaded into Beckmann Coulter Ultracentrifuge Tubes. The samples were 
centrifuged at 30,000 rpm (~35,000 xg) for 30 mins at 4°C in a Beckmann Coulter 
Optima ultracentrifuge, equipped with a TLA100 rotor. Following this, 150 μL of 
supernatant was removed from the tube. For BSA, the remaining pellet was re-
suspended in 200 μL of 6M guanidine hydrochloride in 25 mM Tris HCl buffer, pH 
6.0. This pellet fraction was then diluted to a final volume of 2 mL and left overnight 
at room temperature. 50 μL of the supernatant was also diluted to 2 mL final 
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volume and incubated overnight at room temperature. The A280 of each sample 
was then recorded by UV-visible spectroscopy (Section 2.2.1).  
For the mAbs, 200 μL of 6M guanidine hydrochloride in 25 mM Tris HCl buffer, 
pH 6.0 was added to each pellet fraction, the tubes sealed with Parafilm and 
incubated at 4°C overnight. 50 μL of the supernatant was added to 200 μL of the 
same denaturing buffer and incubated overnight at 4°C. The A280 of the mAb 
samples were then measured by UV-Visible spectroscopy as above. In Chapter 
4, BSA aggregation landscape data were produced using this mAb protocol. 
Theoretical 
The A280 values for each sample were used to calculate the amount of protein in 
the pellet and supernatant fractions. The extinction coefficients from 2.2.1 were 
used for all proteins, except BSA where the theoretical extinction coefficient was 
used (43,220 M-1cm-1) (Gill and von Hippel, 1989). The difference between these 
was used to calculate the % protein in the pellet fraction (% protein in pellet) 
according to Equation 2.6.  
% 𝑝𝑟𝑜𝑡𝑒𝑖𝑛 𝑖𝑛 𝑝𝑒𝑙𝑙𝑒𝑡 =  (
([𝑃] − [𝑆])
([𝑝𝑟𝑜𝑡𝑒𝑖𝑛0])
) × 100 
Equation 2.6. Equation to calculate the % protein in pellet. [P] and [S] are the 
molar concentrations of protein in the pellet and supernatant fractions 
respectively. [Protein0] is the molar concentration of the native protein stock, e.g. 
0.5 mg mL-1 mAb ~ 3.5 μM. N.B. Total recovery of insoluble protein from the 
pellet fraction was validated by calculating (([P] +[S])/2) and comparing this to 
the [protein0] above. 




Stressed or quiescent BSA samples were analysed using native electrospray 
ionisation-mass spectrometry (ESI-MS) using a Synapt HDMS mass 
spectrometer (Waters Corporation). Home-made sputter coated capillaries (Sutter 
instruments) were used to infuse the sample into the spectrometer. The 
spectrometer was operated in positive ion mode with the following settings: 
capillary cone voltage 1.2 kV, sample cone voltage 80 V, extraction cone 4 V, 
source temperature 40 °C, backing pressure 5–6 mBar, trap voltage 20 V, 
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trap/transfer gas flow 3 mL min -1. The instrument was calibrated using aqueous 
caesium iodide (CsI) (Sigma Life sciences) ions. 
BSA samples were analysed at a concentration of 10 μM, with samples being 
unclarified or centrifuged at 4°C for ten minutes at 8,000 xg in a bench-top 
centrifuge (Progen) prior to infusion into the spectrometer (see Section 3.2.)  
A series of 25 mM ammonium acetate solutions were also prepared at pH 6.8, 
5.1, pH 4 and pH 3, with titrations performed with glacial acetic acid. Native 
purified BSA was diluted down (in large excess) to a final concentration of 10 μM 
in these buffers, left to equilibrate for one hour at room temperature and then 
measured by mass spectrometry. 
Data processing 
 
Data were processed in MassLynx 4.1 to determine the mass-to charge ratio of 
each peak (m/z) and to assign peak masses. 
 
2.2.9 Fluorescence correlation spectroscopy (FCS) of 
BSA 
Experimental 
To fluorescently label BSA, a 1 mg mL-1 BSA solution was prepared in 4 M urea 
in 25 mM Tris.HCl, pH 7.5 (by Dr Amit Kumar). This was mixed 1:10 (mol:mol) 
with the sulfhydryl reactive dye, Alexa Fluor 488 C5 Maleimide (Molecular Probes, 
ThermoFisher Scientific) and the conjugation reaction allowed to proceed for 4 hr 
at room temperature. The labelled protein was purified from unlabelled protein 
and dye using a Superdex 10/300 GL gel-filtration column (GE Healthcare). 
Fractions were pooled and stored in black Eppendorf tubes at - 20°C. 
In flow experiments, 10 μL labelled BSA (concentration = 1 mg mL-1) was added 
to 500 μL of the BSA solution to be stressed, or to a quiescent sample. Following 
stress, the sample was analysed with a home-built FCS apparatus with a 1 fL 
confocal volume (Gell et al., 2008). 100 μL was loaded into the apparatus and 10 






Data were analysed by Dr Roman Tuma (University of Leeds) using non-linear 
least squares fitting using MATLAB scripts (Mathworks) (Tipping et al., 2015). The 
diffusion coefficients obtained were converted to apparent hydrodynamic radii by 
calibrating against the free dye. The general analytical expression of the auto-

























Equation 2.7 Equation for the auto-correlation function obtained by FCS. ?̅? is 
the average number of fluorophores in the point-spread function (the efficiency 
of fluorescence collection inside an instrument’s confocal volume) at any time, z0 
is the 1/e2 sample volume in the direction of the optical axis, ω0 is the sample 
volume perpendicular to the optical axis, DC is the value of the autocorrelation 
as τ  ∞ (typically = 1), τD is the molecular diffusion time and D is the 
translational diffusion coefficient of the molecule. Taken from (Gell et al., 2006). 
The hydrodynamic radii extracted from the fitting above were processed in 
Microsoft Excel and plotted in Origin. 
 
2.2.10 IAEDANS labelling of BSA in the presence and 
absence of TCEP 
Experimental 
 
5 mM  5-{2-(iodoacetamido)Ethylamino}Napthalene-1-sulphonic acid (IAEDANS) 
(Molecular Probes), from a 167 mM stock prepared in 1 M Tris.HCl, pH 8, was 
added to 5 mg mL-1 BSA (in 25 mM ammonium acetate, pH 5.1) and stressed for 
0–100 passes in the EFD at a plunger velocity of 8 mm s-1. For experiments 
containing Tris(2-carboxyethyl)phosphine (TCEP), this was either added to the 
BSA on isolation prior to stress, or added to the dye mixture (final concentration 
= 0.5 mM from a 250 mM stock) before addition to the BSA as stated above. In 
ex situ labelling experiments, 5 mg mL-1 BSA was stressed in the EFD under the 
conditions above, then incubated with the dye (with and without TCEP) for the 
same length of time as the flow experiment. All IAEDANS labelling experiments 
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were quenched with SDS-PAGE loading dye containing 200 mM dithiothreitol 
(DTT). The samples were then electrophoresed (Section 2.2.2) on a 12% (w/v) 
SDS-PAGE gel. 
Data processing 
The gel was irradiated with UV light using a Syngene Gel Documentation UV-
transluminator. The intensities of the fluorescent bands were quantified using the 
Gene Tool software supplied with the instrument. The gel was then subsequently 
stained with Coomassie Brilliant Blue. The gel experiment and images were 
performed and processed by Dr Amit Kumar.  
 
2.2.11 Nile Red and 8-Anilinonapthalene-1-sulphonic 
acid (ANS) fluorescence spectroscopy 
 
Nile Red (Sigma-Aldrich) was dissolved in 1 mL of DMSO (Sigma-Aldrich) and a 
180 µM stock prepared using a ε552 of 19,600 M-1 cm-1 in DMSO (Castro et al., 
2005). 0.5 mg mL-1 samples of STT and WFL in 0.1 M sodium phosphate, pH 7.4 
were stressed for 10 passes at a plunger velocity of 8 mm s-1 in the EFD. 10 μM 
Nile Red (final concentration) was added to 500 μL of the protein stock either 
before stress (in situ) or after (ex situ). Quiescent samples were prepared by 
incubating the dye with protein at room temperature for 2 min. Following 
incubation, the samples were transferred to 1 cm path length quartz cuvettes 
(Hellma) and diluted 1:1 with 0.1 M sodium phosphate buffer, pH 7.4. Samples 
were then analysed using fluorescence emission spectroscopy using a PTI 
fluorescence spectrometer. Samples were excited at 550 nm and emission 
recorded at 560–740 nm with 5 nm slit widths. Three spectra were recorded and 
averaged in Microsoft Excel. The spectrum for the dye in buffer control was 
subtracted away from all spectra.  
For ANS experiments, a 250 μM stock was prepared in 1 mL of Milli-Q H2O. The 
stock concentration was determined using a ε350 = 4,900 M-1 cm-1 (Azzi, 1974). 
Protein samples were prepared as above, except 25 μM ANS was used instead 
of Nile Red. A BSA reference sample was prepared by adding 25 μM ANS to 6.8 
mg mL-1 BSA in 25 mM ammonium acetate, pH 5.1. Fluorescence emission 
spectroscopy was performed using the PTI spectrometer, with 7.5 nm slit widths. 
Samples were excited at 380 nm, with emission monitored between 400–600 nm. 
Three spectra were recorded for each sample, as well the dye in buffer reference 
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(subtracted away from all spectra as above). All spectral data were processed in 
Microsoft Excel and the final graphs produced in Origin. 
 
2.2.12 Chemical cross-linking of WFL with BS3 
 
Chemical cross-linking 
WFL was dialysed into 100 mM sodium phosphate buffer, pH 7.4. A 1:1 mixture 
of BS3 cross-linker (XL) and BS3-d4, its deuterated analogue, was prepared in 20 
mM sodium phosphate, pH 7.4. The 12.6 mM stock was incubated on ice. WFL 
(at a concentration of 0.5 mg mL-1) was stressed for 10 passes with either a 50x 
or 100x molar excess (~175 or 350 µM) of XL mixture in-situ at a plunger velocity 
of 8 mm s-1. WFL was also stressed for 10 passes, then XL added ex-situ. A 
quiescent WFL sample was also incubated with XL. All samples were incubated 
with cross-linker for four minutes in total at room temperature, before quenching 
the reaction with 20 mM (final) Tris.HCl, pH 8.0. Both reducing and native gel 
samples were prepared by adding protein: dye in a 5:1 ratio. Samples were boiled 
or unboiled as stated in Chapter 5. 15 µL of the native samples were loaded onto 
either an 8% or 12% SDS-PAGE gel and electrophoresed at 50 mA overnight. 
The gels were then stained using Coomassie Brilliant Blue and imaged using the 
SynGene Gel Documentation instrument.  
 
Cross-link identification by mass spectrometry 
Following this, peptides were analysed using Liquid Chromatography & Mass 
Spectrometry using a Synapt G2si instrument by Rachel George and Dr Patrick 
Knight in the Mass Spectrometry Facility, University of Leeds. Spectra were 
processed using StravroX software to identify cross-linked peptides 
(https://www.stavrox.com/) (Götze et al., 2012). The following software settings 
were used: WFL sequence in FASTA format; Minimum detection threshold of 10 
ppm and 0.1 Da mass error; Expected modifications: reduction and alkylation of 
Cys (+ AcO-) and oxidation of Met; BS3 cross-linker with d4 also selected (‘heavy’); 





2.2.13 High-performance liquid chromatography 
(HPLC) monomer loss assay 
 
Experimental 
WFL, mAb1 and STT were stressed for 0–100 passes at a plunger velocity of 8 
mm s-1. The protein concentration was either 0.25 or 0.5 mg mL-1, with all proteins 
dissolved in 150 mM ammonium acetate, pH 6.0. Following stress, the samples 
were initially clarified using 0.22 μm syringe filters. 100 μL of filtrate was then 
diluted 1:1 with a 5x stock of buffer (125 mM L-arginine, 20 mM sodium succinate 
pH 6.0) and put into HPLC vials and sealed. Later samples were clarified by 
performing the insoluble protein pelleting assay (Section 2.2.7), then adding 100 
μL of supernatant to the quench solution as above. All samples were kept at 4°C 
in Dionex automated sample injector.  50 μL of each sample was injected onto a 
TOSOH G3000 SWXL gel filtration column equilibrated with either 150 mM 
ammonium acetate, pH 6.0 or 125 mM L-arginine, 20 mM sodium succinate, pH 
6.0. The column was operated at a flow rate of 0.4 mL min-1. Control samples 
were loaded in triplicate (technical replicates) to calculate the HPLC loading error. 
The number of replicates for each sample is given in the text in Chapter 5. 
Data processing 
HPLC chromatograms were integrated in the Chromeleon software (Version 6.4). 
The path length of the HPLC UV detector was 1 cm. The peak areas from the 
integration were converted to the mass of monomer in Microsoft Excel. All data 
were plotted in Origin Pro. 
2.2.14 Semi-denaturing sodium dodecyl sulphate 
polyacrylamide gel electrophoresis (SD-SDS-PAGE) 
 
WFL, STT and mAb1 samples were stressed for 0–100 passes at a plunger 
velocity of 8 mm s-1 under the same conditions as Section 2.2.13. Following 
stress, 50 μL of sample was added to 10 μL of native loading dye (no reducing 
agent or SDS) and the sample kept on ice. 25 μL of each sample was loaded onto 
a 6% (w/v) separating SDS-PAGE gel (no stacking gel) and electrophoresed at 
45 mA for 3 hours. The gel was then stained with Coomassie Brilliant Blue 
(Expedeon Instant Blue) or silver stained using the manufacturer’s (Invitrogen 
SilverXpress Silver Staining Kit) protocol. All incubation steps below were 
performed with shaking on an orbital shaker (AQS Shaker Manufacturing). 
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Briefly, the gel was washed twice with Milli-Q H2O. The gel was fixed by adding 
Milli-Q water, methanol (Fisher Scientific) and acetic acid (Fisher Scientific) in a 
6:5:1 (v/v/v) ratio (50 mL final volume), then left for ten minutes. The gel was then 
sensitised by adding Milli-Q water, methanol and Sensitiser (20:20:1 v/v/v ratio, 
25 mL final volume) and incubating for 30 mins. This solution was discarded and 
the sensitisation step repeated. The gel was then washed for 5 mins in 50 mL of 
Milli-Q H2O, the solution discarded and the step repeated. The gel was then 
stained with Stainer A, Stainer B and Milli-Q H2O (1:1:98 v/v/v, 25 mL total volume) 
for 15 mins. Developing solution (1.5 mL of Developer and ~24 mL of ddH2O) was 
added carefully to the gel until bands appeared, with constant shaking. 
Development was terminated by pipetting 5 mL of Stopper solution into the 
Developing solution, with constant agitation. The gel was left to stop for ten 
minutes, before the gel was washed three times with 50 mL Milli-Q H2O washes. 
The gels were imaged at the end of each staining protocol using the SynGene 





2.2.15 Batch mode static light scattering 
 
WFL, STT and mAb1 samples were prepared as in 2.2.13. Samples were injected 
into the Wyatt miniDAWN Treos instrument as in Section 2.2.4. The instrument 
simultaneously collects static light scattering at the angles 40°, 90° and 131° in 
addition to DLS. The light scattering data were analysed in the ASTRA 6 software 
by setting the concentration of the sample and using a dn/dc value of 0.186 g/cm 
(Section 1.3.4). Data were fit to the Debye mass model as shown in Equations 










= 𝑀𝑃(𝜃) − 2𝐴2𝑐𝑀
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Equation 2.8. Reciprocal version of the Zimm equation for static light scattering. 
c = mass concentration of solute (g mL-1), M = weight-average molar mass ( g 
mol-1), A2 is the second osmotic virial coefficient (sometimes called B22) (mol mL 
g-2), K* is an optical constant, with n0 being the refractive index of the solvent at 
the incident wavelength (658 nm), NA is Avogadro’s number (6.022 x 10
23 mol-1), 
dn/dc is the differential refractive index increment (0.186 mL g-1,Section 1.3.4), 
P(θ) is the theoretical form factor (describing the size and shape of the solute), 
<r2> is the root-mean square radius and Rθ is the excess Rayleigh ratio (cm
-1). 
The Debye fit plots Rθ/K*c against sin2(θ/2). As θ  0, P(θ)  1.  
𝑅0
𝐾∗𝑐
= 𝑀 − 2𝐴2𝑐𝑀




Equation 2.9. Debye equation for SLS data. Plotting this yields a straight line of 
y = c- mx. Plotting x and y yields the weight-averaged molecular weight of the 
sample at the y-intercept  and the gradient = <r> or root-mean square radius of 
the solute (Wyatt, 1993). 
When operated in batch mode, error in the weight-average mass measurement 







Equation 2.10. Calculation for the uncertainty-weighted average molar mass 










Equation 2.11. Calculation for the uncertainty in the molar mass measurement, 
as defined by the Wyatt Astra 6.1 software manual. 
 
2.2.16 Seeding and cross-seeding assays 
 
BSA at a concentration of 5 mg mL-1 was prepared as in Section 2.2.1. WFL and 
STT were also prepared as above to a concentration of 0.5 mg mL-1 in 150 mM 
ammonium acetate, pH 6.0. Seed material was prepared by stressing each 
protein for the stated number of passes, then putting this material on ice. Seeding 
reactions were performed by adding 10% (v/v) seed material to native protein, 
then stressing the protein for the given number of passes at a plunger velocity of 
8 mm s-1. Following stress, the samples, including the quiescent controls, were 
analysed using the insoluble protein pelleting assay (Section 2.2.7) 
For cross-seeding assays, a 10% (v/v) addition of seed material from protein x 
was added to a native stock of protein y and vice-versa. Stress experiments and 
quiescent samples were prepared and analysed as stated above. 
2.2.17 Adimab protein dataset experiments and 
analyses 
Choice of 33 mAbs from Jain et al. 2017 dataset 
Of the 133 IgG1s in the Jain et al. 2017 dataset, 56 were chosen by selecting 
subsets of mAbs from the five clusters in Figure 4 of the Jain et al, 2017 paper 
(see Chapter 6): 22 from Cluster 1; 10 each from Clusters 2 and 3 and; 7 each 
from Clusters 4 and 5.  VH and VL sequences for each of the mAbs were input into 
ProtParam to calculate their pI and molecular weight (Gasteiger et al., 2005). The 
intrinsic CamSol score of each VH-VL pair at pH 7 was also calculated by inputting 
protein sequences into the CamSol webserver (Section 1.3.1; http://www-
mvsoftware.ch.cam.ac.uk/index.php/login) (Sormanni et al., 2015). Initially, five 
mAbs were selected which had wide separation in the Jain study: Daratumumab 
(1), Tabalumab (2), Denosumab (3), Ipililmumab (4) and Ixekizumab (5). The 
other 28 mAbs were selected from the initial subset, with alternatives suggested 
by Jain et al. depending on the availability of the molecules. This led to a final 
panel of 33 mAbs (Appendix Table 1.2). 
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Phylogenetic tree construction with Clustal Ω 
The VH and VL sequences of the 33 mAbs were input into the Clustal Ω webserver 
(https://www.ebi.ac.uk/Tools/msa/clustalo/) (Sievers et al., 2011). The tree was 
downloaded and manually annotated according to the Figure legend in Section 
6.4.2. 
Extensional flow experiments on the Adimab proteins 
All Adimab proteins were prepared according to Section 2.2.2. Daratumumab (1) 
was initially stressed between 0–100 passes (at a concentration of 0.5 mg mL-1) 
at a plunger velocity of 8 mm s-1, before subjecting the samples to analysis by the 
pelleting assay. This preliminary assay led to the choice of 200 passes, 8 mm s-1 
plunger velocity, 0.5 mg mL-1 protein as the parameters used to test the proteins. 
Quiescent samples were incubated alongside the stressed samples for 20 mins 
at ambient temperature prior to analysis with the pelleting assay (Section 2.2.7). 
Flow experiments were performed on mAbs 1–5 in duplicate (biological repeats). 
Proteins from the additional 28 were initially stressed in groups of 6 or 5, with the 
composition of each group determined randomly. For the repeat of this set, the 
composition of each group of proteins was again selected randomly. Errors were 
then propagated according to Section 2.2.18. 
Spearman’s Rank analysis of the mAbs with and without flow data 
Statistical analysis of the mAb data was performed by Tushar Jain (Adimab, MA, 
USA) according to Jain et al. 2017.  To assess the correlation between the relative 
rankings of the mAbs within each group of assays, Spearman’s rank correlations 
were calculated for all pairwise combinations of antibody characteristics. A p-
value was calculated for each pairwise combination to assess the statistical 
significance of each correlation. In essence, the performance of a mAb in assay 
x was compared to that of assay y. This was performed on data for each of the 
33 mAbs from the Jain et al. paper (Chapter 6), augmented with data from the 
EFD. 
Rank analysis using ‘distance from ideal measurement’ 
For the four groups of assays (Section 6.1), ‘ideal’ values were derived. For 
example, the ideal mAb would show 0% aggregation in a monomer loss assay, or 
0% aggregation in the pelleting assay from the EFD. The pairwise distances for 
the 33 mAbs above, including and excluding extensional flow, were performed by 
Tushar Jain. Briefly, a mAb, i, was assigned a red flag if it exceeded the threshold 







Equation 2.12. Equation for the scaled value for a mAb i, in an assay j. y = 
measured value, Y50%, Y80% and Y20%  are the median, 80
th and 20th percentile of 
the 137 or 33 mAbs being analysed. 
The assay values were then scaled to allow comparison between assays, omitting 
SGAC-SINS data. Scaled values were limited between V_ij ± 2 scaled units. An 
ideal value for each assay was then assigned according to Equation 2.13. 
𝑉𝑗(𝑖𝑑𝑒𝑎𝑙) = min(𝑉𝑖𝑗) 𝑓𝑜𝑟 𝑒𝑎𝑐ℎ 𝑎𝑠𝑠𝑎𝑦, 𝑗 
Equation 2.13. Equation for the ideal value for an assay j, based on the 
minimum scaled value in Equation 2.12 for each assay. 
These values were then subtracted from one another (to yield the ideal assay 
value for each group of assays identified from the Spearman’s rank analysis to 
give Equation 2.14. 
 
𝑆𝑖𝑗 = 𝑉𝑖𝑗 − 𝑉𝑗 
∴   𝑆𝑖𝑗 =  ?̅?(𝑆𝑖𝑗) 𝑓𝑜𝑟 𝑎𝑛 𝑎𝑠𝑠𝑎𝑦 𝑗 𝑝𝑒𝑟 𝑔𝑟𝑜𝑢𝑝 
Equation 2.14. Equation for the ideal value for an assay j, based on the 
minimum scaled value in Equation 2.12 for each assay. 
Finally, the ‘distance from ideal’ values were calculated for each group of assays 
(1–4 excluding flow or 1–5 including flow) according to Equation 2.15. 
𝑑𝑖 = √
(∑ 𝑆𝑖𝑗2)
4 (𝑜𝑟 5 𝑖𝑛𝑐𝑙. 𝐸𝐹𝐷)
 
Equation 2.15. Equation to calculate the distance from ideal value, di, for each mAb. 
The di values were hierarchically clustered by Tushar Jain in R. Distance from 
ideal measurements were converted to ranks by this author The mAb closest to 
ideal was defined as having a rank of 1. To assign the rank of the mAbs an integer 
(1–33), the mAbs were ordered lowest to highest in Microsoft Excel (1 being best, 
33 being worst).  
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scFv homology model construction  
VH-VL sequence pairs, for each of the 33 mAbs, were input in FASTA format into 
the ABodyBuilder webserver (http://opig.stats.ox.ac.uk/webapps/sabdab-
sabpred/Modelling.php) (Leem et al., 2016). Output models were saved in .pdb 
format and edited in PyMOL. 
APR identification in Solubis 
APRs were identified within each VH-VL sequence pair by inputting the structures 
from above into the Solubis webserver (Section 1.3.1) 
(http://solubis.switchlab.org/) (Van Durme et al., 2016). This performs TANGO to 
calculate the aggregation propensity of a particular APR (higher value = more 
aggregation-prone), as well as running FoldX to determine the contribution of the 
APR to the thermodynamic stability of the protein (ΔGcontrib ≤ 0 = favourable).The 
Solubis score (essentially a structure-corrected TANGO score) for each APR was 
calculated using Microsoft Excel. ΔGcontrib scores for each APR were normalised 
from 0 to 1 (ΔGcontrib -5 to +5), then multiplied by the TANGO score for the APR. 
The solvent accessible surface area (SASA) for each APR was computed in 
PyMOL. ΔSASA calculations were performed in PyMOL by deleting either the VH 
or VL chain and re-computing the SASA of the APRs (see Section 6.4). Once all 
calculations were performed in Microsoft Excel, data were plotted using Origin. 
 
2.2.18 Error propagation method 
All experiments in this thesis were performed in at least duplicate, on separate 
days, unless otherwise stated. For samples where N = 2, with each sample 
yielding two technical replicates or an ensemble average (e.g. insoluble protein 
pelleting assay and Cumulants analysis, respectively), the final mean and error 














Equation 2.16. Error propagation for N = 2 samples. A = mean of replicate A, B 
= mean of replicate B, δA = s.d from replicate A, δB = s.d from replicate B. The 
equation is re-arranged and solved for δC (the propagated error). Large 































3. Characterising protein aggregation 
induced by extensional flow 
3.1 Overview of the extensional flow device (EFD) 
 
As discussed in Sections 1.4 and 1.5, it has long been thought that proteins could 
have their structures perturbed by hydrodynamic forces, leading to an increase in 
their aggregation propensity. To date, this link has been tenuous, in part caused 
by the lack of clarity surrounding the fluid flows present in some studies. How 
extensional flow, in particular, affects proteins has been largely understudied. To 
investigate whether or not extensional flow has the ability to induce aggregation 
in globular proteins, a custom-made flow device was designed and validated by 
my colleague, Dr John Dobson (see Acknowledgements and Section 2.2.3). 
3.1.1. Computational fluid dynamics under standard flow 
conditions 
 
There are several different methods available to generate extensional flow fields 
(Section 1.4.1). A syringe-based device, incorporating a reduction in cross-
sectional area was chosen for this study, owing to its simplicity, low sample 
volume, lack of air-water interfaces and laminar flow conditions. Computational 
fluid dynamics (CFD) allows one to model how the mass, momentum and energy 
of a fluid changes as a function of time. The basis of CFD are the Navier-Stokes 
equations, which describe the flow in terms of its pressure and velocity at a given 
point (Aris, 1962). The fluid is modelled by dividing it into packets or ‘cells’, which 
are then combined to form a mesh. The differential Navier-Stokes equations are 
then solved for each packet in the mesh (Sharma et al., 2011). With the device in 
mind, CFD was performed, modelling the fluid at a plunger velocity of 8 mm s-1, 
which was selected as a baseline value. The CFD results are shown as part of a 








Figure 3.1. CFD results for the device, overlaid on a schematic of the EFD.  
i) The direction of flow is shown by the blue arrow. ii) At the point of contraction 
(red arrow) between the syringe and capillary, the fluid is forced to accelerate. 
The CFD profile (plunger velocity of 8 mm s-1) at the top shows the resulting 
increase in the velocity of the fluid, whilst the bottom profile shows the strain rate 
at the contraction point. The contraction point thus represents the extensional 
flow region, whereas the velocity gradient across the width of the capillary 
represents the high shear region. CFD was performed by Dr John Dobson, 
University of Leeds, in COMSOL version 4.0. 
The results show there is a rapid rate of increase in the velocity of the fluid (~238-
fold) at the point of contraction between the syringe and capillary, due to the 
incompressible nature of the fluid, highlighting the extensional flow region 
characterised by the strain rate, ε̇. The shear rate γ = 52,000 s-1 at the capillary 
wall. The shear stress = 46.3 Pa at the capillary wall. The increases in velocity 
and strain rate, at the contraction point, take place over a short distance of just 2 







Figure 3.2. CFD result for the central streamline at a plunger velocity of 8 
mm s-1. The CFD results show the centre-line strain rate = 11,750 s-1, with the 
velocity increasing from 8 mm s-1 to 1.9 m s-1. A profile position of 0.01 m 
corresponds to the point of contraction. Calculations performed by Dr John 
Dobson, University of Leeds. 
 
Under these standard flow conditions (plunger velocity of 8 mm s-1), during one 
pass (defined as the complete emptying of one syringe into the other driven by 
the stepper motor, Section 2.2.3), a protein within the fluid occupies: the barrels 
of the syringe for ~5 s; the extensional flow region (the contraction point) for 18 x 
10-6 s and the high shear capillary region for 1 x 10-3 s. The more passes a protein 
experiences in the device, the more times it encounters these defined stresses. 
The Reynolds number was calculated according to Equation 1.5 (Section 1.4.1) 
for the fluid in the syringe and capillary.  




Equation 1.5. Equation for Reynolds number, reproduced from Section 1.4.1. 
In the CFD model, at 20 °C, ρ = 997 kg m-3 and η = 1.0016 N s m-2. In the syringe, 
L = 4.61 x 10-3 m and ν = 8 x 10-3 m s-1. In the capillary, L = 3 x 10-4 m and ν = 1.9 
m s-1. Solving Equation 1.5 with the parameters above, Re ≈ 37 in the syringe and 




3.1.2. Computational fluid dynamics under variable flow 
conditions 
 
The EFD syringe plungers can be driven by the stepper motor at a variety of 
velocities. Maintaining the device geometry described in Section 2.2.3., CFD was 
performed at a range of plunger velocities (1–25 mm s-1), with the strain rate, 
shear rate and exposure time to extensional flow being the principal outcomes. 
These results are shown in Figure 3.3. 
a)                b) 

























































   


















Plunger velocity (mms-1)  
Figure 3.3. CFD results for the EFD at variable plunger velocity. a) Plot of 
strain rate (black) and capillary wall shear rate (blue) in the EFD at the plunger 
velocities shown. Linear trend lines (R2 = 1) were fit to the data to guide the eye. 
b) Plot of exposure time of fluid elements exposed to 50% (black), 75% (red) or 
90% (blue) of the maximum centre-line strain rate. Power law fits of the form y = 
ax-0.94) were fitted to the data in Origin (R2 > 0.995 in all cases). CFD data 
generated and fitted by Dr John Dobson, University of Leeds. 
The data show that the centre-line strain rate and capillary wall shear rate vary 
linearly with plunger velocity. As the velocity increases, the length of time the fluid 
element is exposed to extensional flow decreases, as shown in Figure 3.3b. 
Further analysis of the CFD calculations revealed that the flow is no longer laminar 
in the capillary at plunger velocities exceeding 25 mm s-1. Experiments which 
subjected proteins to increased strain rates (> 11,750 s-1) were thus capped at a 
plunger velocity of 16 mm s-1, in agreement with the criteria set out in Section 1.5. 
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3.2 Characterisation of BSA aggregation under 
defined fluid fields 
3.2.1. Characterising BSA aggregate quantity and 
morphology 
 
With an understanding of the strain and shear rates present within the device at 
a given plunger velocity, as well as knowledge of the length of time proteins will 
be exposed to these flow fields, experiments could be performed to examine if 
and how these flows affect protein aggregation. BSA, purchased from Sigma-
Aldrich at 98% purity, was further purified (with Dr Amit Kumar, University of 
Leeds) using gel filtration chromatography (Section 2.2.1). A representative 









































Figure 3.4. Further purification of BSA using gel-filtration chromatography 
(see Methods Section 2.2.1).  (Top) A representative chromatogram for the 
purification process. (Bottom) 12% (w/v) SDS-PAGE gel for BSA. Lanes 1–3 = 
higher-molecular weight (HMW) species, 4–9 = dimer shoulder peak, 10–12 = 
monomer peak. Lane 13 = reconstituted BSA. 14 = MW ladder (standard 
masses given in kDa). 2 mL fractions were pooled between 156–190 mL as the 
monomeric protein, with the elution volume corresponding to a ~70 kDa protein. 
Purified BSA (Section 2.2.1) was then stressed in the EFD, at a quantify protein 
loss from solution as a function of pass number (Section 2.2.7). The results are 
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Figure 3.5. Determination of the amount of BSA lost from solution 
following hydrodynamic stress in the EFD, as determined using the 
pelleting assay (Section 2.2.7). Samples were stressed for 500–2000 passes 
at the concentrations shown in the legend. The plunger velocity = 8 mm s-1, ε̇ = 
11,750 s-1, γ = 52,000 s-1.  The data were normalised to the quiescent samples, 
which showed no aggregation (100% in solution). Errors from two independent 
experiments were propagated according to Section 2.2.18. 
The data show that as the number of passes increases, there is a decrease in the 
amount of protein left in solution, as quantified with the pelleting assay. The observed 
effect is sensitive to concentration after 1500 passes. For example, little aggregation 
(<10% loss of soluble protein) observed at 1 mg mL-1 compared to ~35% loss of 
protein from solution at 10 mg mL-1 after 2000 passes. The quiescent protein samples, 
incubated at ambient temperature for the duration of the flow experiment did not show 
any loss of protein from solution. 
 
To understand the consequences of aggregation at a coarse level, the morphology of 
the aggregates formed in the EFD was assessed using TEM, Section 2.2.6. In 
addition to stressing the samples for long periods of time (500–2000 passes take 50–
200 minutes to complete), samples were also analysed by TEM after 50 and 100 
passes. EM grids were prepared immediately after stress, prior to analysis of the 









Figure 3.6. TEM images of BSA after subjection to hydrodynamic stress in 
the EFD at a plunger velocity of 8 mm s-1 for the number of passes and 
concentration stated. The images shown were taken at 10,000 x magnification, 
with the scale bar = 500 nm. 
The images above clearly show that the BSA aggregates which form in the EFD 
are amorphous in nature and several microns in size. At lower concentrations (1 
and 2 mg mL-1, light blue and green bars respectively), the aggregates appear 
much more disperse across the grids, only forming large amorphous species after 
500 passes. Importantly, no amorphous aggregates were observed on the grids 
prepared from the quiescent samples. Together with the pelleting data, it is clear 
that following exposure to the hydrodynamic forces found in the EFD, BSA forms 







3.2.2 Measuring aggregate size and dispersity using 
biophysical techniques 
 
According to the Lumry-Eyring Nucleation Polymerisation (LENP) model 
(discussed in Section 1.2; Andrews and Roberts, 2007; Li and Roberts, 2009; 
Lumry and Eyring, 1954), proteins typically aggregate to large, amorphous 
species along a pathway. The smaller oligomers which form en route to insoluble 
aggregates can be detected using an array of light scattering technologies 
(Section 1.3.4). DLS and NTA have both been used to size particles and 
aggregates in the 1 nm to 2 μm size range (Filipe et al., 2010), including  BSA 
aggregates (Borzova et al., 2017).  
To monitor the formation and growth of BSA aggregates as a function of pass 
number, BSA solutions were stressed for 10–2000 passes at a concentration of 
1, 2, 5 or 10 mg mL-1 at a plunger velocity of 8 mm s-1. Quiescent samples were 
also prepared as stated in the Methods. The samples were then analysed by DLS 
(see Section 2.2.4). The autocorrelation functions initially obtained from the DLS 
analysis assume monodispersity, as only a single exponential decay is fitted. 
Representative correlation functions for the BSA samples are shown in Figure 
3.7.  




























































Figure 3.7. Representative correlation functions obtained by DLS for 
Quiescent BSA (left) and BSA after 2000 passes in the EFD (right). The 
samples were diluted 1:2 with buffer as stated in Section 2.2.4. The R2 values 
shown are for the goodness of fit for a single-exponential decay to the data. 
The autocorrelation functions show that quiescent samples are predominantly 
monodisperse and the species contained within them are small, hence the rapid 
decay and good fit observed in Figure 3.7. Conversely, where aggregates 
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dominate the scattering signal, the decay in the correlation function is slow and 
thus the single exponential fit is poor. This is indicative of high dispersity. The DLS 
data were thus deconvolved using both the Cumulants and Regularisation 
methods (see Section 2.2.4). As mentioned in Section 1.3,4, the Cumulants 
method is the simplest, yielding the z-average radius and width (standard 
deviation) of the sample. These data are displayed in Figure 3.8. 
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Figure 3.8. Plot of the z-average radii of BSA stressed for 0 (quiescent 
sample) to 2000 passes at a plunger velocity of 8 mm s-1, obtained by 
Cumulants analysis of the DLS data. BSA was stressed at the concentrations 
shown in the legend. Errors from two independent measurements were 
propagated according to Section 2.2.18, except 2 mg mL-1, 1000 passes (N = 1). 
The data show that until BSA solutions have been subjected to 50 passes of 
stress in the EFD, no aggregation is observed, with the measured z-average radii 
of the samples being in close agreement with the literature value of ~3.5 nm 
(Atmeh et al., 2007; Yadav et al., 2011). Following 50 passes, the average size of 
the aggregates in the samples grows to several hundred nm, over a very broad 
size range, as indicated by the error bars in each point. Aggregates which are 
several microns in size (as shown by TEM, Figure 3.6) are possibly too large to 
diffuse readily into the flow cell, hence the z-average radius does not increase 
steadily as a function of pass number.  The dispersity of the above samples can 
be quantified by the PDI (Section 2.2.4). The PDI of the samples were calculated 
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Figure 3.9. Plot of polydispersity index (PDI) values, calculated from the z-
average radii measurements (and their widths) obtained from Cumulants 
DLS analysis of the BSA samples in Figure 3.8, against the number of 
passes. 
The PDI data show that until 50 passes have been performed, the BSA samples 
remain essentially monodisperse, i.e. their measured PDI is close to 0.1. After 
more passes threshold has been exceeded, the samples become polydisperse, 
with the PDI measurements increasing from ~0.4 – 2.7 as a function of pass 
number. Samples with a PDI >0.6 are considered very disperse, which may 
compromise the accuracy of the size distributions obtained through fitting of the 
DLS data (Roger et al., 2016). 
The Regularisation algorithm is more sophisticated than Cumulants; its increased 
resolving power thus allows one to see how the size distribution of aggregates 
changes as a function of pass number. A representative regularisation plot for a 
stressed and quiescent BSA sample is shown in Figure 3.10, with a complete set 
of values presented in Appendix Table 2. 
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Figure 3.10. DLS regularisation plot for quiescent BSA (black) and BSA 
after 2000 passes of stress at a plunger velocity of 8 mm s-1. The BSA 
concentration = 5 mg mL-1. 
The regularisation plots show that after stress in the EFD, the BSA aggregates 
exist over a broad size range of tens of nm to several microns. Their presence 
greatly reduces the signal intensity from that of the monomeric BSA (the red peak 
at 4.6 nm). However, DLS lacks the resolution to further distinguish populations 
in these broad peaks (Filipe et al., 2010). Nanoparticle tracking analysis was thus 
performed on unstressed and stressed BSA samples in the same manner as 
discussed above (see also Section 2.2.5). Particle concentration vs size plots for 
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c)           d) 








































































































































Figure 3.11. Particle number concentration vs size plots for stressed BSA 
samples analysed using NTA. a) 1 mg mL-1, b) 2 mg mL-1, c) 5 mg mL-1 and d) 
10 mg mL-1. All samples were stressed for the number of passes indicated at a 
plunger velocity of 8 mm s-1. The quiescent samples and those stressed for 10 
or 20 passes had no aggregates present when analysed. The coloured lines 
correspond to: 50 passes (–), 100 passes (–), 500 passes (–), 1000 passes (–), 
1500 passes (–) and 2000 passes (–) respectively. 
The data show that when stressed, BSA forms aggregates over a broad size 
range, from ~40 nm to 1800 nm in diameter. Generally, as the number of passes 
increases, the number of aggregates in the 40–500 nm size range increases. As 
seen in the DLS data, the number of aggregates exceeding 1000 nm in diameter 
varies widely as a function of pass number, possible due to larger aggregates not 
diffusing (inset graphs). The quiescent samples, as well as those stressed for 10 
or 20 passes, did not have any particles present when analysed by NTA, as any 
particles present (including monomer) are too small to be detected. This is in 
agreement with the DLS data in Figures 3.8 and 3.10. The total number of 
particles in a sample can also be quantified using NTA (Carr and Wright, 2015; 
Zhou et al., 2015). This analysis was performed to yield the data in Figure 3.12. 
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Figure 3.12. Total particle count for the stressed BSA samples detected by 
NTA in Figures 3.10 a–d. Errors from two independent experiments were 
propagated according to Section 2.2.18. 
The data show that the total number of particles quantified by NTA, following 
stress in the EFD, ranges from 0.25– 2 x 108 particles mL-1. Whilst the average 
number (amount) of aggregates detected appears to increase as a function of 
both pass number and concentration, the dispersity of the samples (hence width 
of the error bars) makes a firm trend difficult to conclude (see Section 3.5). 
 
Whilst NTA did reveal more information about the aggregates present in the 
stressed samples, it too was unable to detect aggregates in the quiescent 
samples and those stressed up to 20 passes, regardless of concentration. To 
detect whether any aggregates were present during these early events, FCS was 
exploited, based on its increased sensitivity (Tipping et al., 2015) and its previous 
use in monitoring BSA unfolding and aggregation in different chemical 
environments (Pabbathi et al., 2013; Zhang et al., 2015a). BSA fluorescently 
labelled with Alexa-488 BSA was diluted into unlabelled BSA samples (Section 
2.2.9) before stress and the samples measured. The RH values obtained from the 
correlation function fitting data are shown in Figure 3.13. 
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Figure 3.13. Plot of the average RH values obtained from fitting FCS data 
for quiescent (0 passes) and stressed (10 – 2000 passes) BSA solutions. 
Samples were all stressed at a plunger velocity of 8 mm s-1, at the 
concentrations indicated, prior to analysis. FCS measurements were performed 
by Dr Amit Kumar, with analysis performed by Dr Roman Tuma (both University 
of Leeds). 
The data show that after 10 passes, there is a subtle increase in the average RH 
of the labelled diffusing species in the sample, increasing from 2.7–5.2 nm (the 
quiescent sample) to 7.3–16.5 nm. Once again, the most pronounced increase in 
RH is observed across all concentrations after 50 passes of stress has been 
experienced by the samples. After 1000 passes, the aggregates which can still 
diffuse are several microns in size, in agreement with the TEM and DLS data. 
As these values derive from a complex fitting procedure, as well as the averaging 
of many scans to produce the final result, inferring the stoichiometry of any 
oligomers which form en route to the soluble aggregates and then insoluble 
species, is difficult. Ammonium acetate was selected as a buffer to facilitate the 
use of mass spectrometry to attempt to determine such stoichiometry, as has 
been done for a variety of aggregating protein systems (Knight et al., 2018; 
Ruotolo et al., 2008; Smith et al., 2010; Young et al., 2015).  
BSA samples, subjected to stress or incubated quiescently, were thus subjected 
to analysis by native mass spectrometry. Initial attempts to do this with unclarified 
samples were rendered difficult by the presence of broad, overlapping peaks 
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(data not shown). Samples were thus clarified by centrifugation for 10 minutes at 
8,000 xg, (except the quiescent sample), before diluting samples down to 10 μM 
in the same ratio as the native protein. Spectra for BSA at 5 mg mL-1, stressed for 
0, 20 and 100 passes, are shown in Figure 3.14. 
a)                                                          
 
b)                                                           c)                   
 
Figures 3.14. Native mass spectra for a) quiescent BSA (5 mg mL-1) b) after 
20 passes and c) after 100 passes. Spectra were obtained using a 1.2 kV 
capillary voltage with sample concentration ~10 μM. N = 1 for these samples. 
Masses assigned following processing in MassLynx are displayed next to the 
peaks as appropriate. 
These data seem to show that within the quiescent BSA sample, there are some 
oligomers which cannot be detected after purification (by SDS-PAGE), nor by any 
of the other analytical methods discussed above. The high sensitivity of mass 
spectrometry (Section 1.3.2) may explain why these can be observed. The 
general population of oligomers (dimer to pentamer) seems to remain the same 
after 20 passes. Following stress in the EFD, the quality of the spectra obtained, 
in addition to the amount of unfolded protein observed increases, despite being 
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introduced to the gas phase under the same conditions as in 3.14a. Possible 
reasons for this are discussed in Section 3.5. In summary, mass spectrometry did 
not detect an increase in the amount of oligomer in the sample as a result of stress 
due to extensional flow. However, deviation was observed from the native 
sample’s spectrum after 20 passes of stress. How therapeutic proteins fare when 
subjected to extensional flow forms the subject of the next section. 
3.3 Assessing the aggregation of therapeutic 
antibodies under flow 
 
Following the set of experiments performed on BSA in Section 3.2, the effect on 
extensional flow on other proteins were examined in order to meet the objectives 
set out in Sections 1.5 and 1.6. Three IgG1 monoclonal antibodies were provided 
by MedImmune which displayed wide-ranging biophysical properties. MEDI1912 
(WFL herein) is a potent inhibitor of nerve growth factor (NGF), binding to its target 
with a pM affinity. However, it was found to have generally undesirable biophysical 
properties, such as interacting with chromatography matrices and being cleared 
rapidly in vivo (Dobson et al., 2016). Closer biophysical characterisation, using 
the SAP algorithm (Chennamsetty et al., 2009) (Section 1.3.1) and HDX-MS 
(Section 1.3.3), revealed that a solvent-exposed hydrophobic patch was probably 
the cause of such aberrant biophysical behaviour (Dobson et al., 2016). Rational 
mutations (W30S, F31T and L56T; all in the VH domains) were performed on WFL 
to create MEDI1912_STT (STT herein), abrogating the aggregation-propensity of 
the protein whilst maintaining its binding affinity for the NGF target. In addition to 
these highly homologous proteins, a generic IgG1 called Nip109 (mAb1 herein) 
was studied. This is used by MedImmune as an internal standard, as it has 
generally favourable biophysical properties and has no known target. 
WFL and STT show signs of aggregation (WFL more so) at a concentration ≥ 1 
mg mL-1 (Devine, 2016; Dobson et al., 2016), thus the mAbs were all stressed at 
a concentration of 0.5 mg mL-1 in 150 mM ammonium acetate, pH 6.0 (see 
Methods Section 2.2.2). Rather than perform an exhaustive set of experiments on 
these proteins at this stage, it was decided that the samples would be stressed 
for 20 and 100 passes at a plunger velocity of 8 mm s-1. Following this, DLS, NTA, 
TEM and the pelleting assay would be used to analyse the samples. Data from 
the first three techniques above for WFL, STT and mAb1 are shown in Figures 
3.15, 3.16 and 3.17, respectively. 
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117.5  44.9 nm
212  93.5 m
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e)      f)                                                        
                         
Figure 3.15. Biophysical characterisation of WFL following stress in the 
EFD at a concentration of 0.5 mg mL-1 at a plunger velocity of 8 mm s-1. a) 
NTA data for WFL after 20 and 100 passes. No particles were present in the 
quiescent sample. b–d) DLS Regularisation plots for quiescent WFL, 20 passes 
and 100 passes respectively. e & f) TEM images (taken at 10,000x 
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e)          f)                                                        
             
Figure 3.16. Biophysical characterisation of STT following stress in the 
EFD at a concentration of 0.5 mg mL-1 at a plunger velocity of 8 mm s-1.  a) 
NTA data for STT after 100 passes. No particles were present in the quiescent 
and 20 passes samples. b–d) DLS Regularisation plots for quiescent STT, 20 
passes and 100 passes respectively. e & f) TEM images (taken at 10,000x 
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6.82  1.54 nm
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e)             f)                                                        
                
 
Figure 3.17. Biophysical characterisation of mAb1 following stress in the 
EFD at a concentration of 0.5 mg mL-1 at a plunger velocity of 8 mm s-1.  a) 
NTA data for mAb1 after 20 and 100 passes. No particles were visible in the 
quiescent samples. b–d) DLS Regularisation plots for Native STT, 20 passes 
and 100 passes respectively. e & f) TEM images (taken at 10,000x 





The data show that all three mAbs aggregate as a result of being subjected to 
stress in the  extensional flow device. Though WFL and STT differ by just six 
residues (three per VH domain), they exhibit distinct aggregation behaviour. WFL 
begins to aggregate after just 20 passes (Figure 3.15), whereas STT requires 100 
passes of stress to begin to form aggregates under the same flow conditions, as 
evidenced by NTA and DLS (Figure 3.16). No aggregates were present in either 
quiescent sample, nor the STT sample after 20 passes by NTA. mAb1 appears to 
have aggregation characteristics akin to WFL’s, beginning to aggregate after 20 
passes (Figure 3.17). All three mAbs form amorphous aggregates in the EFD, as 
seen in the TEM images in Figures 3.15 – 3.17. However, performing a ranking 
of a protein’s aggregation propensity from these semi-quantitative data is difficult. 
Therefore, BSA and all three mAbs were stressed for 20 – 100 passes at the same 
plunger velocity of 8 mm s-1, then analysed using the pelleting assay. The results 



























































Figure 3.18 Plot of the amount of protein left in solution following 0 
(quiescent), 20 or 100 passes of stress in the flow device, then the 
samples analysed with the insoluble protein pelleting assay. BSA was 
stressed at a concentration of 5 mg mL-1, whilst the mAbs were stressed at a 
concentration of 0.5 mg mL-1. The plunger velocity in all cases was 8 mm s-1. 
The data were normalised to the quiescent samples, which showed no/minimal 
aggregation (~100% in solution).  Errors from two independent experiments 





The data show that BSA appears less sensitive to extensional flow compared to 
mAbs, as minimal aggregation (< 5% protein in pellet) is observed under the same 
flow conditions as the mAbs. After 100 passes, little soluble WFL remains (~15%), 
whereas only 15% of STT is rendered insoluble under the same flow conditions. 
mAb1 exhibits intermediate behaviour between these two homologous proteins, 
with around 25% of the protein going into the pellet fraction following 100 passes 
of stress. Importantly, none of the proteins above showed signs of aggregation 
when the quiescent samples were analysed by any of the techniques above after 
10 minutes incubation under ambient conditions. The fundamental mechanisms 
behind why proteins aggregate in the EFD form the subject of the next section. 
 
3.4 Determining the key drivers of aggregation in 
the extensional flow device 
 
From the data generated and analysed in Sections 3.2 and 3.3, it is apparent that 
after exposure to extensional flow, protein aggregation takes place. The extent of 
aggregation depends on the protein in question, with the heavily disulphide linked 
protein BSA being much more recalcitrant to the forces found in the EFD than the 
three mAbs. As predicted, WFL exhibited more pronounced aggregation than its 
mutant STT, with mAb1 being somewhere in between. Whilst these data clearly 
show that the EFD can induce aggregation, the mechanism by which it does so 
was unclear.  For example, can the shear flow experienced in the capillary trigger 
aggregation? How do different plunger velocities, ergo, different strain and shear 
rates affect the observed levels of protein aggregation. Finally, can flow induce 
the conformational remodelling of proteins? 
With these questions in mind, alternative experiments were performed to establish 
which factors were key to driving aggregation, particularly for BSA given the 
extensive dataset amassed for this model protein both here and elsewhere, for 







3.4.1. Dissecting the role of shear in BSA’s aggregation 
 
As stated in Section 3.1, the EFD consists of an extensional flow region (the point 
of contraction between the syringe and capillary) and a high shear region (along 
the length of the capillary). To assess the role of shear on the aggregation of BSA, 
a 5 mg mL-1 BSA solution was stressed for 1000 passes at a plunger velocity of 8 
mm s-1, using a 37.5 mm capillary instead of 75 mm. This halves the length of 
time the BSA is exposed to the 52,000 s-1 shear rate in the capillary region. 
Aggregation was then characterised using the insoluble protein pelleting assay. 


























Figure 3.19. Plot of the amount of excess protein in the pellet fraction for 5 
mg mL-1 BSA following 1000 passes of stress at 8 mm s-1. The full-length 
capillary = 75 mm long, whereas the half-length = 37.5 mm. Errors from two 
independent experiments were propagated according to Section 2.2.18. 
The data show that when the length of the capillary decreases, the amount of 
insoluble material formed in the device does not decrease, with ~ 7% of the 
material insoluble, regardless of capillary length. Once again, no aggregation was 
present in the quiescent samples (not shown). This result shows that, for BSA, 
the high shear flow that the protein is exposed to in the capillary does not 
dominate the amount of aggregate formed in the device. Instead, it suggests 
extensional flow dominates BSA’s aggregation. 
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3.4.2. Looking for evidence of particle shedding from the 
device 
 
As a control to check that none of the aggregates observed by light scattering 
were a result of shedding of Teflon, glass etc. in the EFD, 25 mM ammonium 
acetate, pH 5.1, was stressed for 1000 passes at a plunger velocity of 8 mm s-1, 
then analysed using DLS and NTA. The results are shown in Figure 3.20. 
























Figure 3.20. Correlation function plot obtained by DLS analysis of 500 μL 
of 25 mM ammonium acetate, pH 5.1 following 1000 passes of stress in the 
EFD (plunger velocity = 8 mm s-1). The R2 value reported is for a single 
exponential decay fit according to Section 2.2.4. 
The data show that no particles are shed from the device following stress. The 
NTA videos were completely blank, with no particles tracked in any of the videos. 
The poor fit of a single-exponential decay to the DLS data in Figure 3.20 is 
indicative of no particles being present in the (very poor signal:noise), with small 
air bubbles being the likely contributor to any signal present (cf. scale in Figure 
3.7 for proteinaceous samples). These data suggest that the light scattering data 
from the collective body of samples measured following stress in the EFD (several 
hundred throughout the thesis) belong predominantly to protein signal, as 




3.4.3 Conformation re-modelling of BSA under 
extensional flow 
 
As stated in Section 1.4, many previous studies on the effects of flow on the 
conformational properties of biomolecules have gathered experimental evidence 
for such phenomena through means of in situ analytics, for example Ashton et al., 
2010; Bekard et al., 2012; Smith et al., 1999. The design of the EFD precludes 
the incorporation of such analytics to probe conformational change at the 
molecular level. Therefore, an alternative strategy was sought from the literature. 
IAEDANS has been used to perform cysteine ‘shotgun sequencing’ on red blood 
cells, probing the dynamics of proteins in given cellular states (Krieger et al., 
2011). BSA has one buried cysteine residue (Cys 34), with its other 34 are 
oxidised as cystines. If extensional flow conformationally remodelled the protein, 
it was hypothesised that this residue may be labelled with the fluorophore, if the 
dye and protein were stressed together in the EFD. Unless Cys 34 is naturally 
exposed due to localised dynamics, the quiescent sample should not label under 
the same chemical conditions.  
To validate this hypothesis, BSA was stressed for 0–100 passes at a plunger 
velocity of 8 mm s-1 in the presence of 5 mM IAEDANS (see Section 2.2.10). 
Furthermore, to assess whether the 17 disulphide bridges of BSA are made 
available for labelling as a result of flow, the reducing agent TCEP was also added 
(0.5 mM final) in some experiments (see Section 2.2.10). These data are shown 
in Figure 3.21a. In all cases, following stress, samples were analysed using an 
SDS-PAGE gel (see Methods Section 2.2.2). In another round of experiments, 
the IAEDANS (with/without TCEP) was added to the BSA solutions after stress, 
to assay the longevity of exposed cysteine residues post-extensional flow. These 









a)                                                  b) 
 
Figure 3.21. SDS-PAGE analyses of 5 mg mL-1 BSA, incubated with 5 mM 
IAEDANS and/or 0.5 mM TCEP, in the presence and absence of flow. a) 
Coomassie Brilliant Blue staining (upper) and fluorescence visualisation (lower) 
and quantitation of BSA labelled with IAEDANS and separated on a 12% (w/v) 
SDS-PAGE gel. These samples were prepared with the chemical additives in 
situ. b) As above, except the chemical additives were added ex situ. Lane 1 = 
Quiescent BSA incubated with IAEDANS. Lane 6 = Quiescent BSA incubated 
with both TCEP and IAEDANS. In all other lanes, samples were stressed for the 
number of passes indicated at a plunger velocity of 8 mm s-1. Further detail is 
provided in Section 2.2.10. Gel electrophoresis, imaging and analysis performed 
by Dr Amit Kumar (University of Leeds). 
The experiments show that in the absence of reducing agent, the greater number 
of passes experienced by the BSA solution increases the labelling that occurs. In 
the presence of reducing agent (TCEP), labelling is much more pronounced. The 
quiescent sample does not label in the absence of flow, with minimal labelling 
observed in the presence of TCEP (Figure 3.21a). Conversely, when the dye/ 
reducing agent mixture is added to the BSA post-stress, labelling is only observed 
in the 100 passes sample with TCEP (Figure 3.21b). This could be due to the 
TCEP’s ability to access some Cys residues in the aggregates which form after 
100 passes in the device (Sections 3.4.2 and 3.4.3). In summary, these 
experiments demonstrate that extensional flow can indeed induce the 
conformational re-modelling of BSA, which then leads to aggregation of the 
resultant, partially unfolded BSA molecules. 
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3.4.4 Assessing the role of energy in the EFD and its 
effects on BSA’s aggregation 
 
Jaspe and Hagen produced a ‘beads on a string’ model to quantify the shear rate 
required to unfold a globular protein (Jaspe and Hagen, 2006). This model, which 
assumes the protein under study unfolds via a ‘dumbbell’-shaped intermediate, 
was used by John Dobson (University of Leeds) to assess whether or not flow 
causes partial or complete unfolding of proteins by comparing the forces 
experienced by a protein in the EFD to those calculated in the model. The model 
is summarised in Figure 3.22, with the results discussed afterwards.  
 
Figure 3.22. Jaspe and Hagen elementary model for proteins unfolding due 
to flow. These terms were computed by Dr John Dobson, University of Leeds. 
The terms in Equation 3.1 are as follows: W =work required to unfold the 
protein, η = viscosity of the fluid, d = distance between the beads on the string, γ 
= shear rate, N = 573 residues (total in BSA), vb = volume of one bead (i.e. one 
amino acid), ν = extensional flow vector, a = area of ball of unfolded protein and 
n = number of residues in the linker. 
At the shear rates and strain rates present in the EFD, the Jaspe and Hagen 
calculations suggest that proteins are likely to only experience forces of ~10 fN. 
Using the CFD modelling, the global energy in the flow device was calculated by 
John Dobson, assuming BSA-sized spheres of fluid with diameters = 3.5 nm. 
These data were then scaled as a rate of energy transfer to the packet of fluid. 
The data are shown in Figure 3.23. 
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a)      b) 
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Figure 3.23. Distributions and dissipation of energy in the EFD. a) Energy in 
the extension (blue) and shear regions (red) of the flow device as a function of 
plunger velocity. b) Rate of energy transfer into the fluid in the extension and 
shear regions as a function of plunger velocity. The CFD was performed by John 
Dobson, University of Leeds, with packets of fluid of 3.5 nm in size. 
The data in Figure 3.23a show that at plunger velocities < 10 mm s-1, the thermal 
energy delivered to the fluid in the shear and extension regions is low (~1.1 and 
2.7 E/kBT in the shear and extension regions respectively). On a rate scale (Figure 
3.23b), because the extensional flow region is very short in the EFD (2 mm, Figure 
3.2), energy is delivered rapidly compared to the shear region. As the plunger 
velocity and strain rate increase, there is an increase in both the extensional flow 
energy rate and that for shear. However, the magnitude of the extensional flow 
energy rate remains ~ 1000-fold higher. As shown in Figure 3.3b, at higher 
plunger velocities, proteins are exposed to these damaging extensional flow 
forces for decreasing amounts of time. To see which of energy and time were key 
to driving BSA’s aggregation, a    5 mg mL-1 solution of BSA was stressed for 100 
passes at plunger velocities of 2-, 4- and 8–16 mm s-1. The samples were then 
analysed using the pelleting assay. To validate that extension was driving 
aggregation compared to shear, the ‘shear experiment’ (i.e. the halving of the 
capillary length as in Section 3.4.1) was performed at the highest plunger velocity 
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Capillary length  
Figure 3.24. Quantification of the amount of insoluble BSA formed when 
stressed at different strain rates. a) Plot of percentage protein in the pellet 
fraction after stressing 5 mg mL-1 BSA for 100 passes at the stated plunger 
velocities. The strain and shear rates are in Figure 3.3. b) Plot of excess BSA in 
the pellet fraction of 5 mg mL-1 stressed for 100 passes at a plunger velocity of 
16 mm s-1 with a full-(75 mm) or half-length (37.5 mm) capillary. Errors were 
propagated according to Section 2.2.18. 
The data show that below a plunger velocity of 12 mm s-1, significant levels of 
aggregation (i.e. above the noise of the experiment) are not observed (Figure 
3.24a). NTA experiments were also performed at these lower velocities (2–6 mm 
s-1), with no aggregates present in the samples. After 100 passes at 16 mm s-1 (ε̇ 
= 23,421 s-1, γ = 104,000 s-1), ~15% of the protein has been lost from solution. In 
Figure 3.5, 1500 passes were necessary to induce this level of aggregation at a 
plunger velocity of 8 mm s-1. Despite the very high shear rate in the capillary, 
reduced exposure of BSA to this flow field did not reduce the amount of 
aggregation observed in the shear experiment (Figure 3.24b). To summarise, 
BSA’s aggregation is driven by extensional flow energy, with increased force at 
higher strain rates leading to more pronounced aggregation than that seen 









As introduced in Sections 1.4 and 1.5, previous studies which investigated how 
hydrodynamic flow affects biomolecular conformation have focussed on shear 
flow, neglecting extensional flow. The device characterised in this section (and 
the rest of the thesis) subjects proteins to an extensional flow event, followed by 
high shear along the length of the capillary. Focussing on BSA as a test protein, 
it is evident that the these flow fields have the ability to induce the unfolding and 
aggregation of proteins, as has been seen by other groups using unrelated 
devices (Ashton et al., 2010; Bekard et al., 2012; Simon et al., 2011). By using an 
array of experimental techniques, aggregation could be characterised from the 
monomeric BSA through to insoluble aggregates (> 10 μm).  
The aggregates which form in the device cover a broad size arrange and are 
highly disperse. Once extensively stressed in the device, the PDI of the samples 
often exceeds 0.6, with this being a threshold of a highly disperse sample (Roger 
et al., 2016). The aggregate sizes reported by DLS in such samples will be 
adversely affected by such dispersity, which may explain the very wide widths 
observed in Cumulants analysis of the DLS data. The Regularisation algorithm 
can still detect the monomeric BSA in all of the stressed samples, partly because 
these species make up the majority of the samples (Fischer and Schmidt, 2016), 
as evidenced by the insoluble protein pelleting assay.  
Whilst NTA allowed for better resolution of the aggregate species, as can be seen 
by the numerous peaks within a sample curve in Figure 3.11, it too has its 
problems: the monomer cannot be sized/detected in both stressed and control 
samples; the traces look ‘flat’ beyond 1000 nm in many samples, despite larger 
species being detected in other assays; the total particle count obtained from the 
averaged samples varies widely. For this last point, the viewing area in NTA is 
very small (~40 nL). To obtain a y-axis of 108 particles mL-1, the particles counted 
by the software undergo an extrapolation of ~ 15 million (Zhou et al., 2015). If any 
particles settled during the analysis, they would not have diffused and may 





The increased sensitivity of FCS allowed for the detection of aggregation in BSA 
after just 10 passes of stress in all samples. Whilst it was thought that the 
sensitivity of mass spectrometry would aid in the detection of early aggregation 
events, this was not the case; despite clarification with centrifugation, any residual 
aggregates impeded the transfer of proteins from the solution phase to the gas 
phase. The relatively large size of these complexes (a BSA tetramer has a mass 
~ 266 kDa) also hindered this process (Ruotolo et al., 2008). The increased levels 
of unfolded protein observed in the stressed samples could be due to monomer 
ejection from a complex state, i.e. a partially-unfolded protein dissociates from a 
complex in the gas phase, hence higher charge states are observed (for the 
ejected monomer) (Uetrecht et al., 2010). At pH 3, it is known that BSA undergoes 
a structural change to a partially unfolded ‘molten globule’ state (Bhattacharya et 
al., 2011). Performing MS on BSA at this pH does indeed lead to many highly 
charged ions being seen for the monomer in the gas phase (Appendix Figure A3), 
supporting this observation. 
How elongated biomolecules (e.g. DNA, spider silk fibroins and vWF) unfold and 
undergo conformational change due to flow has been extensively studied (Perkins 
et al., 1997; Proudfoot et al., 2017; Rammensee et al., 2008; Zhang et al., 2009). 
It seems logical that these molecules would align in a flow field. The simulations 
performed by colleagues in the field verify these experimental observations (Sing 
and Alexander-Katz, 2010; Szymczak and Cieplak, 2007; Szymczak and Cieplak, 
2011). How globular proteins might align under flow and respond to the strain 
imparted on them by the fluid has not been studied in detail other than by Jaspe 
and Hagen. Their model proposed that very high shear rates, despite the model 
focussing on strain (extensional flow) would be necessary to fully unfold a globular 
protein (Jaspe and Hagen, 2006).  
The CFD and dumbbell model calculations suggest that proteins in the device are 
subjected to forces far below those required to fully unfold them (typically tens of 
pN) as shown from Atomic Force Microscopy (AFM) experiments (Brockwell 
2007). Furthermore, the capillary length experiments show that BSA’s flow-
induced aggregation is not dominated by shear flow. Complete unfolding of 
proteins is not necessary to cause them to aggregate (Roberts, 2014). This partial 
unfolding event was captured in vitro using IAEDANS to capture the exposure of 
BSA’s usually buried free cysteine residue. This strategy was used previously to 
capture the dynamics of erythrocyte proteins as the red blood cells undergo shear 
stress, with more pronounced labelling observed when the shear stress was 
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increased (Krieger et al., 2011). This agrees with the data in Figure 3.21, with the 
degree of labelling increasing as a function of pass number. Importantly, the 
quiescent sample did not label when incubated for 10 mins with the dye; local 
dynamics of BSA did not account for the labelling. When TCEP was added as a 
reducing agent, to probe BSA’s disulphides during these experiments, labelling 
was indeed more pronounced. This only occurred in the presence of extensional 
flow, thus flow must have exposed these recalcitrant residues, which are then 
reduced, enabling them to react with the dye and form irreversible covalent 
carbon-sulphur bonds. It is known that reducing agents can influence the 
aggregation kinetics and conformation of BSA by perturbing the protein’s 
disulphide bridge network (Borzova et al., 2015; David et al., 2008; Katchalski et 
al., 1957). In the experiments in Section 3.4.3, increased aggregation of BSA was 
observed in the presence of TCEP as quantified with the pelleting assay 
(Appendix A2). Together, these experiments provide the key experimental 
evidence for extensional flow having the ability to partially unfold and induce the 
aggregation of globular proteins. 
Under the limited experimental conditions explored in this chapter, the three mAbs 
exhibited varied aggregation behaviour once they had been subjected to 
extensional flow. The largest contrast was seen between WFL and STT; despite 
differing by just six amino acids in total, WFL showed a ~six-fold increase in the 
amount of insoluble protein formed under the same flow conditions as its mutant. 
The ‘generic’ mAb1 was somewhere in between these two proteins in terms of 
aggregation behaviour. mAb1 was not as sensitive to extensional flow as WFL, 
with aggregation was observed after just 20 passes using the four main 
biophysical techniques from this section (DLS, NTA, TEM and the pelleting 
assay)- the same threshold as observed for WFL. A striking observation can be 
made about all three mAbs; their aggregation triggered by hydrodynamic forces 
was revealed at a concentration of just 0.5 mg mL-1. In molar terms, this is 5x 
lower than the lowest BSA concentration used (1 mg mL-1 BSA ~15 μM), yet a 
broad dynamic range in response to flow was observed. This could be due to the 
fact that larger proteins have generally been shown to be more sensitive to 
hydrodynamic forces than smaller proteins (Simon et al., 2011; Springer, 2016). 
However, a detailed model for how these proteins, of a completely different 




In conclusion, the results presented in this chapter show that the EFD has the 
ability to induce the partial unfolding and subsequent aggregation of globular 
proteins. An array of quantitative and qualitative biophysical methods have been 
identified to characterise the aggregates formed in the device. The defined nature 
of the flow fields in the EFD, validated using computational fluid dynamics, allow 
for conclusions to be drawn between the energy imparted into the protein solution 
on the observed levels of aggregation. Together with the fact that antibodies are 
sensitive to the effects of flow (aggregation observed at low concentration), this 
opens up the opportunity to use the flow device to chart wide areas of parameter 
















































4. Mapping the aggregation landscapes of 
proteins under defined fluid fields 
 
4.1. Determining the aggregation landscapes of BSA, 
WFL, mAb1 and STT 
 
In Chapter 3, protein aggregation induced by extensional flow was characterised 
using an array of experimental techniques. Of those methods, the insoluble 
protein pelleting assay proved to be a robust, quantitative measure of the extent 
of aggregation for a sample under a given set of flow conditions. This assay 
showed that increasing the number of passes increased the extent of aggregation 
and that the strain rate and protein also affected aggregation. In addition to these 
experimentally investigated factors, the physicochemical environment (pH, 
protein concentration and ionic strength) along with shear flow may also affect 









Figure 4.1. Overview of the parameter space that could potentially be 
explored with the flow device. The number of passes dictates the total time 
proteins in the EFD are exposed to hydrodynamic stress (extensional flow and 
high shear rates) in the EFD. The plunger velocity dictates not only how much 
force will be applied on a protein in the flow, but also how long that force will be 
applied for. At higher plunger velocities, proteins spend less time in the 
extension and shear regions and vice-versa. These are thought to be the key 
operational parameters which will affect the amount of aggregate formed, as 
measured by the pelleting assay. Plotting the amount of protein aggregate 
formed when both passes and velocity are varied will produce an ‘aggregation 
landscape’ or response surface for a given protein. The ‘clouds’ which hang over 
the landscape, namely: the concentration, sequence and topology of the protein, 
the buffer components and the sensitivity of the protein to flow. All of these may 
modulate the landscape.  
To reduce the number of factors from Figure 4.1 needed to produce an 
aggregation landscape, the parameters in the clouds (concentration, buffer 
composition and capillary length) were initially fixed for each protein. Therefore, 
BSA and the two contrasting mAbs (WFL and STT) were stressed for different 
numbers of passes (0–200), at different plunger velocities (2–16 mm s-1), in the 
EFD (Section 2.2.3). The amount of insoluble protein was then quantified with the 
ultracentrifugation pelleting assay (Section 2.2.7). The data were then plotted as 
three-dimensional surfaces. These are shown in Figure 4.2 a–c respectively. 
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a) BSA               b) WFL 
 
c) mAb1                d) STT       
 
Figure 4.2. Aggregation landscapes for a) BSA, b) WFL c) mAb1 and d) 
STT. Each three-dimensional aggregation landscape shows the amount of 
insoluble protein following stress in the EFD for the stated number of passes, at 
the plunger velocities indicated. a) BSA was stressed at a concentration of 5 mg 
mL-1 in 25 mM ammonium acetate, pH 5.1. The data for 100 passes are from 
Figure 3.22a. b) WFL, c) mAb1 and d) STT were each stressed at a 
concentration of 0.5 mg mL-1 in 150 mM ammonium acetate, pH 6.0. Data points 
shown are an average of two independent experiments. Green lines guide the 
eye to a protein’s response to different strain rates after 100 passes, whilst red 
lines guide the eye to pass-dependence at 8 mm s-1. Data in a, b and d) were 
collected alongside Dr Amit Kumar, with those in c) collected alongside Ms 
Elizabeth Allen, (both University of Leeds). 
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The data in Figures 4.2 a–d show that each protein has a unique aggregation 
landscape when stressed under the stated flow conditions. BSA, which was 
characterised in Chapter 3, has a relatively flat aggregation landscape (Figure 
4.2a). It is clear that, for BSA, when the number of passes doubles from 100 to 
200, the amount of aggregate in the pellet fraction also doubles, but only above a 
strain rate threshold of 14,634 s-1 (equivalent to a plunger velocity of 10 mm s-1, 
Section 3.4.4). Below this threshold, the landscape has low levels of aggregation 
(<10% protein in pellet).  
Figure 4.2b shows that WFL exhibits a strain-independent, pass-dependent 
response to aggregation in the flow device. Strain rates as low as 3,184 s-1 can 
‘activate’ WFL molecules for aggregation, with the aggregation reaction reaching 
completion (80–100% insoluble protein) after 100 passes. 
Figure 4.2c shows that mAb1 demonstrates a linear response to increased pass 
number, which is similar to WFL. However, the extent of aggregation after 100 
passes is around half that of WFL. When mAb1 is stressed in a strain-rate 
dependent fashion, the amount of aggregate observed is reduced at a strain rate 
of 3,184 s-1 (equivalent to a plunger velocity of 2 mm s-1). Above this threshold, 
the aggregation of mAb1 is largely independent of strain rate, except when the 
protein is stressed above a strain rate of 14,634 s-1. Together, these trends show 
that whilst mAb1 follows similar aggregation trends to WFL, it is not as sensitive 
to extensional flow as this highly aggregation-prone protein. 
STT, on the other hand, possesses a much richer aggregation landscape (Figure 
4.2d) to BSA, WFL and mAb1. STT responds to flow in a similar fashion to BSA 
when stressed for 100 passes or less, with increased aggregation seen when the 
plunger velocity exceeds 10 mm s-1. When the number of passes doubles from 
100 to 200, various levels of aggregation are observed. The ‘low aggregation 
plateau’ (plunger velocities of 2–8 mm s-1) has a shallow gradient, with 
approximately double the amount of aggregated protein after 200 passes 
compared to after 100. On the other hand, higher plunger velocities appear to 
greatly damage STT, with 95% aggregation observed after 200 passes at 16 mm 
s-1. Whilst differences in flow sensitivity for each protein could be observed in 
Figure 3.18 (Chapter 3), the landscape analyses reveal how passes and strain 




The data for BSA suggests that proteins have a threshold for strain rate below 
which the protein does not aggregate under flow, i.e. the force per unit time 
applied by the fluid is not sufficient to conformationally alter the protein. To 
investigate whether mAbs exhibited similar behaviour, WFL and STT were 
stressed for 20 and 50 passes, respectively, at a plunger velocity of 0.5 mm s-1 (ε̇ 
= 871 s-1, γ = 3,149 s-1). These pass numbers were chosen as they represent the 
minimum number of passes where aggregation was observed in each protein’s 
respective aggregation landscape. The samples were then analysed with the 
insoluble protein pelleting assay (Section 2.2.7). The results are shown in Figure 
4.3. 
 


















Figure 4.3. Plot of percentage aggregates protein for WFL (green) and STT 
(blue) following 20 and 50 passes of stress in the EFD (respectively) at a 
concentration of 0.5 mg mL-1 at a plunger velocity of 0.5 mm s-1. Both 
proteins were stressed in 150 mM ammonium acetate, pH 6.0. The error from 
two independent experiments were propagated according to Section 2.2.18. 
The data show that minimal aggregation is observed (<10% protein in pellet) for 
both mAbs. For one replicate of WFL, the prolonged exposure to ambient 
conditions (the experiment takes ~30 mins to complete at 0.5 mm s-1) clearly 
induced some aggregation in the quiescent sample. In any event, the levels of 
aggregate seem previously (>20% protein in pellet) are reduced when this 
aggregation-prone protein is stressed at this strain rate. In summary, these data 
show that the three proteins exhibit complex responses to passes and strain rate 
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in the device. Most strikingly, STT and WFL have very different response 
surfaces, despite differing by just six residues (out of ~1400). 
4.2 The effect of concentration on the extent of flow-
induced aggregation 
 
As outlined in Chapter 1, and demonstrated for BSA in Chapter 3, protein 
aggregation is a concentration-dependent phenomenon. Performing extensional 
flow experiments at higher protein concentrations, i.e. increasing the protein 
concentration from 0.5 mg mL-1, is predicted to increase protein aggregation. 
Furthermore the concentration-dependent aggregation of WFL and STT, studied 
previously under quiescent conditions (Dobson et al., 2016), could be investigated 
under flow. To examine the validity of this hypothesis, WFL and STT were 
stressed for 100 passes at concentrations of 0.5, 1, 2 and 5 mg mL-1 at a plunger 
velocity of 8 mm s-1. mAb1 was only stressed at 1, 2 and 5 mg mL-1 for these 
experiments, thus the 0.5 mg mL-1 data from Figure 4.4 are plotted alongside 
these data as highlighted. The extent of aggregation in the quiescent and stressed 
samples was quantified using the insoluble protein pelleting assay. The results 

































Figure 4.4 Titration plot of % protein in pellet for WFL (green), STT (blue) 
and mAb1 (magenta) following stress for 100 passes in the EFD at 
different concentrations. All samples were stressed in 150 mM ammonium 
acetate pH 6.0 at a plunger velocity of 8 mm s-1. The mAb1 100 passes, 0.5 mg 
mL-1 data point is from Figure 4.4 (circled in red). Errors from two independent 
experiments were propagated according to Section 2.2.18. N = 1 for mAb1 
(except the circled point). 
The data show that the three mAbs have varying sensitivity to concentration over 
the range investigated. STT is most sensitive, with 88% of the protein rendered 
insoluble at a concentration of 2 mg mL-1 or higher. mAb1, once again, exhibits 
intermediate behaviour, with its aggregate extent plateauing at a concentration of 
1 mg mL-1 or above. WFL shows almost complete aggregation (ranging from 80–
94%), regardless of concentration. The reasons for these concentration effects 







4.3 Understanding the role of shear in monoclonal 
antibody aggregation 
 
For BSA, it was found that exposure to high shear rates did not influence 
aggregation (Chapter 3, Figures 3.19 and 3.24b). As shown in Chapter 3 and the 
preceding figures here, mAbs are much more sensitive to hydrodynamic flow than 
BSA. It was thought, therefore, that mAbs may also show sensitivity to shear flows 
than BSA, despite previous work showing that these molecules were insensitive 
to this flow field (Bee et al., 2009).  
To test this hypothesis, all three mAbs were stressed at a concentration of 0.5 mg 
mL-1 at a plunger velocity of 8 mm s-1. The length of the capillary used was either 
75 mm (full-length), 50 mm (2/3 length) or 37.5 mm (half-length). The proteins 
were subjected to: 20, 50 and 100 passes for WFL, mAb1 and STT respectively. 
These conditions were chosen as similar levels of aggregation (~ 20–30 % protein 
in pellet) were predicted to be observed from each mAb’s respective landscape 
in Figure 4. Samples were then analysed using the pelleting assay. The data are 
displayed in Figure 4.5. 



















 WFL 20 passes
 mAb 1 50 passes
 STT 100 passes
 
Figure 4.5 Shear-length dependence of the three IgG1s in the EFD. All 
three mAbs were stressed at a concentration of 0.5 mg mL-1 in 150 mM 
ammonium acetate pH 6.0. The plunger velocity in the device = 8 mm s-1 (γ = 
52,000 s-1). Errors from two independent experiments were propagated 
according to Section 2.2.18. 
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The data show that mAb1 and STT are insensitive to shear flow, with the same 
amount of aggregate forming after flow stress (~ 30% and 22% insoluble protein 
respectively), regardless of capillary length. WFL on the other hand shows 
profound shear sensitivity, with the amount of aggregate formed after stress in the 
EFD approximately halving upon reducing the capillary length from 75 to 37.5 mm. 
The fact that the EFD initially subjects proteins to an extensional flow event, then 
shear flow along the capillary may account for the discrepancy with Bee et al. 
2009. The result in Figure 4.5 suggests that shear plays a key role in the flow-
induced aggregation mechanism of proteins, such as WFL. Proteins such as STT, 
mAb1 and BSA are not sensitive to shear, instead being much more sensitive to 
extensional flows as evidenced in Sections 4.1 and 4.2.  
 
4.4 The role of the buffer environment in flow-induced 
mAb aggregation 
 
As mentioned in Section 1.2.4, the formulation of mAbs into kinetically stable 
therapeutic dose forms is an area of intensive study in the biopharmaceutical 
industry (Allmendinger et al., 2015; Goldberg et al., 2011; Goldberg et al., 2017; 
Wang, 2015). Clearly, the composition of the buffer (especially the buffer salts 
used, pH and ionic strength) will influence the aggregation behaviour of mAbs. 
150 mM ammonium acetate, pH 6.0 has been used previously to study the 
physicochemical properties of WFL and STT using mass spectrometry (Devine, 
2016; Dobson et al., 2016), hence its use thus far in the thesis. To assess how 
different buffers affect aggregation under flow, STT, mAb1 and WFL were 
dialysed into four buffers in which the quiescent aggregation of WFL and STT are 
known (Dobson et al, 2016). 125 mM L-arginine + 20 mM sodium succinate pH 
6.0 was also used, as these are the predominant components of the WFL, STT 
and mAb1 storage buffer (Dobson et al, 2016). The proteins were dialysed into 
these buffers (Section 2.2.1), then diluted down to a concentration of 0.5 mg mL-
1 and stressed for 100 passes at a plunger velocity of 8 mm s-1. The resulting 

















































Histidine Acetate Succinate Phosphate Arg/Succinate
 
Figure 4.6. Buffer screen of the mAbs with the EFD. WFL (green), STT 
(blue) and mAb1 (magenta) were dialysed into (left to right): 10 mM L-
histidine pH 6.0, 10 mM sodium acetate pH 6.0, 10 mM sodium succinate pH 
6.0, 10 mM sodium phosphate pH 7.2 and 125 mM L-arginine + 20 mM sodium 
succinate pH 6.0. Samples were stressed for 100 passes in the EFD at a 
plunger velocity of 8 mm s-1. The final mAb concentration was 0.5 mg mL-1 in 
each case. Errors from two independent experiments were propagated 
according to Section 2.2.18. 
The data show that WFL’s sensitivity to extensional flow is not ameliorated by any 
buffer except arginine+succinate. STT behaves worst in L-histidine and best in 
phosphate and vice-versa for mAb1. The suppression of aggregation for all three 
mAbs in arginine+succinate is perhaps unsurprising, given its widespread use as 
an excipient in biopharmaceutical formulations (Baynes et al., 2005; Kim et al., 
2016). In previous experiments with WFL and STT in these buffers, DLS was used 
to detect aggregation (Appendix Figure A4). Whilst stabilising buffers were 
identified for WFL at concentrations as low as 1 mg mL-1 (with phosphate 
conferring the greatest suppression of aggregation), L-histidine was only identified 
as being the most stabilising to STT above a protein concentration of 4 mg mL-1. 
The different results obtained here suggest that the behaviour proteins exhibit in 
the EFD is very sensitive to the buffer environment. The fact that differences in 
the aggregation-propensities of the mAbs could be identified at protein 
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concentrations of just 0.5 mg mL-1 highlights the potential for the EFD to be used 
as a formulation tool in mAb development (see Section 4.6). 
 
4.5 Manipulating the aggregation pathways of WFL and 
STT  
 
The data presented in this chapter have demonstrated how the strain rate, shear 
rate and buffer environment significantly affect the aggregation of monoclonal 
antibodies under flow. From these observations, it was hypothesised that: a) WFL 
would behave like STT (i.e. to aggregate independent of shear length) when 
stressed in the presence of arginine, as its WFL motif would be blocked by the 
excipient and b) STT may be shear-sensitive at high strain rates (as STT seems 
to behave like WFL at high strain rates (plunger velocity = 16 mm s-1)). To test 
these two hypotheses, shear experiments were performed with each protein. WFL 
was stressed at a concentration of 0.5 mg mL-1 and a plunger velocity of 8 mm s-
1 for 100 passes in 125 mM L-arginine + 20 mM sodium succinate buffer, pH 6.0. 
The samples were then analysed using the pelleting assay. The results are shown 



























Capillary length (mm)  
Figure 4.7 Shear-dependence of WFL stressed for 100 passes in 
arginine+succinate buffer. Samples were stressed at a concentration of 0.5 
mg mL-1 and a plunger velocity of 8 mm s-1 for 100 passes in 125 mM L-arginine 
+ 20 mM sodium succinate buffer, pH 6.0. Errors from two independent 
experiments were propagated according to Section 2.2.18. 
The data show that when in the presence of arginine, WFL is no longer sensitive 
to the high shear rate present in the capillary. After 100 passes in arginine, ~20% 
of the protein is rendered insoluble, regardless of the capillary length. This is in 
direct contrast to the data in Figure 4.5, where decreasing the capillary length 
decreased the levels of aggregation observed. Arginine must therefore affect the 
aggregation mechanism of WFL by putting the protein into an STT-like state. To 
investigate whether or not STT aggregates in a WFL-like state at high plunger 
velocities, the protein was stressed in 150 mM ammonium acetate for 100 passes, 
at a plunger velocity of 16 mm s-1. Full-length and half-length capillaries were used 
in the experiment. The samples were then analysed using the pelleting assay. 
The data are shown in Figure 4.8. 
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Capillary length (mm)  
Figure 4.8 Shear-dependence of STT at a plunger velocity of 16 mm s-1 (ε̇ 
=23,421 s-1, γ = 104,000 s-1). STT was stressed in 150 mM ammonium acetate, 
pH 6.0 at a concentration of 0.5 mg mL-1. Errors from two independent 
experiments were propagated according to Section 2.2.18. 
 
 
The data show that, on average, decreasing the length of the capillary decreases 
the amount of aggregate measured with the pelleting assay for STT (from 34% to 
20%). Whilst this difference is not as large (nor as significant) as that observed 
for WFL in Figure 4.5, these data seem to suggest that STT does behave very 
differently at this high plunger velocity than under the ‘standard’ flow conditions of 












Through varying both the plunger velocity and the number of passes a protein 
solution is exposed to in the EFD, it is possible to assess how the magnitude and 
frequency of flow events affect protein aggregation. The variation of these two 
parameters was principally explored for BSA and the three mAbs, WFL, mAb1 
and STT. In Chapter 3, it was shown that BSA has a strain rate threshold above 
which it begins to aggregate after 100 passes in the EFD. It was also shown that 
monoclonal antibodies, which have both double the mass and a distinct topology 
to BSA, are much more sensitive to the effects of hydrodynamic force than BSA. 
It was thus hypothesised that the strain rate threshold for these molecules would 
be much lower than for BSA, i.e. lower than 14,634 s-1 (equivalent to a plunger 
velocity of 10 mm s-1). The data outlined in Figure 4.2a showed this was largely 
not the case. WFL showed pronounced levels of aggregation, with ~30% of the 
protein being rendered insoluble after just 20 passes through the device (Figure 
4.2b). The strain-rate threshold where aggregation is minimised for this protein is 
very low indeed, (ε̇ = 871 s-1, Figure 4.3). This may suggest that little structural 
perturbation, induced by hydrodynamic forces, is required to expose aggregation-
prone regions in this protein, with the amount of aggregate increasing as a 
function of pass number.  
mAb1 possesses an ‘intermediate’ response to flow when compared to WFL and 
STT (Figure 4.2c). When the number of passes increases, so too does the level 
of aggregate formed. At lower plunger velocities (2 and 4 mm s-1), the flow-
induced aggregation of mAb1 is reduced. At higher plunger velocities, two 
plateaus of aggregation can be seen (4–8 mm s-1 and 10–14 mm s-1). The 72% 
sequence identity of mAb1 to WFL and STT may account for the ‘intermediate’ 
flow-induced aggregation behaviour possessed by this generic protein. 
Conversely, STT’s aggregation landscape (Figure 4.2d) has a large region of 
parameter space where few aggregates form, with less than 30% aggregation 
observed below 100 passes regardless of strain rate. The landscape analysis 
reveals regions of equivalence, e.g. 150 passes at low plunger velocities (2–6 mm 
s-1) causes the same amount of aggregation as when the protein experiences 50 
passes at high plunger velocities (16 mm s-1). This highlights the complex 
relationship between these variables and their effect on the observed levels of 
aggregation. This was observed despite WFL and STT having >99% sequence 
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identity, differing by just three residues in each VH domain. The exposure times 
and magnitudes to shear flow in bioprocessing are reasonably well-known (Bee 
et al., 2009; Thomas and Geer, 2011). For example, it is thought that mAbs are 
exposed to similar shear rates and exposure times in the EFD as they are during 
fill-finish operations (Bee et al., 2009). The equivalent calculations for strain rates 
are reported less frequently (exceptions include: (Biddlecombe et al., 2009; 
Tavakoli-Keshe et al., 2014)). The data in Figure 4.2 could inform bioprocessing 
if these calculations are made for plant-scale equipment and the conditions 
matched to the data in Figure 4.2. By operating equipment under less damaging 
conditions, like the zone discussed for STT above, yields of the final product could 
be maximised by avoiding the extreme, damaging conditions in the top corner of 
the landscape (200 passes at 16 mm s-1) during processing. 
To further flesh out the differences between these three mAbs, the concentration 
of protein was varied (Figure 4.4). At increased concentrations (1 or 2 mg mL-1 for 
mAb1 and STT, respectively), the amount of aggregate formed in the EFD 
increases and plateaus. The concentrations explored in this study are low (5 mg 
mL-1 being the highest used) compared to the concentrations typically found for 
mAb products (Garidel et al., 2017), although they be representative of some 
points within the bioprocess train (Cromwell et al., 2006). This not only minimised 
sample consumption, but also ensured that the fluid remained Newtonian, i.e. the 
viscosity did not change with shear rate (Castellanos et al., 2014), important as 
the strain rates would change in a non-Newtonian system (King, 2002). This is 
vital considering the device criteria, set out in the aims (Section 1.6). 
When the length of time the mAbs were exposed to shear flow (following 
extension) was changed, different levels of aggregate were observed (depending 
on the protein and the buffer conditions used). WFL’s aggregation appears to be 
strongly influenced by shear, with decreased aggregation seen when the capillary 
length was decreased (Figure 4.5, green bars). From a practical perspective, it 
was unfeasible to adapt the current EFD to have a capillary smaller than 37.5 mm 
in order to explore this effect further, i.e. investigate if WFL’s flow-induced 
aggregation can be solely attributed to shear flow. The fact that WFL is sensitive 
to these conditions is in direct contrast to the data of Bee and others, who have 
suggested that shear flow does not adversely affect proteins (Bee et al., 2009; 
Jaspe and Hagen 2006). This result also accentuates the disparity in aggregation 




This behaviour, as well as the general aggregation propensity of WFL, could be 
suppressed by performing the flow experiments in the presence of arginine + 
succinate buffer. It is thought that the aliphatic part of the arginine side-chain can 
compete for aggregation-prone regions. In addition, the charged moieties of 
arginine could block polar protein-protein interactions, thus preventing protein 
aggregation (Kim et al., 2016). Whether this is the mechanism by which mAbs are 
protected in the EFD is as yet unclear. The fact that the device could identify de-
/stabilising buffers using such low concentrations of protein (much lower than 
those used in the literature (Dobson et al., 2016; Goldberg et al., 2017)) opens up 
the possibility of the EFD being a formulation tool in the biopharmaceutical 
industry. 
Another result with an unclear explanation is why STT exhibits some shear-
sensitivity when stressed at a plunger velocity of 16 mm s-1. It could be that 
statistically, more STT molecules are put into an activated state following stress 
under these conditions. Another possibility is that more of the STT molecule is 
unfolded when it is stressed at this higher strain rate, i.e. the size of the 
aggregation-prone region and its ‘stickiness’ becomes more like that found in 
WFL. These 16 mm s-1 activated STT molecules then behave like WFL in the flow 
device. This suggests that the flow-induced aggregation pathway of a mAb may 
be dependent on the extent of unfolding it undergoes. 
To conclude, through variation of many parameters in the EFD, distinct 
aggregation behaviours could be identified for BSA and three mAbs. Focussing 
on the antibodies, conditions were identified whereby these molecules are 
aggregation-prone or resistant, and the effects of shear, concentration and the 
buffer environment quantified. The mainly observational data generated in this 
Chapter, together with the data obtained in Chapter 3, seem to suggest two 
different pathways through which mAbs aggregate when subjected to extensional 
flow. A variety of techniques will need to be implemented, not just insoluble 
pelleting assays, to dissect such an aggregation pathway. This mechanistic work 





5.Towards a mechanism of flow-induced 




Thus far, data have been presented which show that proteins aggregate when 
they are subjected to extensional and shear flows. In Chapter 3, the aggregation 
pathway for BSA induced by extensional flow was interrogated. Not only was 
evidence gathered for conformational remodelling of the monomeric protein, but 
quantitative data on the end-point of the reaction (amount of insoluble protein 
found following stress), were also generated. In Chapter 4, a thorough analysis 
was performed to investigate how the aggregation end-point of mAbs changed in 
response to changing the wide array of variables present in the EFD. All of these 
data suggest mAbs may aggregate in the EFD via two competing pathways, with 
the quantity and type of aggregates present along the pathway being protein and 









Figure 5.1. Outline of the proposed mechanism of aggregation of mAb 
aggregation induced by extensional flow. The top pathway is traversed 
by mAbs which rapidly aggregate through specific interfaces, such as WFL. 
The bottom pathway is traversed by mAbs which are more resistant to 
aggregation. i) The monomeric native mAb is put into an aggregation-prone 
N* state by extensional flow. Sensitive proteins such as WFL are put into this 
state more readily than resistant proteins, such as STT. ii) These N* species 
can either re-fold back to the native state, or will self-associate to form 
soluble aggregates along the aggregation pathway (iii). Once the aggregates 
reach a certain size, they will no longer be soluble, nor will they be reversible 
(iv). kf  and kr are the apparent rate constants for the formation of the N*state/ 
its refolding respectively. kf 
‘
 and kr
’ are the apparent rate constants for the 
association of N* species and the dissociation of aggregates respectively.  
 
The mechanism proposed in Figure 5.1 is based on the established aggregation 
pathways within the LENP model, as discussed in Section 1.1 (see also Figure 
1.2). Whilst much is known about the end-point of the antibody aggregation 
reaction (i.e. the amount of insoluble aggregate formed), there are many 
unanswered questions surrounding the mechanism en route to insoluble protein: 
At what point is aggregation irreversible? What species (if any) nucleate the 
aggregation pathway? Do the aggregate size distributions reach equilibrium at a 
given time point? What is the minimum number of passes needed to trigger 
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aggregation? What is the nature of the N* state? At what rate do all of the above 
processes take place? 
In this Chapter, data will be presented to attempt to answer the questions above, 
moving towards a mechanistic understanding of mAb aggregation under flow. 
5.2 Using chemical tools to probe the N* state 
 
As outlined in Figure 5.1, it is thought that the initial step in the flow-induced mAb 
aggregation pathway is the formation of an N* state. As these species underpin 
the whole pathway, detecting their formation under extensional flow would be 
highly desirable. For BSA, the free Cys 34 could be exploited to capture 
conformational re-modelling of the protein using IAEDANS (Chapter 3.4.3). 
However, all of the Cys residues in WFL, STT and mAb1 form disulphide bridges. 
An alternative strategy was thus sought from the literature. Recently, Wolfrum et 
al. (2017) used their four-roll mill device (see Section 1.4.4.) to capture mAb 
unfolding and aggregation, both in situ and ex situ, by using the extrinsic 
fluorophore Nile Red (Wolfrum et al., 2017). The authors used this 
environmentally sensitive dye to detect the exposure of hydrophobic patches 
(APRs) upon subjection to flow. 
To test if this strategy could be used with the EFD, the extrinsic fluorophores Nile 
Red and ANS were incubated with WFL and STT samples either before (in situ) 
or after (ex situ) stress. No signal change was observed between the quiescent 
samples and those subjected to hydrodynamic stress (data not shown).  
Chemical cross-linking was then used as an alternative probe of the N* state. In 
previous work, the aggregation interface of WFL under quiescent conditions was 
identified using chemical cross-linking, followed by mass spectrometry (Devine, 





Figure 5.2. Chemical cross-linking of WFL to identify its dimer 
interface. a) Cross-linking with BS3-BS3-d4 identified a cross-link between 
the VH N-terminus and K54 in VL (orange). The key residues in the interface 
(W30, F31 and L56) are magnified. b) The model proposed by Dobson et al. 
for WFL aggregation, with monomers self-associating through Fab-Fab 
interactions. Figure taken from Dobson et al. 2016. 
Based on these results, it was hypothesised that if flow altered the conformation 
of WFL, then a different interface, or many interfaces, would become exposed. 
These N* species would then aggregate through these new interfaces. 
Conversely, identification of the same cross-link would suggest that flow facilitates 
the formation of the WFL-WFL interaction, thus catalysing the aggregation of the 
protein. Attempts to identify this cross-link under both quiescent conditions under 
flow were unsuccessful (data not shown). In summary, under the conditions 
attempted, the N* state of WFL (nor STT in the fluorescence experiments) could 
not be reproducibly or definitively captured by either extrinsic fluorescence or 
cross-linking (see Discussion). However, a pathway describing how monomers 
associate to form oligomers, which then become insoluble according to Figure 
5.1, can still be constructed using other techniques. These form the basis of the 
next section of this chapter. 
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5.3 Following the pathway of mAbs from 
monomers to aggregates 
 
5.3.1 Using HPLC to determine the loss of monomer as 
a function of pass number 
 
According to the pathway proposed in Figure 5.1, as is the case for all protein 
aggregation mechanisms, the loss of monomer underpins the whole aggregation 
pathway (Li and Roberts, 2009; Meisl et al., 2016). This is because, as defined in 
Section 1.1, an aggregate consists of two or more non-native protein monomers. 
Measurement of the loss of monomer as a function of time thus means the exact 
amount of protein which has formed aggregate can be measured. To do this, 
HPLC was exploited, as this is the ‘gold-standard’ technique used by both 
industrial and academic groups to quantify mAb aggregation (Nicoud et al., 2014; 
Philo, 2006). 
Consequently, WFL, mAb1 and STT were dialysed into 150 mM ammonium 
acetate, pH 6.0 and stressed for 0–100 passes at a plunger velocity of 8 mm s-1. 
The protein concentration was kept at 0.5 mg mL-1. Following stress, the samples 
were clarified by ultracentrifugation and the extent of aggregation quantified using 
the pelleting assay (Section 2.2.7). Subsequently, 100 μL of supernatant from 
each tube was combined with 200 μL of quench solution (625 mM L-arginine + 
100 mM sodium succinate pH 6.0). The samples were then analysed by HPLC 
using a TOSOH G3000SWXL gel filtration column (Section 2.2.13). The 









a) WFL      b) mAb1     c) STT 







































































































































































































Figure 5.3. HPLC chromatograms for a) WFL, b) mAb1 and c) STT after stress for the given number of passes at a plunger 
velocity of 8 mm s-1. All protein samples were initially stressed at a concentration of 0.5 mg mL-1 in 150 mM ammonium acetate pH 6.0. 
50 μL injections of quenched sample (Section 2.2.13) were loaded onto a TOSOH G3000SWXL column, equilibrated in 125 mM L-
arginine + 20 mM sodium succinate pH 6.0, running at 0.4 mL min-1. One representative trace is shown per sample. Traces are 
coloured: 0 passes (–), 1 pass (–), 5 passes (–), 10 passes (–), 20 passes (–), 50 passes (–), 80 passes (–) and 100 passes (–). In 





The data for WFL in Figure 5.3a are very difficult to interpret. Though arginine is 
thought to minimise the interaction of hydrophobic proteins (like WFL) with gel 
chromatography matrices (Nicoud et al., 2014), this running buffer was not able 
to prevent aberrant, non-specific interactions with the column. Significant carry-
over was observed from one run to another in some samples, with the quench 
buffer solvent exchange peak eluting before the WFL mAb (see i, ii and iii in Figure 
5.3a). This behaviour has been reported previously for WFL, but in a different 
running buffer (100 mM sodium phosphate, 100 mM sodium sulphate pH 6.8) 
(Dobson et al., 2016). This rendered quantification of the loss of WFL monomer 
futile. On the other hand, both mAb1 and STT show a loss of peak area as a 
function of pass number, eluting at ~ 8 mL in each case, as expected for a mAb 
from previous data (Devine, 2016) (Figures 5.3b and c, respectively).  
Each peak was integrated, with the resulting areas used to calculate the mass of 
protein in the injection and thus the monomer concentration. The plot of % 
monomer lost by HPLC, as well as % loss of supernatant by the pelleting assay 
















































Figure 5.4. Plot of percentage monomer lost as determined by HPLC 
(left-hand y- axis and black lines) vs loss of protein from the 
supernatant (right-hand y-axis and blue lines) as a function of the 
number of passes through the device (x-axis). The data for STT (circles) 
and mAb1 (triangles) are the same samples as those in Figure 5.3. 
The data seem to show that the amount of monomer lost as measured by HPLC 
is approximately the same for both proteins after 100 passes (~30%, black 
symbols). By pelleting, more mAb1 is lost from solution than STT under the same 
flow conditions (40 and 30% respectively, blue symbols). Given that mAb1 and 
STT can be readily differentiated by a variety of assays (Chapters 3–5), this 
identical behaviour in the HPLC assay seems unusual, as well as the shape of 
the monomer-loss curves. In summary, for this limited number of samples, HPLC 
could monitor the loss of monomer, induced by extensional flow, as a function of 
time. However, how these data compare to those from other assays remains 
inconclusive. Characterising the early events in the aggregation pathway 






5.3.2 Detecting oligomer formation using SD-SDS-
PAGE 
 
As shown in Section 5.3.1, it appears that monomeric protein is lost as a function 
of pass number in the EFD. But where do the monomers go? Determining the 
stoichiometry of an aggregation reaction is important with regards to any 
mechanistic models one may wish to construct from the data (Li and Roberts, 
2010).  
With these observations in mind, WFL, mAb1 and STT were stressed in 150 mM 
ammonium acetate, pH 6.0, for 0–100 passes at a concentration of 0.5 mg mL-1. 
The plunger velocity in all experiments was 8 mm s-1. Following stress, Semi-
Denaturing (SD) SDS-PAGE samples were prepared according to Section 2.2.14, 
with no reducing agent or SDS in the loading dye. Gel samples were then loaded 
onto a 6% (w/v) SDS-PAGE resolving gel, then electrophoresed for 3 hours. 
Following this, the samples were initially stained using Coomassie Blue (Figures 
5.5 a–c for WFL, mAb1 and STT respectively). In later experiments, gels were 
stained with both SilverXpress and Coomassie Brilliant Blue (Amit Kumar, 
University of Leeds). Representative silver/blue gels for WFL, mAb1 and STT are 

















b) mAb1      c) STT 
  
Figure 5.5. 6% (w/v) Semi-denaturing SDS-PAGE of a) WFL (green), b) 
mAb1 (magenta) and c) STT (blue) samples following stress in the EFD. 
The number of passes each mAb was subjected to is indicated in each lane. 
L = Molecular weight marker (MW in kDa). 25 μL of each sample was loaded 
(~10 μg per lane). Stress in the EFD was performed at a plunger velocity of 
8 mm s-1. Gels were electrophoresed at 45 mA for 3 hr. Images shown are 






b) mAb1     c) STT 
     
Figure 5.6. Semi-denaturing SDS-PAGE of a) WFL, b) mAb1 and c) STT 
samples following stress in the EFD. The number of passes each mAb 
was subjected to is indicated in each lane. L= Molecular weight marker (MW 
in kDa). 25 μL of each sample was loaded (~10 μg per lane). Stress in the 
EFD was performed at a plunger velocity of 8 mm s-1. Gels shown are 
representative from at least two independent experiments. Gel preparation, 
loading and staining was mainly performed by Dr Amit Kumar, University of 
Leeds. Arrows indicate: dimers (), trimers () and higher oligomers (). 
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The data in Figure 5.5 show that oligomerisation is generally difficult to detect in 
any samples which have undergone hydrodynamic stress in the EFD. When large 
amounts of aggregate formed, the aggregates did not permeate into the gel, as 
seen at the top of some lanes, e.g. 50–100 passes in Figures 5.5b and c. 
Interestingly, the different proteins seem to run as monomers at different levels 
on the gel; WFL has a ‘streaky’ monomeric band which runs above the 150 kDa 
MW marker (Figure 5.5a), mAb1 runs below 150 kDa (Figure 5.5b) and STT at 
the same level as the marker (Figure 5.5c) (see Discussion). 
As the oligomer stoichiometry was the focus of this experiment, when gels were 
stained by SilverXPress, these gels were run until the 150 kDa marker was ~1 cm 
from the bottom of the gel (Figures 5.6a–c). Here, the enhanced sensitivity of 
SilverXpress staining shows that traces of dimers are present in all quiescent 
samples (red arrows). The dimer population seems to enrich as a function of pass 
number between 1–20 passes. Following 10 or 20 passes, unique conformations 
of dimers are particularly prominent on the mAb1 gel (Figure 5.6b). On the STT 
gel (Figure 5.6a), the dimer band appears to disappear after 20–100 passes. On 
all three gels, a higher Mw band that appears to migrate ~ half the distance of the 
150 and 300 kDa bands is visible, suggestive of a trimer (green arrows). The gel 
then cannot resolve any higher oligomers (blue arrows). In many samples, 
especially those of WFL, aggregates can be detected at the top of the gel following 
stress by both silver and Coomassie staining, with the size of the band increasing 
as a function of pass number. To summarise, SD-SDS-PAGE seems to be able 
to report on the conformation of monomers and dimers present in the mAb 
samples. The dimer population changes as a function of pass number, with the 
next resolvable oligomer being a trimer. The onset of aggregation appears to be 
10 passes. Other orthogonal techniques are necessary to aid the interpretation of 
this result; these form the basis of the next section. 
5.3.3 Using light scattering techniques to track the size 
and mass of aggregates over time 
 
In Chapter 3, the growth of BSA aggregates and their dispersity over time was 
tracked using DLS, NTA and FCS. BSA aggregation was detected by DLS after 
50 passes, whereas mAb aggregation could be detected after just 20 passes 
(Section 3.3). DLS is a completely orthogonal method to SD-SDS-PAGE and has 
been used to measure the onset of aggregation, as well as the size distributions, 
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of model antibody aggregation systems by many in the field (Arosio et al., 2012; 
Biddlecombe et al., 2009; Singla et al., 2016). The Wyatt miniDAWN instrument 
collects static light scattering data, as well as dynamic light scattering data. If the 
protein concentration of the sample is known, then the ensemble averaged mass 
of scattering species can be inferred. This strategy has also been used to track 
mAb aggregation under a range of conditions (Arosio et al., 2012; Barnett et al., 
2015; Nicoud et al., 2016). 
With this in mind, WFL and mAb1 were stressed for 0–20 passes, whilst STT was 
stressed for 0–100 passes at a plunger velocity of 8 mm s-1 in 150 mM ammonium 
acetate, pH 6.0. Samples were stressed at a concentration of 0.5 mg mL-1 then 
analysed in the miniDAWN TREOS by both DLS and SLS (see Sections 2.2.4 and 
2.2.15). The DLS data were subjected to both Cumulants and Regularisation 
analysis, as in Chapter 3. However, only the cumulants data (Figure 5.7) and 
resultant PDI’s (Figure 5.8) are displayed. Static light scattering data were fitted 
according to Section 2.2.15 (Figure 5.10). These data are discussed in Figures 
5.7–5.9 respectively. 
0.5 mg mL-1 


































Figure 5.7. Cumulants analysis of DLS data for WFL (green), mAb1 
(pink) and STT (blue) obtained following no stress (0 passes) or 1–100 
passes in the EFD. Samples were stressed in the EFD at a concentration 
0.5 mg mL-1and a plunger velocity of 8 mm s-1. Errors were propagated from 
N=2 experiments according to Section 2.2.18. 
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Figure 5.8. Polydispersity index (PDI) calculation of the samples shown 
in Figure 5.7. PDIs were calculated according to Equation 2.5 in Section 
2.2.4. 




















Figure 5.9. Plot of uncertainty averaged molecular weight (Mavg) for 
WFL, mAb1 and STT samples determined using static light scattering. 
Data were fit to the Debye model according to Section 2.2.15. Errors from 
two independent experiments were propagated according to Section 2.2.18. 
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The DLS analysis in Figure 5.7 shows that WFL begins to aggregate after just 5 
passes in the device. mAb1 forms micron-sized aggregates after just 10 passes, 
with STT requiring 100 passes of stress to form such large species. The mAbs in 
the quiescent samples were sized from 5.2–8.8 nm, in accord with the data in 
Chapter 3. When the PDI was calculated from the cumulants data (Figure 5.8), 
the samples below 20 passes were shown to be highly disperse, with many PDI 
values exceeding the 0.6 threshold discussed in Chapter 3. The dispersity of the 
final stressed protein samples (20 passes for WFL and mAb1 and 100 passes for 
STT) appears to decrease to a lower value. This is in contrast to the PDI data for 
BSA in Chapter 3 (Figure 3.9), which generally increased as a function of pass 
number. For the SLS data in Figure 5.9, the average mass of the scattering 
species in the sample increases as a function of pass number. This value 
plateaued after 10 passes of WFL and mAb1 at ~4.5 MDa. STT’s aggregates only 
reach this mass following 100 passes of stress in the EFD. Taken together, these 
light scattering data show that WFL and mAb1 are more sensitive to flow than 
STT.  
In Chapter 4, it was demonstrated that the amount of protein in the pellet fraction 
could be tuned for mAb1 and STT by increasing the protein concentration. But 
what happens at lower concentrations? Are all three mAbs (including WFL) less 
sensitive to flow if the concentration is decreased? These would be interesting 
questions to address in future (see Discussion). To understand the kinetics, 
learning how the size of aggregates changes a function of both time and 
concentration would be necessary. In summary, using DLS and SLS, the onset of 
aggregation and the growth of aggregates over time can be tracked for all three 









5.4 Characterising the size distribution, stability 
and nucleating ability of flow-induced mAb 
aggregates 
 
5.4.1 Using DLS to measure aggregate size 
distributions over time 
 
So far, it has been determined that mAbs appear to aggregate under flow from a 
pool of oligomers, which grow as a function of the number of passes through the 
EFD. There will be a critical size/mass above which the aggregates in Figure 5.1 
are no longer reversible and become insoluble. Presumably, the ‘reversible’ 
species can change size as a function of time until the system reaches equilibrium 
(according to Figure 5.1). To investigate this further, mAb1 was chosen as the 
model protein, as it has been shown to behave in an intermediate fashion to WFL 
and STT throughout this thesis. Regularisation analysis of DLS data generates 
size distributions of species scattering in the sample, from monomers through to 
large (1–5 μm) aggregates (Chapter 3). To see if the size distribution of the 
aggregates changes over time, mAb1 samples were stressed at a concentration 
of 0.5 mg mL-1 in 150 mM ammonium acetate, pH 6.0, for 50 passes. The plunger 
velocity used was 8 mm s-1. Some samples were clarified by ultracentrifugation, 
using the same conditions as the protein pelleting assay (see Section 2.2.7) and 
then the supernatants combined and measured by DLS. Other samples were 
unclarified and analysed immediately following stress. The quiescent sample was 
incubated for 5 minutes at room temperature, then measured by DLS. Following 
analysis, remaining samples were placed on ice and incubated at 4°C for 48 hr. 
The samples were then measured again by DLS. This was performed twice on 
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Rh= 83.3 ± 48.4 m 

























Rh= 9.61± 5.03 nm 
50 passes, t = 0 hr
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Rh= 291± 42.2 nm 
50 passes, t = 48hr
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Supernatant after 50 passes, t = 0 hr
    
































Supernatant after 50 passes, t = 48 hr
 
ci)      cii) 
































Rh= 5.23 ± 1.72 nm
0 passes, t = 0 hr
     





Rh= 4.99 ± 1.41 nm 

























0 passes, t = 48 hr
 
Figure 5.10. Regularisation analysis of DLS data for mAb1 a) after 50 
passes, b) supernatant following 50 passes and centrifugation and c) 
quiescent mAb1. In i) samples were analysed immediately. In ii), samples 
were analysed after a 48hr incubation at 4°C. All samples were stressed at a 
plunger velocity of 8 mm s-1. Protein concentration = 0.5 mg mL-1. N= 2 for 
all samples, with one replicate shown above. 
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The data in Figure 5.10a show that the aggregates which form after 50 passes 
cover a large size range, as seen in Chapter 3 and in Section 5.3.2. After 48 hours, 
the largest aggregates in the tens of μm size range prevail, whilst those in the low 
μm size range revert to smaller oligomers and monomers. The intensity of the 
‘monomer’ peak increases, as the large aggregates present in the sample no 
longer dominate the scattering signal. Both the clarified supernatant (Figure 
5.10b) and the quiescent mAb1 (Figure 5.10c) samples show no signs of 
aggregation after 48 hours. These results would suggest that after the cessation 
of flow, the soluble aggregates which form can revert to smaller species over this 
timescale. The stressed sample did not appear to contain more aggregate after 
48 hours, nor did the other samples. This suggests the EFD is acting as a catalyst 
for aggregation and that flow is necessary to propel the aggregation reaction 
forwards. If aggregates are present within the sample being stressed, can further 
aggregation be promoted? This forms the basis of the next section. 
5.4.2 Investigating mAb-aggregate nucleation under 
flow 
As mentioned in Section 1.1 and Figure 5.1, nucleation is a common component 
of protein aggregation mechanisms. It is thought that some proteinaceous 
aggregates can act as ‘nuclei’ for aggregation, triggering an acceleration in the 
rate of aggregate formation or its extent, compared to an aggregate reaction 
taking place in the absence of such nuclei.  For example, it is known that amyloid 
fibrils can act as a ‘template’ for monomeric proteins, inducing the aggregation of 
the latter in the amyloid cascade (Törnquist et al., 2018). The large surface area 
of aggregates, which catalyse such ‘secondary nucleation’ events, led to the 
hypothesis that the larger aggregates, formed due to flow, can accelerate the 
aggregation reaction.  
With this in mind, 0.5 mg mL-1 WFL and STT stocks were prepared in 150 mM 
ammonium acetate pH 6.0 and stressed for 20 and 100 passes, respectively, at 
a plunger velocity of 8 mm s-1 . The samples were then analysed with the pelleting 
assay, as described previously. 300 μL (from the 500 μL in the EFD) of one 
sample was kept on ice following stress, with the other 200 μL clarified with the 
pelleting assay protocol, thus generating clarified (C) and unclarified (U) ‘seed’ 
material. Seeding assays were performed by adding a 10% (v/v) spike of the 
relevant seed material to quiescent protein stock, then stressing the samples 
under the same conditions as above. These samples were then analysed, along 
with control samples, with the pelleting assay. In a separate set of experiments, 
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the supernatants of WFL and STT following flow were characterised using DLS 
as in Figure 5.10. Data for the above experiments are presented in Figure 5.11a) 
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RH= 6.5  2.9 nm 
Supernatant, 20 passes
 































RH= 5 ± 1.6 nm
Supernatant, 100 passes
 
aiii)      biii) 

































RH= 7.3  3.5 nm 
0 passes
  





























RH = 5.5 2 nm 
RH= 3 ± 9 nm
0 passes
 
Figure 5.11. Seeding experiment and supernatant characterisation with a) 
WFL (green) and b) STT (blue). Protein concentration = 0.5 mg mL-1and plunger 
velocity = 8 mm s-1 in all experiments.  i) Seeding experiments (Section 2.2.16). 
No. of passes indicated outside brackets. C = clarified seed material, U = 
unclarified seed material, Q = quiescent (0 passes). Seed was added (10% v/v) 
to native protein stocks. All samples were analysed using the pelleting assay (N 
=1, technical replicate s.d. shown). ii) Regularisation analysis of DLS data for WFL 
and STT supernatant following stress. iii) As in ii) but for Quiescent samples of 
WFL and STT. N = 2 for all DLS experiments, with one replicate shown. Pelleting 
data were obtained with Dr Amit Kumar, University of Leeds. 
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The complex data present in Figure 5.11 point towards which species are involved 
in nucleating the flow-induced mAb aggregation pathway. When supernatant is 
added as the ‘seed’ material to either WFL or STT (3rd bar in Figures 5.11 a and 
b), the level of aggregate quantified using pelleting approximately doubles. By 
DLS, this supernatant seed appears aggregate-free, i.e. no soluble aggregates 
were detected (a and b ii). This could be because the monomers in the 
supernatant fraction are less conformationally stable than their quiescent 
counterparts, causing the apparent increase in the amount of insoluble protein. 
Furthermore, the quiescent sample containing seed material did appear to have 
3x more protein in the pellet fraction than the native sample, relative to the ~3% 
(v/v) aggregate added to the sample. This could indicate that seeds can induce 
some protein aggregation under quiescent conditions. Most interestingly, for both 
WFL and STT, when the entire aggregate ensemble is used as the seed material 
(designated ‘unclarified’ in the legend), the amount of protein in the pellet fraction 
appears to double for WFL and ~quadruple for STT (4th bar from left, Figures 
5.11a and b respectively). This suggests that the larger aggregates, which form 
due to hydrodynamic stress, can drive the aggregation reaction further towards 
completion when compared to un-seeded reactions under the same flow 
conditions. 
This dramatic effect on STT was somewhat unexpected give its general 
resistance to aggregation compared to WFL. It was hypothesised that the 
aggregates of either WFL or STT could be ‘stickier’, i.e. have more of a catalytic 
effect on the extent of aggregation of each protein. The aggregates from these 
proteins could also coalesce, as has been observed for some amyloidogenic 
proteins (Dubey et al., 2014).  
To validate this hypothesis, cross-seeding assays were performed, using ‘whole’ 
stressed samples as the seed material (see Section 2.2.16). Additional control 
samples were prepared where each quiescent protein was added to the other, 
e.g. a 10% (v/v) addition of quiescent native STT was added to WFL and vice-
versa. This was performed as it is known that some Abs can cross-aggregate 
(Jacobs et al., 2010). These experiments were performed under the same buffer 






































































































Figure 5.12. Cross-seeding assay of WFL (green) with STT (blue) in 150 
mM ammonium acetate buffer, pH 6.0. All passes were performed at a 
plunger velocity of 8 mm s-1, with a protein concentration of 0.5 mg mL-1. 
Wherever ‘(sample) + x’ is written, ‘x’ denotes the species being added 10 % 
(v/v) to the specified sample. The numbers outside brackets denote the 
number of passes, U = unclarified seed, Q = quiescent. Errors were 
propagated from N =2 experiments according to Section 2.2.18. Pelleting 
data were obtained with Dr Amit Kumar, University of Leeds. 
The data in Figure 5.12 show that when WFL is seeded with itself                                
{(WFL + WFL U) 20)}, as opposed to with STT {(WFL + STT U) 20}, the levels of 
aggregation observed are 4x higher than without seeding. This is similar to the 
behaviour observed in Figure 5.11ai. STT appears to be very sensitive to seeding 
in general, as both WFL and STT seeds increase the amount of aggregate 
quantified after 100 passes (to ~60% in both cases, 4th and 6th bars from left). This 
appears to rule out the possibility of WFL seeds being ‘stickier’ than STT’s; instead 
WFL prefers to self-associate rather than cross-associate. This provides further 
evidence for a specific flow-induced aggregation pathway for WFL vs a generic 
pathway for STT. 
In Chapter 4, it was demonstrated that arginine+succinate buffer can suppress 
the flow-induced aggregation of both WFL and STT. WFL behaves in an STT-like 
fashion in this buffer compared to in ammonium acetate, as the arginine probably 
competes for WFL’s specific binding interface. It follows that WFL’s seeding and 
cross-seeding behaviour may appear like STT’s if these experiments were 
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performed in this buffer. The obvious caveat to this experiment is the fact that 
observed aggregation is diminished to low levels, thus both proteins were 
stressed for 100 passes as in Figure 4.6, Section 4.4. The samples were then 
analysed as above. These data are presented in Figure 5.13, plotted on the same 





































































































Figure 5.13. Cross-seeding assay of WFL (green) with STT (blue) in 125 
mM L-arginine + 20 mM sodium succinate buffer, pH 6.0. All passes 
were performed at a plunger velocity of 8 mm s-1, with a protein 
concentration of 0.5 mg mL-1. Wherever ‘(sample) + x’ is written, ‘x’ denotes 
the species being added 10 % (v/v) to the specified sample. The numbers 
outside brackets denote the number of passes, U = unclarified seed, Q = 
quiescent. Errors were propagated from N =2 experiments according to 
Section 2.2.18. Pelleting data were obtained with Dr Amit Kumar, University 
of Leeds. 
The data in Figure 5.13 show that less than 10% of the protein is rendered 
insoluble following 100 passes of stress in the EFD. When WFL and STT were 
stressed in the presence of their own, unclarified seed material, the measured 
levels of aggregate trebled and doubled, respectively, compared to the unseeded 
conditions. When WFL was cross-seeded with STT aggregates {(WFL + STT U) 
100}, in arginine+succinate buffer, the level of aggregation observed is equivalent 
to the ‘self-seeded’ samples (~30% protein in pellet). STT’s ‘cross-seeded’ 
samples are equivalent to its self-seeded (~15% protein in pellet), with both 
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seeded samples having ~3x the amount of aggregate as the unseeded sample. 
Little aggregation (<10% protein in pellet) is observed in any of the quiescent 
samples. These data provide further evidence of the ability of arginine to suppress 
the flow-induced aggregation of both WFL and STT, in particular, the potential 
role arginine plays in diverting the aggregation pathway of WFL under extensional 
flow to one more akin to that of STT. 
In summary, through the addition of aggregated protein to quiescent, native 
samples, the amount of aggregate observed following extensional flow can be 
augmented. This response is dependent on both the protein(s) involved and the 
buffer environment. These data demonstrate the role of pre-formed seeds driving 
the flow-induced aggregation of mAbs.  
5.5. Discussion 
5.5.1 N*-state characterisation 
 
This Chapter set out to gain experimental evidence for the mechanism of flow-
induced aggregation for the model IgG1 antibodies used throughout the study 
(WFL, mAb1 and STT). The pathways proposed in Figure 5.1 are based on the 
data obtained for BSA in Chapter 3, where the conformational remodelling of the 
protein, subsequent aggregation into small oligomers and eventually insoluble 
aggregates was monitored. The recent study of Wolfrum et al. (2017) built on the 
work of Simon et al. 2011, using a four-roll mill device to subject mAbs to 
hydrodynamic forces. The onset of unfolding and aggregation of the protein was 
monitored using the environmentally sensitive extrinsic fluorophore Nile Red 
(Wolfrum et al., 2017). Inspired by this, the dye was used to attempt to capture 
the N* aggregation-prone state of WFL and STT induced by extensional flow. This 
proved to be very irreproducible, perhaps due to the morphology of the 
aggregates formed in the EFD inefficiently binding the dye, thus not producing a 
significant fluorescence increase. Upon closer inspection of the Wolfrum et al., 
2017 data, the error bars for their fluorescence measurements are very wide. A 
gradual decrease in fluorescence was also observed when fluorescence 
measurements were recorded on the WFL and STT samples. This could have 
been due to precipitation of the dye and/or the protein from solution, which may 
also account for the errors in Wolfrum’s ex situ data (Wolfrum et al., 2017). 
Furthermore, the failure of ANS to capture this state meant that an alternative 




Chemical cross-linking is gaining ground in the structural mass spectrometry field 
as a means of capturing transient protein-protein interactions, such as those 
formed by aggregation-prone proteins (Iacobucci and Sinz, 2017; Martin et al., 
2018). The bis-maleimide cross-linking reagent BS3 has been used previously to 
identify the aggregation interface of WFL in solution under quiescent conditions 
(Figure 5.2, Devine, 2016; Dobson et al., 2016). If extensional flow causes the 
conformational remodelling of proteins, then perhaps this interface would be 
different when the cross-linking reaction was performed under flow. Despite 
attempts to adapt the protocol to the EFD, the only cross-links identified by 
tandem mass-spectrometry were either dead-end or intramolecular. When this 
cross-linking strategy was originally applied, attempts to try and improve the 
abundance of intermolecular cross-links included separation of the cross-linked 
peptides by size-exclusion chromatography and increasing the cross-linker 
concentration (Devine, 2016). These efforts still led to the identification of just one 
cross-link between WFL species. As mAbs are large proteins (150 kDa), the 
isolation of a specific, cross-linked peptide for tandem mass spectrometry 
analysis is practically difficult. Improved mass detection methods such as the 
Orbitrap (Makarov et al., 2006), as well as the use of different cross-linking 
chemistries, may help facilitate the identification of the flow-induced cross link in 
future (see Chapter 7). 
5.5.2 Tracking aggregation as a function of pass number 
 
Learning the minimum number of passes necessary to observe the aggregation 
of mAbs could be achieved through a range of strategies. Monomer quantification 
using HPLC is the analytical workhorse of the biopharmaceutical industry (Philo, 
2006). This approach has also been used to monitor the loss of monomer (and in 
some case, oligomer formation) over time to solve aggregation mechanisms of 
monoclonal antibodies. This approach was not straightforward for the three mAbs 
explored thus far because: WFL interacted unfavourably with the chromatography 
matrix, despite the inclusion of arginine + succinate to minimise this possibility; 
the quality of the columns used deteriorated with time (note the peak shapes 
obtained for mAb1 in Figure 5.3b vs those for STT in Figure 5.3c); the number of 
clarification steps to remove the large aggregates which form due to flow prior to 
analysis; the inclusion of an additional quench step which may have adversely 
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affected the data quality. These issues have long been of concern in the field 
(Carpenter et al., 2010). Despite these issues, data for the loss of monomer as a 
function of time was obtained. The selection of a ‘time’ axis for extensional flow is 
difficult for the reasons stated in Chapter 3.1; proteins spend 18 μs in the 
extension region, 40 ms in the shear region of the capillary and ~ 5 s in the syringe 
barrel during one pass. Furthermore, there is a small delay after one pass before 
the next one takes place (~ 1 s when the plunger velocity is 8 mm s-1), in addition 
to mixing when the protein solution enters the empty syringe. Considerations will 
have to be made about these different time regimes when fitting future kinetic data 
to models, i.e. whether to define time in region x of the EFD (in seconds) or as the 
number of passes.  
Semi-denaturing agarose gels have been used to determine oligomer 
stoichiometry (Halfmann and Lindquist, 2008), as well as estimate the molecular 
weights of large proteins following enzymatic cleavage under shear flow (Lippok 
et al., 2016). Adapting these strategies for acrylamide gels, SD-SDS-PAGE could 
identify both the onset of aggregation for the mAbs (10 passes for all three mAbs), 
and differing electrophoretic mobility amongst the monomers, dimers and trimers 
observed. All three mAb monomers (WFL, mAb1 and STT) run at different 
apparent molecular weights on an SD-SDS-PAGE gel. This could be due to the 
proteins possessing different local conformations. It could also be due to the 
interactions between the proteins themselves and the polyacrylamide gel matrix 
(Hames, 1990). The distinction between these two phenomena would require 
further investigation. The aggregates appear to grow in a linear fashion, i.e. 1mer, 
2mer, 3mer…) rather than through dimeric states (2mer, 4mer, 6mer…). This is in 
agreement with previous data obtained for WFL (Devine, 2016), as well as for 
other mAbs in the literature (Li and Roberts, 2009; Nicoud et al., 2014; Singla et 
al., 2016). 
The onset of aggregation and its subsequent evolution was tracked in more detail 
using dynamic and static light scattering. The intensity of light scattered by a 
macromolecule increases by a 6th power with the size of the scatterer, e.g. a 60 
nm protein aggregate would scatter light at one million times the intensity of a 6 
nm mAb monomer (Filipe et al., 2010). Therefore, when the z-average radii of the 
mAbs measured by DLS increase as a function of pass number, the sensitivity of 
DLS allows the onset of aggregation to be easily identified. mAb1 and WFL were 
most sensitive to extensional flow, with their measured aggregates plateauing at 
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~8 μm after 20 passes, compared to STT. This was when the proteins were 
stressed at a concentration of 0.5 mg mL-1.  
Static light scattering has been used by many in the mAb aggregation kinetics 
field to monitor the mass increase of aggregates as a function of time (Arosio et 
al., 2012; Barnett et al., 2015; Kalonia et al., 2016). In our case, ‘time’ can be 
considered as the number of passes through the EFD. Just as DLS has caveats 
surrounding larger macromolecules, so too does SLS. The amount of light 
scattered by a macromolecule scales linearly with mass (see Section 1.3.4). 
When the uncertainty-averaged molecular mass of a sample is determined, the 
more aggregates present in the sample, the greater the overall magnitude of this 
value. At 0.5 mg mL-1, the uncertainty-averaged molecular mass increased as a 
function of pass number in the same fashion as the DLS data. The end-point 
masses for all three mAbs varied as a function of concentration: 0.5 mg mL-1 ≈ 4 
MDa ≈ 27mer and 0.25 mg mL-1 ≈ 11 MDa ≈ 73mer (data not shown). This plateauing 
effect could be due to: an artefact of the instrument (only three scattering angles 
are present, compromising the accuracy of the fit compared to a 15-angle 
goniometer, e.g. (Arosio et al., 2012); the species measured at this point represent 
the maximum size of the soluble aggregates present, with the coalescence of 
these forming insoluble aggregates. The aggregates formed at 0.5 mg mL-1 break 
up under shear flow, as has been proposed for various systems (Hoare et al., 
1982; Ren et al., 2015; Sadegh-Vaziri et al., 2018). The Smoluchowski equations 
describe the kinetics of amorphous aggregate growth (Arosio et al., 2012; Schmitt 
et al., 2000; Zidar et al., 2018). If more data were obtained tracking flow-induced 
mAb aggregate growth, then fitting these equations to the data could help obtain 
a rate-constant for soluble aggregate growth of the mAbs triggered by extensional 
flow. 
The Roberts group in Delaware have developed an array of experimental 
signatures typical of amorphous proteins when they aggregate, depending on 
whether or not their aggregation is dominated by unfolding, nucleation and so on 
(Li and Roberts, 2009). These signatures, identified through monomer loss 
assays and light scattering measurements, could possibly account for the 
mechanistic reason behind the observations made in this chapter. Further work is 




5.5.3 Characterising nucleation in the EFD 
 
The identification of species which nucleate a protein aggregation pathway is of 
interest to many researchers in the field (Silva et al., 2017; Törnquist et al., 2018). 
The initial use of mAb1 as a surrogate for WFL and STT, based on its intermediate 
behaviour, confirmed that the size distributions of aggregates do change over a 
long time period, with large (tens of microns in size) aggregates remaining stable, 
whilst smaller aggregates dissociate to smaller species. Most importantly, the 
presence of aggregates left quiescently in this manner does not induce more 
aggregation in a sample – flow is necessary to catalyse this. Furthermore, these 
experiments showed that stressed samples clarified using centrifugation do not 
aggregate over a two day period, nor do the quiescent samples. This could have 
implications for future experiments (see Chapter 7). The subsequent seeding and 
cross-seeding experiments performed with WFL and STT showed that 
aggregated protein can nucleate extensional flow-induced aggregation; this is the 
first demonstration of this to this author’s knowledge. These experiments also 
provide further evidence for WFL’s avidity for its hydrophobic ‘WFL’ motif, as its 
aggregation is influenced to a greater extent by its seeds rather than those of its 
99.6% sequence relative STT. Arginine could be successfully out-competing WFL 
monomers for this motif, moving its aggregation pathway from the top route in 
Figure 5.1 to the pathway traversed by STT. 
5.5.4. The EFD mechanism data in the context of 
established aggregation models 
 
The data in Section 5.2 do not provide conclusive, direct evidence for the induction 
of protein aggregation under flow in terms of the formation of an aggregation-
prone activated N* state. However, the fact that the quiescent samples are shown 
to be free of aggregate by many orthogonal assays means that one can still 
conclude flow acts a catalyst of mAb aggregation. The mAbs aggregate to form 
oligomers and soluble aggregates following 5–20 passes through the EFD, 
depending on the protein and the technique used to detect aggregation. The 
absolute size and mass of these aggregates, as well as how they grow, is possibly 
concentration-dependent. If so, one or many steps in the aggregation-pathway 
(containing a k’obs
 term) would be very sensitive to concentration. Further work 
would be necessary to understand this. 
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The more passes the mAb solution experiences, the more the aggregation 
pathway in Figure 5.1 is driven to the right, i.e. away from monomer towards the 
formation of soluble and insoluble aggregates. Allowing the system to reach 
equilibrium, it is clear that soluble aggregate formation on the pathway is 
reversible. Adding aggregated material in the form of seeds, in the presence of 
flow, propels the pathway towards the right, as more aggregate is observed in 
such seeded samples than those without seeds. In addition, it has been proposed 
that proteinaceous aggregates and other colloids can readily adsorb to gas-liquid 
and liquid-solid interfaces, with layers then being sloughed from these surfaces 
due to shear flow (Bee et al., 2011; Bee et al., 2012; Grigolato et al., 2017; Koepf 
et al., 2018; Sediq et al., 2016). If these aggregates broke up under flow (Sadegh-
Vaziri et al., 2018), and these species were able to nucleate the pathway, then 
the impact on the aggregation kinetics of mAbs in such environments may be 
profound (Törnquist et al., 2018). These proposed models are summarised in 
Figure 5.14. 
 
Figure 5.14. Proposed aggregation models in the EFD. a) Extensional flow 
events promote the formation of aggregation-prone species (red) from native 
monomers (blue) (cf. Figure 5.1). b) ‘Seed’ material could incorporate mis-folded 
monomers (i), or the aggregates could themselves coalesce, accelerating the 
formation of insoluble aggregate (ii). c) Large aggregates could interact with the 
glass surfaces of the EFD (i). During an extensional flow event (one pass), 
aggregates could be sloughed from the surface (ii). This could facilitate the 
accelerated aggregation phenomena discussed in b (iii). 
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Many more experiments are necessary to fully understand this pathway. The large 
body of data gathered using the EFD to look at how hydrodynamic forces induce 
protein aggregation could be used to inform the development of next generation 






















6. Screening the aggregation propensity of 
therapeutic mAbs using the extensional flow 
device 
6.1 Overview of the Jain, Sun et al. Proc. Natl. 
Acad. Sci. (2017) Adimab paper 
 
As discussed in Section 1.2 and throughout this thesis, biopharmaceuticals 
currently approved or in development, are dominated by the monoclonal antibody 
scaffold. During the drug development pipeline, the identification of mAbs with 
desirable biophysical properties is of the utmost importance, for the reasons 
discussed in Figure 1.6, Section 1.2. For small-molecule therapies, such 
‘desirable’ properties were defined in a seminal paper by Lipinski et al., leading to 
the ‘Rules of five’. These state that an oral medication should typically have: 
5>hydrogen-bond donors; Molecular weight < 500 Da; log P< 5; 10> hydrogen-
bond acceptors (Lipinski et al., 1997).  
However, no such sets of drug discovery ‘rules’ exist for biological therapies, 
except for guidelines surrounding the ‘quality’ of the molecule under the QbD 
framework (Section 1.4). Generally, a desirable mAb would be: easy to express 
in mammalian systems; highly soluble; stable in terms of both colloidal and 
conformational stability; highly specific for its target and non-immunogenic in vivo. 
With this in mind, a team of researchers at Adimab LLC (a spin-out from MIT 
founded by Prof Dane Wittrup) set out to define a ‘Lipinksi’s Rules of five’ for 
mAbs. At the time of writing the paper (accepted Dec 2016), the team at Adimab 
had characterised the 137 mAb-based therapies that were either approved, in 
Phase-III or in Phase-II clinical trials. The workflow was as follows: Take the 
variable sequences (VH and VL) of the above mAbs; Graft the variable sequences 
(VH and VL)  of the 137 mAbs into a common IgG1 scaffold; Over-express the 
sequences in HEK293 cells; Purify the mAbs by Protein-A chromatography; 
Formulate the mAbs in HEPES-buffered saline and finally, characterise the mAbs 
using twelve different biophysical techniques. These techniques were chosen by 
Adimab as they have at least one literature reference and use less than 1 mg of 





Table 6.1 Summary of the twelve techniques used to analyse the 137 mAbs 






HEK Titre The amount of mg L-1 of 
protein expressed in the 
HEK293 cell line. 
Aggregation-





(Jacobs et al., 
2010) 
Polyclonal antibodies 
conjugated to column 
matrix. mAbs of interest 
loaded onto column. 






(Xu et al., 2013) 
Biotinylated membrane 
proteins used as PSR. IgG-
presenting yeast, similar to 
those in Section 1.2.3 
incubated with these 
samples. MFI used to 
quantify substrate binding. 






(Sun et al., 2013) 
Human IgG loaded onto a 
biosensor. mAb of interest 
incubated for 5 mins, with 
association measured using 












conjugated to goat anti-
human IgG Fc fragments 
and polyclonal goat mAbs. 
Particles incubated with 
mAb of interest. Large 
wavelength shift gives a 
negative result. 
Aggregation-
propensity of the 
mAbs of interest. 
SG (Salt-gradient) 
AC-SINS 










Gold nanoparticles (as 
above) incubated with mAb 
of interest for 30 mins. 
Samples then diluted into 
0.3–1M ammonium 
sulphate. 560 nm shift 
plotted against salt 
concentration. 
Aggregation-
propensity of the 








(He et al., 2011) 
mAb of interest mixes with 
SYPRO orange. Plate 
scanned from 40°C to 95°C 
at 0.25°C min-1. 
Fluorescence followed as a 
function of time to allow Fab 
Tm to be assigned in BioRad 
software. 
Thermal stability of the 





(Kohli et al., 2015) 
Zenix SEC-300 column 
features a monolayer of 
silica. Longer retention times 
correlate with poor colloidal 
stability of the mAb. 
Colloidal stability of 
the mAb of interest. 
AS (Accelerated 
stress) SEC Slope 
1 mg mL-1 mAb samples 
incubated for 30 days at 
40°C. Various time points 
taken, with samples 
measured by gel-filtration 
chromatography. The 
amount of aggregate was 
quantified and the gradient 
calculated. 
Aggregation-
propensity / thermal 
stability of mAb of 





(Estep et al., 2015) 
 
 
mAb of interest spiked into 
1M ammonium sulphate 
buffer. Samples loaded onto 
butyl-NP5 HIC column. 
Retention times noted. 
Hydrophobicity of the 





(Mouquet et al., 
2010) 
The antigens Cardiolipin, 
keyhole limpet 
haemocyanin, 
lipopolysaccharide, ss- and 
ds-DNA and insulin were 
coated onto ELISA plates 
overnight. Blocking and 
wash steps then performed. 
mAb of interest added to 
plate. mAb-antigen binding 
detected using anti-human 





(Hötzel et al., 2012) 
As above, except 
baculovirus particles were 
used in place of the antigens 
listed for the ELISA assay. 
Unfavourable 
pharmacokinetics of 
the mAb of interest, 





Following analysis of the data generated from analysing the 137 mAbs with the 
methods in Table 6.1, it was apparent that some mAbs performed unfavourably 
in some assays, with the majority of mAbs performing favourably. When the data 
obtained for each technique were plotted on a frequency vs measured assay 
value, most of the techniques yielded a long-tailed distribution, with the tails 
pointing in the unfavourable direction, e.g. Figure 6.1a. (Jain et al., 2017). The 
only assays showing a Gaussian distribution of mAbs were the HEK titre and Tm 
assays (Figure 6.1b). To understand the relationship between each assay, the 
data were hierarchically clustered and subjected to Spearman’s rank correlation 
analysis. This produced a ‘family tree’ of assays, grouped by relatedness (Figure 
6.1c). 
 
Figure 6.1. Hierarchical clustering tree of biophysical assays in the 
Jain et al. paper. a) Example of a long-tailed distribution for an assay, in 
this case PSR. b) Example of a Gaussian distribution for an assay, in this 
case the Tm. c) The assays grouped together by colour were found to be 
statistically related (see text). The HEK/Tm family is most distinct from the 
PSR family of assays according to their Spearman’s rank order correlation. 






The clustering found that mAbs which generally expressed well in HEK had a 
stable Fab as measured by Tm (orange boxes). The other branches probed 
different biophysical properties of the proteins: self-association and adsorption to 
chromatography matrices (dark-blue boxes). Whilst in its own family, accelerated 
stress (green box) was found to be more closely linked to assays probing non-
specific association (purple and light-blue boxes) than self-interaction. 
 
In further analysis, because CHO cells are typically used for mAb production, the 
orange assay group was discarded. To derive their ‘Rules of five’ for mAbs, Jain 
et al. were interested in looking at how the approved mAbs in the dataset (48/137) 
behaved in the different assays. To do this, each assay was assigned a threshold 
value which, if exceeded, suggests the protein displays non-ideal behaviour. For 
example, a retention time in the HIC assay exceeding 11.7±0.6 min would be 
indicative of a poorly performing mAb (full list of values shown in Appendix Table 
A3). Exceeding one of the thresholds from any assay within a cluster would lead 
to a mAb being given a ‘red flag’. Jain et al. noted that generally, the approved 
mAbs possessed fewer red flags than those in Phase-III and Phase-II (Jain et al., 
2017). The mAbs were then further scrutinised and compared to one another 
through computing their pairwise distances (Section 2.2.17) to produce a cluster 




Figure 6.2. Cluster diagram of the 137 mAbs according to their 
relatedness in the biophysical assays. On the axes, Approved mAbs are 
labelled in red, Phase-III in yellow and Phase-II in green. Dark green 
squares in the plot = highly related mAbs, yellow = poorly related. The mAbs 
group into 5 Clusters (coloured squares). Taken from Jain et al. 2017 and 
appended with arrows. 
The data in Figure 6.2 show that the mAbs form five ‘clusters’ of relatedness. The 
largest such cluster (top-left corner) contains 81 of the 137 mAbs, which possess 
the most similar biophysical properties in the four groups of assays. This group 
includes 34 of the 48 approved mAbs. As one moves along the diagonal indicated 
by the red arrow, the number of red flags assigned to a mAb increases, whilst the 
number of approved mAbs in a cluster decreases. In spite of the caveats in this 
reference dataset (see Discussion, Section 6.5), Jain concluded that the results 
and analysis presented here will serve as a tool for industrial and academic 
scientists alike to aid the development of next-generation mAb therapies, based 
on the cut-offs defined above.  
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With this reference dataset in mind, a collaboration was established with Adimab 
to answer the following: 
 Can the EFD distinguish between mAbs both within and between clusters, 
using the % protein in pellet (following ultracentrifugation) as a readout? 
 Are approved mAbs more resilient to hydrodynamic forces than those in 
Phase-II? 
 How does the EFD compare to the assays and groups defined in Figure 6.1? 
Could the EFD replace any/all of the assays used by Jain et al.? 
 Can emerging bioinformatics tools help rationalise the aggregation data 
generated from the EFD on these mAbs? 
The answers to these questions form the basis of the rest of this Chapter. 
6.2 Selection of a new mAb family from the Adimab 
dataset 
 
Subjecting all 137 mAbs to stress in the flow device is far beyond the scope of 
this project. In order to select an appropriate number of mAbs for stress in the flow 
device, a rank order of the mAbs was produced by Tushar Jain (Adimab, LLC) 
using a ‘distance from ideal’ analysis of the red flag data from Jain et al. 2017 (see 
Section 2.2.17). In brief, an ideal mAb’s measured values in the biophysical 
assays from Figure 6.1 would be the top values in the favourable direction, for 
example, the lowest retention time on a HIC column.  A mAb from the Adimab 
dataset closest to this ‘ideal’ mAb would thus attain a rank of 1/137. Conversely, 
a mAb which performed the worst in the assays would be the furthest away from 
ideal and thus attain a rank of 137/137. The rank orders produced in this fashion 
were plotted against the numerical order of each mAb in Figure 6.2. The mAbs 































Figure 6.3. Plot of ‘distance from ideal’ red flag rank against protein 
number from Figure 6.2. The five clusters are colour-coded according to 
Figure 6.2, with Cluster 1 (blue) being in the top-left corner and Cluster 5 
being in the bottom-right corner. A linear trend line was fitted to the data in 
Origin Pro to guide the eye. 
 
The data show that as the cluster number increases, the red flag rank number 
assigned to each mAb from the Jain et al analysis also increases. This would 
agree with the data in Figure 6.2, as the smaller clusters (Clusters 4 and 5) 
generally possess fewer approved antibodies, more Phase-II antibodies and more 
mAbs with red flags than the larger clusters (colour-coding on axes of Figure 6.2). 
There is a large spread in rank amongst the antibodies in Cluster 1, possible due 
to the large number of mAbs (80/137) in this cluster. Conversely, the spread in 
rank is very similar between Cluster 2 and 3, as well as between Clusters 4 and 
5.   
Rather than analyse all 137 mAbs, an initial set of 50 were selected from Figure 
6.3 of differing rank and cluster number. The list was sent to Adimab, who selected 
the final set of 33 mAbs to be tested with the EFD: 15 from Cluster 1, 6 from 
Cluster 2, 5 from Cluster 3, 4 from Cluster 4 and 3 from Cluster 5. The cluster 
numbers of the mAbs, alongside bioinformatics data, are in Appendix Table 1.2.  
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6.3 Screening the Adimab IgGs using the extensional 
flow device 
 
6.3.1 Generating the EFD pelleting data 
 
In the Jain et al. paper, the mAbs were formulated into 25 mM HEPES + 150 mM 
sodium chloride, pH 7.3. Whilst some assays required different running buffers 
etc. to work, the decision was made to stress the Adimab proteins in this 
formulation buffer. Initially, a series of ‘ranging shot’ experiments were performed 
with Daratumumab. This was chosen as it is an approved mAb from Cluster 1, 
thus it was hypothesised that it would be resistant to extensional flow, like STT 
from Chapters 3–5. To validate this hypothesis, Daratumumab was stressed for 
0, 20, 50 and 100 passes at a plunger velocity of 8 mm s-1 and a protein 
concentration of 0.5 mg mL-1. Following this, the samples were analysed using 
the insoluble protein pelleting assay. The data are shown in Figure 6.4. 
 
 
Figure 6.4. ‘Ranging shot’ for Daratumumab.  The protein was stressed at 
a concentration of 0.5 mg mL-1 for 0 (quiescent control sample), 20, 50 and 
100 passes at a plunger velocity of 8 mm s-1. The samples were then 
analysed using the pelleting assay. Errors from two independent 
experiments were propagated according to Section 2.2.18. 
 
 
























The data confirm that Daratumumab is fairly resistant to extensional flow, with 
~20% of the protein being rendered insoluble after 100 passes in the EFD. This 
is similar to how STT behaved in the flow device when stressed in ammonium 
acetate (~18%, Chapter 4). Assuming that the other mAbs in this cluster would 
yield similar data, it was decided to double the number of passes to 200, to try 
and increase the dynamic range observed. At first, Daratumumab, Tabalumab, 
Denosumab, Ipilimumab and Ixekizumab were stressed for 200 passes under the 
same flow and buffer conditions as above. The remaining 28 mAbs were then 
selected at random, according to Section 2.2.17. Quiescent samples were 
incubated at room temperature for 20 minutes. All experiments were performed 
in duplicate, with the samples analysed using the insoluble protein pelleting 





















































































































































































































Figure 6.5. Plot of the percentage insoluble protein following stress in the 
EFD. The 33 Adimab proteins were stressed in the EFD for 200 passes at a 
plunger velocity of 8 mm s-1 in 25 mM HEPES + 150 mM sodium chloride, pH 
7.3. Samples were analysed using the insoluble protein pelleting assay. 0–5% 
aggregate was seen in all quiescent samples (data not shown). Errors from two 
independent experiments were propagated according to Section 2.2.18. 
Pelleting data were collected with the assistance of Dr Amit Kumar, University of 
Leeds. 
The data show that the mAbs aggregate to widely differing extents when 
subjected to stress in the EFD, with Vedolizumab yielding ~10% and Foralumab 
~80% protein in pellet, respectively. Visually, there appears to be three different 
aggregation response levels to stress in the EFD: low (0–20%), medium (20–
60%) and high (+60%). In the Jain et al. paper, long-tailed distributions were 
observed for 10/12 of the assays employed to interrogate the biophysical 
properties of the mAbs (Section 6.1). To assess the statistical relationships in the 
pelleting results, the data from Figure 6.5 were plotted as a histogram, with a bin 
size of 10% protein in pellet. These data are displayed in Figure 6.6. Further 
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Figure 6.6. Histogram and cumulative frequency diagram for the 


















% protein in pellet  
 
Figure 6.7. Box and whisker diagram showing the common statistical 
features in the pelleting data from Figure 6.5.  The data points from 
Figure 6.5 are shown as red diamonds on the left. The whiskers of the box 
represent the 99% (top) and 1% (bottom) quartiles. The box comprises the 




Statistical analysis of the data shows that the % protein in pellet following stress 
has a long-tailed distribution, i.e. it is not Gaussian. The approval rating of the 
mAb appeared to not affect the level of aggregation seen (Appendix Figure A5). 
Whilst the pelleting data for some mAbs were quite variable between replicates, 
the average propagated error between replicates is low, at around 7%. This is 
typical of the error threshold seen for STT, mAb1 and WFL in the previous 
chapters. In isolation, the data on their own merely show that, under these flow 
and buffer conditions, those mAbs in the 0–20% range (Vedolizumab to 
Guselkumab) are more resilient to stress under extensional flow than those in the 
+60% range (Alemtuzumab to Foralumab). To compare how the EFD data 
compare to the Adimab dataset, further statistical analysis is necessary. 
 
6.3.2. Statistical comparison of the EFD data to those 
from twelve alternative biophysical assays. 
 
Following the generation of the EFD data, the values of mean % protein in pellet 
for each mAb were sent to Tushar Jain (Adimab) for analysis with the statistical 
clustering methods discussed in Section 6.1. All of the analyses performed on the 
original 137 mAbs were repeated using the 33 mAbs selected in Section 6.2. 
These analyses were performed with and without the flow data. The first such 
analysis was Spearman’s rank clustering of the assays themselves. The 
hierarchical clustering trees for each set of assays (with and without flow) are 










Figure 6.8. Hierarchical clustering ‘Family trees’ of assays used to assay the biophysical properties of the 33 Adimab IgG1s. 
The tree on the left shows the clustering data for the 33 mAbs selected for this study without the extensional flow data. The tree on the 




The data in Figure 6.8 contain an interesting set of trends. When the data for the 
33 mAbs in this study were correlated using Spearman’s rank in the absence of 
flow, the hierarchical clustering deviates from that in Figure 6.1. With the full set 
of mAbs (all 137), CIC tended to give similar results to PSR, AC-SINS and CSI 
(light-blue boxes, Figure 6.1). The CIC data for the mAbs selected for this study 
tended to be more similar to the assays probing self-interaction (dark-blue boxes, 
left-hand side, Figure 6.8). When extensional flow is included as a ‘13th’ assay, 
the hierarchical arrangement of the assays changes quite dramatically. The 
performance by mAbs in the EFD tend to be most related to the assays which 
probe poly-specificity (purple and light-blue boxes) than the others. The EFD also 
has its own branch on the tree; it does not pair with another assay directly. This 
analysis suggests, therefore, that the EFD (and pelleting assay) is a distinct assay 
to those used by Jain et al. (2017). This means that what the EFD data tell one 
about the ‘developability’ of a mAb is distinct to those from ELISAs etc. The 
implications of this are discussed in Section 6.5. 
The hierarchical clustering of the mAbs themselves, from their assay data 
including and excluding the EFD, was performed as in Figure 6.2. Once again, 
the HEK titre and Tm data were excluded from the analysis. The two cluster 




















Figure 6.9. Cluster diagrams for the 33 mAbs according to their relatedness in the biophysical assays, both without (left) and with 
(right) flow data. On the axes, Approved mAbs are labelled in red, Phase-III in yellow and Phase-II in green. Dark green squares in the plot 
= highly related mAbs, yellow = poor relatedness. Analysis by Tushar Jain, Adimab.
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The diagrams in Figure 6.9 show that flow clearly affects how the mAbs are 
grouped into clusters. The largest group of related mAbs in the top-left corner 
decreases in size from 17 to 15 when the EFD data are included. The other 
clusters also appear more distinct (for the 33 mAbs analysed) when the EFD data 
are included (right-hand plot) than in its absence (left-hand plot). The general 
trend that more approved mAbs tend to pool in the top left remains, except for 
when flow is included as an assay, where three approved mAbs group together 
in the bottom-right cluster. Following this, the relationship between the cluster a 
mAb finds itself in and the amount of aggregation observed in the EFD assay were 
correlated with the clusters above. This is shown in Figure 6.10. 
6.10a)     6.10b) 







































Cluster Number  
Figure 6.10. Plot of % protein in pellet following stress in the EFD 
against the cluster number for the Adimab mAbs when a) flow is 
excluded and b) included in the analysis. Data shown are the same as in 
Figure 6.5. 
 
The data show that whilst the spread of aggregation behaviour by mAbs in 
Clusters 1–3 remains steady, both the position and spread of observed 
aggregation by mAbs in Clusters 4 and 5 changes. For example, the mAbs in 
Cluster 4 (when flow is not included as an assay in the clustering analysis) in 
Figure 6.10a tended to all be fairly aggregation-prone. Therefore, when the EFD 
data are included in the analysis, the overall relatedness to the other mAbs 
changes, with all three of these mAbs changing cluster. These data show that the 
EFD affects the grouping of some mAbs more than others. Using the ‘distance 
from ideal’ red flag analysis, the rank of each mAb including and excluding the 
EFD data can be calculated to see how the ranks of the mAbs change with the 
inclusion of this new assay branch. The data are shown in Figure 6.11. 
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Figure 6.11. Scatter plot of the rank of each mAb including and 
excluding data from the extensional flow device. A rank of 1 was 
ascribed to the mAb closest to ideal, whilst the mAb furthest away was 
ascribed a rank of 33.  mAbs circled in red are examples which are ranked 
far worse with EFD data included. mAbs circled in green are examples which 
are ranked far better with EFD data excluded. Distance from ideal 
calculations were performed by Tushar Jain, Adimab LLC. 
The data show that some mAbs retain their rank regardless of whether or not flow 
is included as an assay. Several points have moved position slightly away from 
the line, indicating that flow has changed their position negligibly, e.g. from 2nd to 
3rd. However, some mAbs move several positions when flow is included in the 
analysis. For example, Alemtuzumab moves from a rank of 4/33 to 7/33 (lower 
red circle). Some mAbs appear more favourable when the EFD data are included. 
For example, Denosumab moves from a rank of 26/33 to 22/33. The mAbs circled 
in red will be discussed further in Sections 6.4 and 6.5. This plot seems to suggest 
that a single EFD assay cannot replace all the assays used by Jain et al. To 
confirm this was the case, the mAbs in Figure 6.5 were ranked from best to worst 
(1–33) and plotted against the distance from ideal rank of the mAbs excluding the 
EFD from Figure 6.11 (Appendix A6). No correlation was observed, confirming 
that the EFD augments the array of assays with which one could appraise the 
‘developability’ of a mAb. But why do some mAbs behave differently in the EFD 
to the other assays? Are there any sequence-related features that could help 
rationalise the data?  These questions will be answered in Section 6.4. 
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6.4. Using bioinformatics to attempt to rationalise the 
EFD data obtained for the 33 mAbs 
6.4.1. Are some families of mAbs more aggregation-prone than 
others? 
 
So far, it is clear that the 33 mAbs selected from the Adimab dataset cluster 
together in terms of their relatedness: within an assay, between assays (i.e. 
amongst one another) and within one assay category (i.e. a branch on the 
phylogenetic trees in Figure 6.8). With this latter point in mind, it was postulated 
whether or not a set of mAbs with high sequence homology exhibited similar or 
diverse levels of aggregation in the EFD. This is particularly pertinent given the 
data for WFL and STT in Chapters 3–5, where it was demonstrated that despite 
possessing 99.6% sequence identity, the two mAbs have markedly different 
aggregation behaviour. The mAb VH and VL sequences were input into Clustal Ω 
(see Section 2.2.17) and a phylogenetic tree constructed. The tree was annotated 
with the amount of aggregate observed: ● = 0–20%, ■ = 21–60% and ▲ = 61%< 
protein in pellet after 200 passes. The rank of the protein in the flow assay was 
also added onto this diagram. Furthermore, to see how the families identified 
relate to the clusters in Figure 6.9, these too were added to tree. The phylogenetic 









Figure 6.12. Phylogenetic tree for the 33 mAbs. The mAbs at the 
bottom of the tree are least related to those at the top. ● = 0–20%, ■ = 
21–60% and ▲ = 61%< protein in pellet, respectively. Numbers in black 
denotes the rank in the EFD. Cluster x/ Cluster y = Cluster number without 
flow/ Cluster number with EFD data, from Figure 6.9. The length of the 
branch is proportional to the number of mutations away from the ancestral 
sequence. The tree was constructed using Clustal Ω according to Section 
2.2.17, then the tree annotated in Microsoft Powerpoint. 
The data in Figure 6.12, whilst complex, show that the majority of the families of 
mAbs identified possess mAbs which aggregated to different extents in the EFD. 
Exceptions include Cixutumumab and Tralokinumab (30/33 and 31/33 
respectively) and Etrolizumab and Onartuzumab (2/33 and 6/33 respectively). 
mAbs from the same cluster which are related in sequence, e.g. Zalutumumab 
and Fularnumab (bottom sequences) can have differing behaviour. This is in 
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direct agreement with the data obtained previously for WFL and STT. The data 
show, therefore, that aggregation-propensity in the EFD is not a ‘family trait’. 
6.4.2 Do the simple, intrinsic properties of the mAb sequences 
correlate with the amount of aggregate formed by the EFD? 
 
A significant advantage of the Jain et al. (2017) paper to similar studies is the 
availability of the VH and VL sequences as a dataset for all of the mAbs used in 
the study. IgG1s have incredibly similar structures, with variability typically limited 
to the CDRs in the variable domains, as opposed to the framework regions. With 
this in mind, an array of bioinformatics tools were employed to try and correlate 
the intrinsic biophysical characteristic of the 33 mAbs with their aggregation 
behaviour under extensional and shear flow. As stated in Section 6.2, the pI and 
intrinsic CamSol scores for the VH and VL sequences were computed for each 
mAb (see Section 2.2.17), as these solubility-based calculations may explain why 
some mAbs are more susceptible to hydrodynamic forces/more aggregation-
prone than others (Sormanni et al., 2017) . These were plotted against the % 
protein in pellet for each mAb. The data are shown in Figures 6.13a) and b) 
respectively. 
 
a)          b) 







































Intrinsic CamSol Score at pH 7  
Figure 6.13. Plot of the % protein in pellet (from Figure 6.5) against a) pI 
and b) Intrinsic CamSol score at pH 7 for the scFv of the 33 mAbs 
stressed in the study. VH and VL sequences were input into ProtParam and 
CamSol according to Section 2.2.17.  
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The data in Figures 6.13 show that the trend between the pI (a) or intrinsic CamSol 
score (b) and the extent of aggregation observed in the EFD for the Adimab 
proteins, is not simple. The mAbs stressed in the device near their pI (~ pH 7) had 
low levels of aggregation in the EFD (0–20%) (Figure 6.13a). The most basic 
mAbs (pI> 8.5) appear to have generally worse aggregation behaviour in the EFD. 
More sophisticated statistical tests would be needed to interrogate the 
significance of this observation. A CamSol score below -1 is indicative of a poorly-
soluble sequence (Sormanni et al., 2015). None of the VH+VL sequence 
combinations for each mAb exceed this threshold. Despite this, even the 
sequences predicted to be the most insoluble behaved favourably in the EFD. 
These data suggest that attractive interactions between native state proteins, 
coupled with the intrinsic solubility of the binding domains, does not lead to 
increased levels of aggregation in the EFD. It should be noted that the CamSol 
score is averaged across the whole sequence, thus localised regions with poor 
solubility can be masked with such an approach. 
The amino acids found in the CDRs are crucial to both antigen binding and 
resistance to aggregation (Dudgeon et al., 2012; Peng et al., 2014). A recent 
paper analysed the correlation of the AC-SINS assay with the net charge of the 
CDRs for the Adimab dataset. The authors found that the more positive the net 
charge at pH 7, the worse the mAb behaved in the AC-SINS assay (Alam et al., 
2018). Additionally, as CDRs drive the affinity of a mAb to its target, it was posited 
that affinity maturation may render mAbs more aggregation-prone. To examine 
whether the physico-chemical properties of the CDRs correlate with EFD rank, 
the net CDRs of the 33 mAbs were calculated in ProtParam, according to the 
strategy of Alam et al. A literature search for the binding affinities of the 33 mAbs 
was also performed, with 26 identified. These values were plotted against the EFD 
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CDR net charge at pH 7



















KD (nM)  
Figure 6.14. Plot of the % protein in pellet (from Figure 6.5) against a) 
Net CDR net charge at pH 7 for all 33 mAbs and b) KD for 26/33 mAbs 
stressed in the study against their targets. CDR Net charges were 
calculated according to the method of Alam et al., 2018 (Section 2.2.17). KD 
values for the 26 mAbs shown above were obtained from the literature, with 
references give in Appendix Table A4. 
These data show, once again, that the correlation between the biophysical 
characteristics possessed by the mAbs and their apparently complex response to 
hydrodynamic forces, is not simple. The CDR analysis (Figure 6.14a) shows that 
even when the CDR charge is positive, which is thought to lead to high degrees 
of self-association, the flow-induced aggregation data cover the full dynamic 
range seen in Figure 6.5 (~10%–80%). The same trend is seen when the binding 
affinity for 26 of the mAbs is plotted against their observed aggregation (Figure 
6.14b). The most potent mAbs have pM binding affinities, with their observed EFD 
aggregation levels covering a large dynamic range. This is similar to WFL and 
STT in Chapters 3–5, as both mAbs have similar binding affinities (Dobson et al., 
2016), yet markedly different aggregation behaviour in the EFD. Once again, 






6.4.3 Using Solubis to identify APRs in the variable domains of 
the Adimab proteins 
Where are the APRs distributed in the 33 mAbs? 
 
Rather than the global, intrinsic physico-chemical properties of the 33 mAb 
sequences, local regions could be driving aggregation in the EFD, as seen for 
WFL in the previous chapters. As discussed in Section 1.3.1, some APR 
predictors have recently emerged which allow structural information to be 
incorporated into the analysis, rather than just sequence. The Solubis algorithm 
was developed to combine the TANGO APR algorithm with the FoldX force-field 
to aid the design of thermodynamically stable mAbs (Van Durme et al., 2016; van 
der Kant et al., 2017). The use of this webserver relies on having structural 
information for the protein of interest. Clearly, solving the crystal structures for all 
33 mAbs used was not practical.  
 
Homology models of mAbs can, however, readily be constructed with reasonable 
precision using ABodyBuilder (Leem et al., 2016). The 33 mAbs’ VH and VL 
sequences were input into the ABodyBuilder webserver to generate homology 
models for all of the proteins (see Section 2.2.17). These PDB files were then 
analysed with the Solubis webserver to identify APRs within the proteins. This 
yields both the TANGO score of the APR (i.e. its stickiness) and its contribution 
to the thermodynamic stability of the mAb (via the ΔGcontrib term). 175 APRs were 
identified for the 33 mAbs. The homology models were then annotated with the 
APRs (identified above) in PyMol. For brevity, the structures of only twelve mAbs 
of interest are shown. The four mAbs circled in red from Figure 6.11, which are 
ranked quite differently when flow is included as an assay, are presented in Figure 
6.15. The four mAbs which move by two or more clusters when flow is included 
as an assay are in Figure 6.16. Finally, the four mAbs which did best and worst in 
the EFD, and best and worst overall (closest and furthest to ideal, respectively) 
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Figure 6.15. scFv homology models (VH and VL, left and right 
respectively) for a) Alemtuzumab, b) Etrolizumab, c) Guselkumab and 
d) Bevakizumab. APRs identified in Solubis are highlighted in red, with the 












a)      b) 
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Figure 6.16. scFv homology models (VH and VL, left and right 
respectively) for a) Galiximab, b) Ipilimumab, c) Fezakinumab and d) 
Golimumab. APRs identified in Solubis are highlighted in red, with the rest 












a)      b) 
  
c)      d) 
  
Figure 6.17. scFv homology models (VH and VL, left and right 
respectively) for a) Vedolizumab, b) Foralumab, c) Daclizumab and d) 
Cixutumumab. APRs identified in Solubis are highlighted in red, with the 
rest of the structure shown in green. 
 
The models shown throughout Figures 6.15–6.17 present some interesting 
features. Generally, the APRs in the scFvs tend to be localised along the β-sheets 
comprising the VH-VL interface (discussed later). Some mAbs, e.g. Etrolizumab 
(6.15b), Galiximab (6.16a) and Cixutumumab (6.17d) have particularly long 
CDRH3 loops, which feature/ are adjacent to APRs. Interestingly, Galiximab 
(6.16a) does not possess any APRs in its VL domains, the only protein of the 33 






How aggregation-prone are the APRs identified in the 33 mAbs? 
 
To further understand the aggregation propensity of these regions, the 175 APRs 
from all 33 mAbs were graphed as a ‘stretch plot’ (Section 2.2.17), along with the 
extent of aggregation of the mAbs under flow, using the three levels described 
























Figure 6.18. ‘Stretch plot’ of the APRs identified in the 33 mAbs using 
Solubis. The higher the TANGO score, the higher the aggregation-
propensity of a given APR. The more negative the ΔGcontrib, the more 
stabilising the APR is to a mAb (i.e. buried not surface-exposed). Symbols 
represent the coarse aggregation propensity of the parent mAb that contains 
that APR (● = 0–20%, ■ = 21–60% and ▲= 61%< aggregation under flow 
respectively). The APRs are coloured according to their parent mAbs from 
Figure 6.5. 
 
These data show that most of the APRs in the mAbs appear to be of reasonably 
low aggregation propensity and buried in the hydrophobic core of the VH and VL 
domains (i.e. bottom-left quadrant). If the levels of aggregation observed in the 
EFD were merely due to surface-exposed, highly sticky APRs, then the top-right 
191 
 
quadrant would contain many triangles. The stretch plot suggests that this is not 
the case. To validate this, the Solubis score was for each APR within each mAb 
was summed and plotted against the amount of insoluble protein quantified after 
the mAb was stressed in the EFD. The data are shown in Figure 6.19. 
 





















Figure 6.19. Plot of the Solubis score (ΔGcontrib x TANGO score for the 
total number of APRs) vs the % protein in pellet formed in the pelleting 
assay for each mAb after stress. All data are taken from and colour-coded 
according to Figure 6.5. 
 
The data show that all of the mAbs possess at least one partially buried APR, as 
the total Solubis score for all but two mAbs is greater than zero. Higher Solubis 
scores correlate with exposed, sticky APRs in a mAb (van der Kant et al., 2017). 
When this structural correction of the TANGO score takes place, it is even clearer 
that the APRs which may form the aggregation interfaces in the 33 Adimab 
proteins stressed in this study are not exposed in the native state. If this was the 
case then Onartuzumab and Galiximab (the teal and dark grey points with Solubis 
scores ~850 and 960 respectively) would aggregate to the greatest extent in the 
EFD. In fact, the converse was observed to be true. These data add further 
evidence to the hypothesis proposed in Chapter 5 that mAbs aggregate through 
a partially unfolded N* state, triggered by extensional flow. 
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Does the VH-VL interface become exposed under flow, driving mAb aggregation? 
 
Upon closer analysis of the APR distribution plots, Vedolizumab (6.17a) and 
Foralumab (6.17b) occupy the poles of the extent of aggregation measured in the 
EFD (best and worst respectively), yet appear to have a similar distribution of 
APRs in their variable domains, as well as low Solubis scores (125 and 74 
respectively). Daclizumab (6.17c) possesses a fairly benign set of APRs (Solubis 
score = 184) and is the best ranked mAb of the 33, whilst Cixutumumab (6.17d) 
has a particularly exposed YYYYYM motif, probably accounting for its high 
Solubis score (740) and worst ranking overall out of 33 proteins. Coincidentally, 
in the original ranking analysis in Figure 6.3, Cixutumumab is ranked 137/137.  
At face value, it appears that Solubis cannot report whether or not a particular 
protein will be sensitive to the effects of extensional flow. It can however identify 
potential APR binding interfaces; as stated below Figure 6.17, many of the mAb 
scFvs have APRs distributed along their VH-VL interface. It was thus posited that 
if this interface was the crucial region where mAbs partially unfold under flow to 
form the N* state, then the unfolding of one domain would increase the stickiness 
of that region by exposing more of this interface to the solvent. The largest 
difference in solvent accessibility when either VH or VL unfolds, leading to the 
exposure of the ‘stickiest’ set of APRs as measured by TANGO, may then 
correlate with the greatest amount of aggregate formed in the EFD. To test this 
hypothesis, the estimated solvent-accessible surface area (SASA) of each APR 
in all 33 mAbs was calculated using PyMol. The VH and VL domains were deleted 
in turn, with the SASA re-calculated after the deletion in each case (see Section 
2.2.17). The ΔSASA, summed TANGO score of the whole scFv and the amount 





Figure 6.20. Plot of the summed TANGO score against the change in 
interfacial APR solvent-accessible surface area for the 33 Adimab 
scFvs. The amount of aggregate formed under flow for each mAb (from 
Figure 6.5) is mapped onto the plot, with the colour and length of each peak 
corresponding to the amount of aggregate quantified in the pellet. 
 
 
The data in Figure 6.20 show that this hypothesis was incorrect. If exposure of 
this interface under flow led to a greater amount of aggregate being observed 
after stress in the flow device, then the large red peaks in Figure 6.20 would all 
be in the top-right corner of the plot. Only Cixutumumab occupies this quadrant, 
which may once again explain its behaviour in the EFD and the other assays. In 
conclusion, whilst Solubis can help generate hypotheses as to why a particular 
mAb may performed as it did in the EFD or another assay, it cannot rationalise 
the data and provide a clear answer for this. Possible reasons for this will be 









As introduced in Sections 1.2 and 1.3, in addition to Section 6.1, various assays 
and methods are employed by the biopharmaceutical industry to determine the 
‘developability’ of a mAb. No one assay provides all of the information necessary 
to determine whether or not a molecule will pose a ‘developability’ issue or not. 
Many high-throughput techniques are employed by industrial laboratories to 
screen both large numbers of conditions and molecules for colloidal and 
conformational stability (Bhirde et al., 2018; Capelle et al., 2007; Chaudhuri et al., 
2014; Goldberg et al., 2011; Zhao et al., 2010). Forced-degradation methods are 
employed to assess the sensitivity of mAbs to different environmental stresses 
(Luo et al., 2011; Nowak et al., 2017). The assay chosen, the physicochemical 
environment and the molecule itself will all impact the result of such developability 
assays- which ultimately dictate whether or not a drug candidate falls out of the 
development pipeline (Yang et al., 2013). 
The generation and analysis of large datasets is gaining attention in the 
biopharmaceutical industry and beyond, under the umbrella of ‘Big Data’ (Costa, 
2014; Szlezák et al., 2014). This is particularly true in today’s era of Quality by 
Design (Section 1.2.4). Just as the analysis of a large set of molecular data led to 
Lipinski’s Rules of five (Lipinski et al., 1997), the work of Jain et al. set out with a 
similar aim for monoclonal antibody therapeutics (Jain et al., 2017). One issue 
limiting the maximal implementation of Big Data in the mAb development field is 
the availability of intellectual-property free molecules and their associated 
biophysical/ colloidal and conformational stability data (Szlezák et al., 2014). The 
NISTmab, a reference molecule developed specifically for the validation of 
biopharmaceutical assays (Saro et al., 2015; Schiel et al., 2015), has been 
employed by many groups to assess different analytical techniques (Hsieh and 
Wyatt, 2017; Karageorgos et al., 2017). The obvious limitation here is that of 
dataset size when correlating the aggregation of NISTmAb with one or more 
attributes from an unrelated mAb (or panel of mAbs). 
The Jain et al. (2017) paper made a large step towards alleviating this problem 
by: (i) using clinically relevant mAbs of which the sequence of the variable 
domains are known; (ii) using established assays from the literature; (iii) clearly 
presenting the analytical framework used to cut through the dataset and (most 
importantly), (iv) making these datasets publicly available. Prior to this chapter, 
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the only mAbs subjected to stress in the EFD were WFL, mAb1 and STT. These 
molecules allowed for the extensive exploration of parameter space in the EFD, 
in addition to the appraisal of the different analytical methods available to this 
author to characterise aggregation. The translation of this research to industry 
would be limited with a dataset of just N = 3 antibodies. Through systematically 
choosing a subset of ~1/4 of the Jain mAbs, it is clear that the EFD can distinguish 
between robust, intermediate and sensitive mAbs under the conditions selected 
for this study. 
It is highly likely, given the data in Chapters 4 and 5 (for WFL, mAb1 and STT), 
that changing the buffer, protein concentration and flow conditions would change 
the levels of aggregation observed for these proteins following extensional flow. 
There are additional caveats with the molecules themselves, as acknowledged by 
Jain et al. (2017): some of the IgGs are originally IgG4’s, not IgG1s; the mAbs are 
not in their designed formulation buffers in any of the assays used by Jain or in 
the EFD (except when defining the cut-offs in the Jain et al. (2017) paper; these 
molecules are based on clinically relevant mAbs- they must have been 
‘developable’ in the eyes of both the proprietor and the regulator to make it into 
the clinic.  
Despite this, the work presented in this Chapter shows that the EFD appears to 
be statistically distinct to other orthologous assays used in the field. Through the 
addition of more assays to the analytical repertoire, it is clear that for certain 
mAbs, e.g. Alemtuzumab in Figure 6.11, that the incorporation of the EFD would 
change the ranking of a mAb in the eyes of a developer. Further work could then 
be performed on the mAb, e.g. formulation screens and landscape generation of 
the type seen in Chapter 4, to stabilise such mAbs against hydrodynamic stress. 
Outright ‘bad’ mAbs such as Cixutumumab may be deemed impossible to develop 
or manufacture. It would be interesting to see how mAbs lower down the 
development pipeline fare in both the EFD and the assays employed by Jain et 
al. (2017). Finally, it is evident that the bioinformatics tools currently available, 
such as CamSol and Solubis, cannot predict or explain why a particular mAb will 
aggregate under extensional flow.  
These methods do allow for the prediction of APR interfaces which may form 
under flow, which open up many questions to be addressed in the future. Such 




7. Concluding remarks and future directions 
 
The aim of the project was to understand whether (and if so, how) extensional 
and shear flows affect proteins to induce aggregation. Specifically, the effects of 
flow on therapeutic proteins was the main focus of this thesis. Initially, a model 
protein was sought from the literature where evidence for conformational change 
and/or aggregation existed. BSA, whilst not a therapeutic protein, was a suitable 
candidate for this role. Its ready availability and low cost (10g, £50) meant that a 
wide array of parameter space in the EFD, in addition to a range of analytical 
methods, could be explored. This allowed for understanding to be gained about 
how the number of passes in the EFD related to both the amount and size of BSA 
aggregates formed due to flow. Crucially, the free Cys34 in BSA could be 
exploited in the IAEDANS assay to show that extensional flow causes 
conformational remodelling and subsequent aggregation of globular proteins, the 
first demonstration of this event to this author’s knowledge. 
The flow fields present in the EFD are well-defined and characterised by CFD. By 
coupling a detailed knowledge of the proteins used in the study to an 
understanding of the flow environment in the EFD, firmer conclusions could be 
drawn as to why a given protein aggregates following stress under extensional 
and shear flow. With therapeutic proteins in mind, WFL and STT represent the 
‘Yin and Yang’ of antibodies. Despite differing by only six residues, the two mAbs 
have been shown to display contrasting aggregation behaviour under quiescent 
conditions (Devine, 2016; Dobson et al., 2016). The device was demonstrated to 
be able to differentiate between these model mAbs and the generic mAb1 under 
a limited set of flow conditions. This initial work (presented in Chapter 3) also 
showed the heightened sensitivity of the three mAbs to hydrodynamic forces 
compared to BSA, as they aggregated to a greater extent than BSA after just 100 
passes at a concentration of 0.5 mg mL-1, ten-fold lower than BSA. 
In Chapter 3, it was observed that as the plunger velocity increases in the EFD, 
the energy imparted into the fluid also increases. For BSA, it was observed that 
above an energy threshold, aggregation becomes more pronounced. In Chapter 
4, the parameter space in the EFD was explored for BSA, WFL, mAb1 and STT. 
The insoluble protein pelleting assay, though crude, allowed for quantitation of 
aggregation as a result of extensional and shear flow. The aggregation 
landscapes generated for the model proteins revealed complex relationships 
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between the number of passes in the EFD (the total time exposed to 
hydrodynamic forces) and the magnitude of the strain and shear rates present, 
with the levels of aggregation observed. This study provided more evidence for 
the striking disparity between WFL and STT in particular, with WFL’s sensitivity to 
extensional flow highlighted. Under certain conditions, these proteins were also 
shown to be sensitive to shear flow, despite numerous studies questioning the 
role such flow fields have in triggering protein aggregation (Bee et al., 2009; Brückl 
et al., 2016; Jaspe and Hagen, 2006; Thomas and Dunnill, 1979). 
The role the buffer plays in flow-induced aggregation was also investigated for the 
first time. This study highlighted the power of arginine+succinate buffer to supress 
protein aggregation under flow. This screen was performed using buffers for 
which WFL and STT’s aggregation behaviour, under quiescent conditions at 
higher protein concentrations, was known (Dobson et al., 2016). However, these 
studies are not perfect- the buffers used were all of low molarity (10 mM) and 
differing ionic strength, factors which are known to affect the colloidal stability of 
proteins (Hofmann and Gieseler, 2018). Furthermore, the formulated 
concentration of therapeutic antibodies are far higher than the 0.5 mg mL-1 
investigated in this thesis. Whilst the conditions in Chapter 4 were advantageous 
for this study, they do not necessarily reflect a ‘real’ mAb formulation. At higher 
concentrations, the viscosity of the solution may change, affecting the 
fundamental fluid mechanics present in the EFD. A more thorough investigation 
of formulations and how they affect flow-induced mAb aggregation/ 
physicochemical properties would be of great interest in the future. 
Much of the work in Chapter 4 looked at the amount of aggregate formed at the 
end of the pathway from monomeric protein to insoluble aggregate. In Chapter 3, 
this pathway could be described for BSA. This was perhaps facilitated by the 
protein: being well-studied historically; possessing a naturally occurring free Cys 
residue and being less topologically complex than mAbs. In Chapter 5, such a 
pathway was sought for the three mAbs. The activated N* state of these proteins 
was difficult to capture. Extrinsic fluorescent dyes were found to be ineffective in 
detecting aggregation in situ. This was perhaps due to differences between the 
proteins, flow fields and buffer conditions in this thesis and the work of Wolfrum 
et al. (Wolfrum et al., 2017).  
Chemical cross-linking experiments were also unsuccessful in capturing the dimer 
aggregation interface of WFL. This is not a trivial exercise- capturing such 
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interactions between 150 kDa proteins in a complex flow environment makes 
downstream analysis difficult. Further optimisation of the cross-linking conditions, 
in addition to implementation of a more sensitive mass spectrometer now 
available to this author, would make this experiment more feasible. Together, the 
chance of detecting low-abundance inter-molecular cross-links may increase. It 
would be highly desirable to have a flow device available where optics etc. could 
be in place to probe the flow-induced formation of the N* state directly in the 
device. At present, the metal collar of the Hamilton syringes make such a design 
impossible. The design and testing of microfluidic extensional flow devices is 
under current investigation within this author’s wider research team (Panagi, 
2018). 
To attempt to gain an idea of the underlying kinetics of monomer loss caused by 
stress in the EFD, HPLC assays were incorporated into the workflow. This assay 
highlighted why WFL was rejected as a mAb candidate by MedImmune; its 
aberrant interaction with the chromatography matrix (despite arginine being 
present) rendered kinetic analysis unfeasible. For STT and mAb1, this assay did 
work in principle, showing a loss of monomer as a function of time (pass number). 
However, the quality of the data was compromised by the age of the column and 
the (later shown to be unnecessary) quench step. It would be desirable to perform 
these experiments again with: a new column, more time points and, more 
concentrations. This would allow better data to be obtained to which kinetic 
models could be fitted.  
The onset of aggregation after just ten passes could be detected using SD-SDS-
PAGE. A detailed understanding of the migration behaviour of mAbs on such gels 
(such as higher apparent molecular weights of monomers, dimers etc.) would be 
interesting to investigate in the future. The data from these gels, coupled to those 
obtained from light scattering, allowed the formation and growth of mAb 
aggregates as a function of pass number to be monitored for WFL, mAb1 and 
STT. In future, by obtaining more data at different concentrations and pass 
numbers, in addition to performing the HPLC experiments described above, a 
comprehensive mechanistic model describing flow-induced mAb aggregation 
could be constructed for the first time. 
The seeding and cross-seeding experiments presented in this thesis showed that 
flow-induced mAb aggregation can be nucleated. These experiments highlighted 
the affinity WFL has for its own aggregates over those of STT. Performing these 
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experiments at different seed concentrations (e.g. 5% v/v) and measuring the 
effect this has on the rate of aggregation, as opposed to just the end-point, would 
be an interesting future study. Overall, obtaining the mechanism of flow-induced 
aggregation would be highly desirable, as the resulting kinetic model then 
becomes predictive. This would maximise applicability in the biopharmaceutical 
industry if the aggregation mechanism of a mAb observed in the EFD is the same 
as that seen in an industrial setting. 
Regardless of the mechanism, the ability of any assay or device to distinguish 
between robust and aggregation-prone proteins is highly pertinent to the 
development of biopharmaceuticals (Chapter 1). If current predictive assays used 
by the biopharmaceutical industry were perfect, then mAb aggregation would not 
be perceived as a problem and much of the work in this thesis would be 
redundant. Clearly, this is not the case, thus new tools are needed to tackle the 
aggregation problem. In Chapter 3–5, the EFD was able to differentiate between 
three model mAbs. How would it fare with a wider panel of mAbs? 
The 2017 paper by Jain et al. generated a large reference dataset of 137 clinically 
relevant mAbs and their biophysical behaviour in twelve different assays. By 
choosing a subset of 33 mAbs, then subjecting them to stress in the EFD and 
pelleting the samples, it was shown that some of the mAbs are recalcitrant to the 
effects of flow (like STT), some are reasonably aggregation-prone (like mAb1) 
and some are very sensitive (like WFL). When the data generated by the EFD 
were compared to the data from Jain et al. (2017), it was shown that the EFD is a 
distinct biophysical tool to those currently used in the biopharmaceutical industry. 
This means one gains unique, additional information about the biophysical 
behaviour of a mAb. Bioinformatics analysis of the mAbs’ variable sequences and 
model structures highlighted possible aggregation-prone regions which may 
become exposed due to extensional flow. However, none of the methods selected 
provide an ‘easy answer’ as to why a mAb should necessarily aggregate when 
subjected to stress in the EFD. The ‘WFL’ motif in MEDI1912 (WFL) ((Dobson et 
al., 2016)) and the YYYYYM loop in Cixutumumab are the exceptions to this rule. 
As the biopharmaceutical industry moves away from the traditional IgG mAb 
towards more exotic, ‘unnatural’ modalities (Section 1.2), the aggregation-
propensity and manufacturability of such molecules may be a problem in the 
future, as the ‘academic territory’ surrounding this is fairly uncharted. In addition, 
personalised on-demand biologic medicines are coming closer to a reality (Boles 
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et al., 2017). How hydrodynamic forces impact such molecules at this scale is not 
known; perhaps the scale of the EFD would be the perfect tool to predict this? For 
better or worse, hydrodynamic forces affect biomolecules both in vivo and in vitro. 
The work presented in this thesis opens many possible avenues of further study. 
It is the hope of this author that the work will facilitate the manufacture of promising 
therapeutic proteins into the medicines of the future. 
To conclude, the work contained within this thesis shows that: 
 Hydrodynamic forces have the ability to induce protein aggregation. The 
extent of aggregation observed is mainly dependent on the protein in question, 
the magnitude of the hydrodynamic forces present in the EFD, the amount of 
times a protein experiences these flow events and the buffer composition. 
 Aggregation-prone proteins, or proteins put into highly aggregation-prone 
states (such as STT at 16 mm s-1), are sensitive to shear flow. 
 Flow-induced aggregation likely proceeds through a pathway involving 
‘activated’ N* species, oligomers and soluble aggregates, culminating in the 
formation of insoluble protein. 
 The ability of different bioinformatics and biophysical methods to predict, 
detect and quantify flow-induced protein aggregation varies depending on the 
method and the sample in question. 
 The aggregation behaviour of mAbs in the EFD is distinct to that observed 














The implications of this work are: 
 Potential for future experiments exploring the mechanisms of flow-induced 
protein aggregation within this author’s wider research group and others in the 
field, building on the data presented in this thesis. 
 The EFD and similar devices could be used to screen mAbs, at small-scale, 
for their ‘manufacturability’, i.e. their relative resistance to hydrodynamic 
forces. Alternative biophysical methods currently used by industry do not 
provide one with this information, as the EFD has been shown to be distinct 
to other assays. As mAbs will encounter extensional and shear flows during 
bioprocessing, identification of robust mAbs earlier on in the development 
pipeline would be beneficial to the biopharmaceutical industry.  
 Knowledge of strain rates and exposure times in the EFD could be compared 
to those found in industry to inform manufacturing practices which minimise 
aggregation. 
 The EFD could be used as a formulation screening tool to stabilise 
aggregation-prone mAbs (such as WFL) against harsh hydrodynamic 

















Appendix 1. Ancillary Tables  
 
Table A1.1 Molecular Weights and molar extinction coefficients 
for the proteins used in the study 
 
Protein Molecular Weight (Da) Molar extinction 
coefficient at 280 nm 
(ε280) (M-1 cm-1). 
BSA 66,430 43,824 
WFL 148,422 239,440 
mAb1 147,483 207,360 
STT 148,107 228,440 
Daratumumab 147,903 210,000 
Denosumab 147,797 210,000 
Tabalumab 149,107 210,000 
Ipilimumab 147,933 210,000 
Ixekizumab 149,357 210,000 
Olaratumab 152,607 210,000 
Panobacumab 148,740 210,000 
Vedolizumab 149,491 210,000 
Fulranumab 148,464 210,000 
Imgatuzumab 147,883 210,000 
Dalotuzumab 148,852 210,000 
Tralokinumab 147,052 210,000 
Onartuzumab 149,813 210,000 
Ofatumumab 148,574 210,000 
Etrolizumab   146,944 210,000 
Guselkumab 146,450 210,000 
Foralumab 148,164 210,000 
Fezakinumab   147,302 210,000 
Daclizumab 146,720 210,000 
Figitumumab               149,084 210,000 
Simtuzumab 148,302 210,000 
Zalutumumab 149,121 210,000 
Golimumab 149,543 210,000 
Galiximab 147,805 210,000 
Otlertuzumab 147,295 210,000 
Bevakizumab 149,132 210,000 
Alemtuzumab 148,652 210,000 
Bimagrumab 145,354 210,000 
Lumiliximab 150,312 210,000 
Sifalimumab    146,838 210,000 
Cixutumumab 148,964 210,000 
Adalimumab 148,079 210,000 




Table A1.2 pI, Intrinsic CamSol score at pH 7, Light-chain class 
and Cluster number from Jain et al. 2017 for the Adimab proteins 
Name of mAb pI CamSol Score (pH 7) λ or κ ? Cluster No. 
Daratumumab 7.9 0.190311 κ 1 
Tabalumab 8.9 0.296595 κ 2 
Denosumab 8.8 -0.437674 κ 1 
Ipilimumab 8.9 -0.105756 κ 3 
Ixekizumab 8.8 -0.199419 κ 5 
Olaratumab 8.3 -0.545537 κ 4 
Panobacumab 8.7 0.17024 κ 1 
Vedolizumab 6.9 -0.289134 κ 1 
Fulranumab 7.9 0.128657 κ 2 
Imgatuzumab 9.1 0.019702 κ 2 
Dalotuzumab 8.8 -0.62771 κ 5 
Tralokinumab 5.9 0.020284 λ 1 
Onartuzumab 8.3 -0.613459 κ 1 
Ofatumumab 8.4 0.038952 κ 1 
Etrolizumab 8.4 0.02221 κ 4 
Guselkumab 8.6 -0.214467 λ 4 
Foralumab 9.3 -0.117484 κ 2 
Fezakinumab 6.9 0.050742 λ 3 
Daclizumab 8.6 -0.071961 κ 1 
Figitumumab 8.8 0.146984 κ 2 
Simtuzumab 8.6 -0.600181 κ 5 
Zalutumumab 7.8 -0.067162 κ 1 
Golimumab 8.8 -0.346518 κ 3 
Galiximab 5.8 -0.339799 λ 3 
Otlertuzumab 8.3 -0.039988 κ 1 
Bevakizumab 7.1 -0.627061 κ 4 
Alemtuzumab 9.1 -0.303701 κ 1 
Bimagrumab 9.1 -0.15951 λ 2 
Lumiliximab 8.4 -0.204455 κ 1 
Sifalimumab 9.0 -0.204455 κ 1 
Cixutumumab 7.8 -0.149332 λ 5 
Adalimumab 8.3 0.36987 κ 1 










Table A2: Table of mean hydrodynamic radii (nm) obtained by 
regularization analysis of DLS data for 1, 2, 5 and 10 mg mL-1 
BSA subjected to extensional flow in Chapter 3.2.2. The 
protein samples were stressed at a plunger velocity of 8 mm s-1 
(strain rate = 11750 s-1 and shear rate = 52000 s-1). One 









Peak 2 (nm) Peak 3 (nm) Peak 4 
(nm) 
1 0 3.4 ± 0.9    
 10 3.1±0.6 1748±434   
 20 3.3±0.9    
 50 3.2±0.8 5955±2106   
 100 3.5±1.2 310±80   
 500 3.3±0.66 77±25 994±357  
 1000 7.0±5.7 1422511450   
 1500 5.2±24 16490±16460   
 2000 3.0± 0.5 139± 20 1915± 576 140564 
± 172260 
2 0 3.3±1    
 10 3.2±0.7    
 20 3.2±0.8    
 50 2.9±0.8 857±812 367715±23735
1 
 
 100 2.2±0.6 98±32 693±227 16215 
±5780 
 500 4.1±1.1 887±705 26911±12802  
N =1 1000 11.2±3.8 58522±129872   
 1500 4.4± 2.2 24678±29920   
 2000 8.4±1.6 1230±571 27912±12189  
5 0 3.2±0.8    
 10 3.4±1.0 506±157   
 20 3.3±0.8 292±76   
 50 3.1±0.6 2146±700 52739±24392  
 100 2.5±0.9 36±9 31158±7720  
 500 3.2±1 352±100 37600±8400  
 1000 4.6±1.4 22636±34198   
 1500 4.2±2.6 13983±20580   
 2000 3.7±0.8 82±21 26683±39806  
10 0 3.3±1.0    
 10 3.3±0.9    
 20 2.7±0.3 15598±4812   
 50 2.4±0.3 520±140 3713±1268  
 100 2.9±1.1 5877±12817   
 500 3.5±0.9 65±9 12383±12494  
 1000 2.8±0.5 26±5 2896±2044 65301 
±23533 
 1500 3.7±1.7 531±441 12722±5140  




Table A3. “Thresholds of biophysical properties derived from 
analysis on samples corresponding to the 48 approved 
antibodies”, i.e. ‘red flag’ thresholds from Jain et al., 2017 
Group Assay Worst 10% 
threshold 
Units (of the flag) 
1 PSR 0.27 ± 0.06 N/A 
 AC-SINS 11.8 ± 6.2 nm (Δλ >) 
 CSI 0.01 ± 0.02 BLI response units (>) 
 CIC 10.1 ± 0.5 Retention time (mins) (>) 
2 HIC 11.7 ± 0.6 Retention time (mins) (>) 
 SMAC 12.8 ± 1.2 Retention time (mins) (>) 
 SGAC-SINS 370 ± 133 Salt concentration (mM) (>) 
3 BVP 4.3 ± 2.2 Fold-over-background (>) 
 ELISA 1.9 ± 1.0 Fold-over-background (>) 























Table A4. Table of dissociation constants for selected 
Adimab proteins with their targets. KDs were extracted from the 
literature, with the appropriate references highlighted. Many 
references were sourced from the IUPHAR Guide to 
Immunopharmacology, available at 
http://www.guidetoimmunopharmacology.org/immuno/index.jsp 
mAb Name KD (nM) Reference 
Tabalumab 0.126 (Manetta et al., 2014) 
Denosumab 0.003 (Casas et al., 2013) 
Ipilimumab 10.6 (Ramagopal et al., 2017) 
Ixekizumab 0.0018 (Liu et al., 2016) 
Olaratumab 0.04 (Loizos and Huber, 2006) 
Panobacumab 0.003 (Horn et al., 2010) 
Fulranumab 0.004 (Wild Jr. et al., 2004) 
Imgatuzumab 18 (Schanzer et al., 2016) 
Dalotuzumab 1 (Brana et al., 2014) 




Foralumab 0.01 (Dean and Depis, 2014) 
Fezakinumab 0.054 (Fouser et al., 2007) 
Daclizumab 10 (Queen et al., 1995) 
Figitumumab 6.6 (Collens et al., 2014) 
Simtuzumab 67 (Smith et al., 2013) 
Zalutumumab 7 (Bleeker et al., 2004) 
Golimumab 0.018 (Shealy et al., 2010) 
Galiximab 200 
 
(Mak and Saunders, 2006) 
Bevakizumab 0.058 (Papadopoulos et al., 2012) 
Alemtuzumab 7500 (Silicon Kinetics, 2016) 
Bimagrumab 0.00173 (Berger et al., 2010) 
Sifalimumab 0.044 (Oganesyan et al., 2015) 
Cixutumumab 0.04 (McKian and Haluska, 2009) 
Adalimumab 0.46 (Tracey et al., 2008) 










Appendix 2. Ancillary Figures 
 
 
Figure A1. Outline of yeast surface display.  The scFv of 
interest (VL and VH) is expressed on the surface of the yeast as a 
fusion protein with Aga2, linked via hemagglutinin. Orange bars 
represent disulphide bridges. Blue lines represent flexible glycine-
serine linkers. The biotinylated antigen (purple) can have its 
binding detected by fluorescently labelled Avidin (red star). An 
epitope tag (c-Myc) can be used to detect expression of the scFv 
by using a fluorescently labelled antibody (green star). Figure 




























































Figure A2. The amount of insoluble protein formed after 
stressing BSA in the presence and absence of reducing 
agent (TCEP). 5 mg mL-1 BSA was stressed for 100 passes at a 
plunger velocity of 8 mm or 14 mm s-1, in the presence/absence of 
0.5 mM TCEP. Errors from two independent experiments were 
















Figure A3. Native mass spectrum of 10 μM BSA in 25 mM 
ammonium acetate, pH 3.0. Spectrometer conditions were as 











Figure A4. Change in diffusion coefficient (D) against the 
concentration of a) WFL and b) STT. The four buffers used were 
10 mM sodium acetate pH 6.0 (red), 10 mM histidine pH 6.0 
(green), 10 mm sodium phosphate pH 7.2 (blue) and 10 mM 


































































































































































































































































Figure A5. Plot of the amount of insoluble protein formed by 
the mAbs after stress in the EFD (from Figure 6.5) according 
to approval rating. Pink = Phase II, Orange = Phase III and 
Approved mAbs are in Green. 
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Figure A6. Plot of the rank order in the EFD of the 33 Adimab proteins against 
the rank derived from the distance from ideal analysis by Jain et al., excluding 
the EFD data. A linear trend line was fit to the data in Origin 2018 to show the lack 
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